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Abstract 
DNA methylation is a biochemical process where a DNA base, usually cytosine, is 
enzymatically methylated at the 5-carbon position.  An epigenetic modification associated 
with gene regulation, DNA methylation plays a key role in a wide variety of biological 
processes.  Changes in DNA methylation patterns have also been implicated in the 
pathogenesis of many human diseases. Following up on a randomised control trial (RCT) 
studying the effects of prolonged folic acid supplementation during pregnancy, we sought to 
identify regions of the genome that altered their methylation status in response to intervention, 
considering the methyl-donor for DNA methyltransferase reactions is a product of folate 
metabolism.  Using a genome-wide, array-based method of analysis on a subset of the cohort 
(n=6) from the RCT, we identified 5 novel folate-sensitive differentially methylated regions 
(FS-DMRs): Inosital hexakisphosphate kinase 1 (IP6K1), Chromosome 9 Open Reading 
Frame 44 (Chr9ORF44), RAS p21 protein activator 4 (RASA4), Sphingosine-1-phosphate 
lyase 1 (SPGL1) and Chromosome 19 Open Reading Frame 75 (Chr19ORF75). A 
confirmation analysis was carried out using a loci-specific method of analysis across the rest 
of the cohort (n = 238) on three of these FS-DMRs (IP6K1, RASA4, and Chr9ORF44), but 
they did not reach statistical significance. In a cell culture model, changes in methylation 
across selected regions were confirmed to have a significant impact on gene expression 
(IP6K1, RASA4 and GPS2). A final analysis of dihydrofolate reductase (DHFR),  responsible 
for reducing folic acid to its active form, investigated whether specific post-translational 
modifications was a feature of this enzyme. Following up on a SUMOylation analysis of 
DHFR previously published in the literature, our own analysis did not yield the same results, 
exposing a potential source of false positive results from a commercially available kit wildly 
used in this field.  
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1.1: Overview  
The aim of this project is to assess the effects of folic acid supplementation on genome-wide 
DNA methylation patterns i.e., to identify human ‘Folate-Sensitive DNA methylation sites.” 
As an epigenetic modification known to influence gene expression, DNA methylation has 
been the focus of extensive research over the past decade due to its potential to be a mechanism 
for the “foetal origins of adult disease” hypothesis, i.e. the effect of nutritional and 
environmental factors during development on health later in life1–3. 
In an intervention study recently carried out by the University of Ulster4, 119 pregnant women 
were recruited and given either a 400μg folic acid supplement every day during their second 
and third trimesters, or a placebo. Blood samples were taken before intervention, after 
intervention, and from the umbilical cord upon delivery (Figure 1.1). DNA from this study, 
called FASSTT (Folic Acid Supplementation during the Second and Third Trimester), was 
the focus of this project, aiming to examine the impact of folic acid supplementation on DNA 
methylation. In order to assess this, a literature review examining and comparing DNA 
methylation methods of analysis was written and published in 20115. Following this, an 
analysis of post-translational modifications affecting dihydrofolate reductase – an enzyme 
involved in producing a functional form of folate from folic acid – was examined in vitro using 
protein recombination technology to provide insight into the regulation of this enzyme. 
1.2: Folate Metabolism 
1.2.1: Folic Acid Supplementation and Neural Tube Defects 
Folic acid is the synthetic form of folate used as dietary supplements and in the fortification 
of food. While biologically inactive itself, folic acid is processed by the cell into its active 
form, tetrahydrofolate (THF), by the enzyme dihydrofolate reductase (DHFR). From here, 
tetrahydrofolate and its derivatives play a key role in one-carbon metabolism, acting as co-
enzymes for many of the reactions involved (Figure 1.2)6,7. As an essential B9 vitamin, folate 
and its derivatives are essential components of a healthy diet; the recommended daily 
allowance is 400μg for adults and 600μg for pregnant women8. 
Neural tube defects (NTDs) are complex multifactorial disorders caused by the failure of the 
neural tube to close during development. This process, known as neurulation, occurs between 
21 and 28 days after conception, usually before the mother knows that she is pregnant9. There 
are two main types of NTDs – cranial and caudal defects – each arising from the position 
along the neural tube the malformation occurs as depicted in Figure 1.310. Anencephaly in an 
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invariably lethal NTD, characterised by severe cerebral and cranial defects11. On the other 
hand, spina bifida is a caudal defect that makes up about two-thirds of NTD cases, and causes 
paraplegia, though is not usually fatal on its own10,11. In 2001, the occurrence of NTDs in 
Ireland was recorded at 0.8 to 1.5 per 1,000 births12. 
The link between micronutrient availability and neural tube defects was first suggested in 
1972, when Smithells et al., examined serum folate, red cell folate, white blood cell vitamin 
C, and riboflavin levels in 900 cases of pregnancy13. Of these pregnancies, 6 resulted in neural 
tube defects. Despite the small numbers, red cell folate levels were found to be significantly 
lower in these individuals when compared to the rest of the sample set. Following this finding, 
the same research group examined this link further, carrying out a nonrandomised control trial 
on 243 women with high-risk pregnancies (i.e. where NTDs had occurred before). An 86% 
lower risk was reported as a result of this intervention14. However, no public health action was 
taken following this, due to the lack of a randomised element to the study10.  
In 1992, a study published in the Lancet by the British Medical Research Council found that 
folic acid supplementation alone has a strong protective effect against the occurrence of 
NTDs15. These results have now been replicated by a large number of studies carried out all 
over the world16–19. 
However, the mechanism of action and the metabolic basis from which folic acid 
supplementation prevents these birth defects is not well understood, and there have been 
questions raised over the possible adverse effects of mandatory fortification20–23. In 2007, data 
from the Aspirin and Folic Acid Polyp Prevention Study (AFPPS) suggested that treatment 
with folic acid leads to an increased risk of colorectal  adenomas and prostate cancer, adding 
to the growing concern24. More recently, a meta-analysis reported in The Lancet demonstrated 
that, in aggregate, these epidemiological trials provide no significant evidence for the effects 
of folic acid supplementation on cancer incidence25.  
There will always be controversy in the field as long as the molecular mechanisms and 
evidence for the benefits of folic acid supplementation remain elusive. For this reason, it is of 
paramount importance that we learn as much as we can about how folic acid supplementation 
works to cause or prevent disease. 
1.2.2: The FASSTT Study 
Today, clear recommendations exist regarding supplementation during pregnancy. Women 
planning on having children are advised to take 600µg of folic acid a day until the end of the 
first trimester. However, there are no guidelines for folic acid supplementation during the latter 
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stages of pregnancy, although a decline in serum folate levels have been observed during the 
second and third trimester in multiple studies26,27.  
Recently, a randomised control trial carried out in the University of Ulster, Coleraine sought 
to examine the effect of continued folic acid supplementation past the first trimester4. The 
study, named FASSTT (Folic Acid Supplementation during the Second and Third Trimester), 
recruited 119 pregnant women attending an antenatal clinic in Northern Ireland. They were 
randomly assigned into two groups, taking either 400µg folic acid daily, or a placebo (Figure 
1.1). All participants had been taking a dose of 400μg/d folic acid prior to recruitment, and all 
had singleton uncomplicated pregnancies. Participants were excluded if they were aged over 
35, or suffered from gastrointestinal, hepatic, renal, or vascular disease. Women who 
previously had pregnancies with NTDs, had first-degree relatives with NTDs, or suffered from 
NTDs themselves were also excluded from the trial. Non-fasting blood samples were taken at 
recruitment, (at approximately week 14 of pregnancy), and at week 36. Food frequency 
questionnaires were taken during the second trimester, focusing on B-vitamin intake. From 
blood samples, plasma homocysteine, serum folate, red cell folate, and serum vitamin B12 
levels were measured using microbial and immunological assays. Genotypes of the MTHFR 
677 C>T polymorphism, known to affect folate metabolism, were also measured using PCR 
coupled with HinF1 restriction digestion4. Clinical and biological data from the FASSTT is 
presented in Table 1.1. 
The FASSTT study found that continued folic acid supplementation can prevent the typical 
decline in folate status typically observed during the latter stages of pregnancy4. Using DNA 
extracted from the buffy coats of these samples, we aim to examine the effect of intervention 
on DNA methylation. 
1.2.3: Folate-mediated One-Carbon Metabolism  
Folate metabolism is compartmentalised between the mitochondria, nucleus, and cytoplasm 
of mammalian cells. Cytoplasmic one-carbon metabolism can be broadly divided into two 
sections: the DNA cycle and the methylation cycle7.  
This metabolic network is outlined in Figure 1.2. First, folic acid and dietary folate are reduced 
by DHFR to their biologically active form, tetrahydrofolate. The one-carbon unit is introduced 
to THF by serine and the enzyme serine hydroxymethyltransferase (SHMT), producing 
glycine and 5,10-methylenetetrahydrofolate, the form of folate required for de novo 
thymidylate synthesis. In rapidly growing cells, the trifunctional enzyme 
methylenetetrahydrofolate dehydrogenase (MTHFD1) may also utilise 5,10-
methylenetetrahydrofolate for purine biosynthesis. It is the significance of the DNA cycle to 
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cell survival that makes methotrexate – an anti-folate drug that competitively inhibits DHFR 
– such a potent chemotherapeutic agent28.  
The methylation cycle is comprised of four reactions. One product of this cycle is S-
adenosylmethionine (SAM), the methyl donor for cellular methylation reactions including 
DNA methylation29–31. The DNA and methylation cycles are linked together by 
methylenetetrahydrofolate reductase (MTHFR), which reduces 5,10-
methylenetetrahydrofolate to 5-methylenetetrahydrofolate. This reaction is vital for feeding 
methyl groups into the methylation cycle. The MTHFR polymorphism 677C>T (Ala222Val)  
reduces MTHFR enzyme activity, possibly steering one-carbon units away from the 
methylation cycle and compromising methylation reactions – including DNA methylation – 
by reducing SAM availability32–34. Elevated risk of NTDs have been associated with the 
homozygous TT variant of the polymorphism35. 
Variations of DHFR, the gene encoding dihydrofolate reductase, have been associated with 
disease risk and the efficacy of methotrexate treatment in patients with cancer or arthritis36. 
Tumour cells have been found to resist this chemotherapeutic effect either by upregulating 
DHFR transcription37, or through mutation of the DHFR gene itself28,38. 
Due to its role in health and disease and its vital function in one-carbon metabolism, DHFR 
has been the subject of extensive investigation since its discovery in 198339. Recently, our 
research group found that DHFRL1, once annotated as a non-functional pseudogene of DHFR, 
is expressed and functional, capable of reducing tetrahydrofolate in DHFR-null mammalian 
cells40. With a lower affinity for DHF than DHFR, DHFRL1 was also found to localise to the 
mitochondria, possibly facilitating on-site synthesis of mitochondrial DNA. McEntee et al., 
(2011)40 also hypothesised that the second reductase enzyme may have a differential response 
to methotrexate treatment, possibly providing an insight to the mechanisms of resistance, or 
new potential therapeutic treatment strategies.   
As aforementioned, one-carbon metabolism is compartmentalised between the nucleus, the 
mitochondria, and the cytoplasm. Whereas McEntee  and colleagues found evidence for 
mitochondrial DHFRL1, DHFR has been well established to localise to the nucleus during the 
S phase of the cell cycle41,42. Anderson et al., (2007)43 have found evidence that this nuclear 
translocation is facilitated by SUMOylation of DHFR, a post-translational modification 
associated with localisation to the nucleus. On the other hand, DHFRL1 does not have a 
mitochondrial targeting sequence in its primary structure, although it does have a 
SUMOylation site. Indeed, all enzymes involved in nuclear one-carbon metabolism have 
consensus sequences for SUMOylation, and have been demonstrated to be substrates for in 
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vitro SUMOylation reactions43,44. No evidence for nuclear DHFRL1 has been uncovered as of 
yet, but this possibility cannot yet be ruled out40.  
As demonstrated by McEntee et al., (2011)40, research into the enzymes of one-carbon 
metabolism is at the very frontier of the field, with many more questions remaining to be 
answered. There is still much to be learned about the compartmentalisation of folate 
metabolism, and the factors that influence localisation of its various components. 
1.3: Epigenetics  
In the 19th century, embryologists trying to discern the ‘developmental plan’ for organisms 
were divided into two groups: those endorsing preformationism – the concept that each cell 
with preformed elements simply grows larger during development, and those who believed 
that development was the result of a complex series of chemical reactions. The latter, now 
known to be most correct, named this theory ‘epigenesis45.’ 
The term ‘epigenetics’ was coined by CH Waddington in 1942 by combining the words 
‘genetics’ and ‘epigenesis46,47.’ Originally used to simply describe the role of genetics during 
development, Waddingtonian epigenetics is quite different from the epigenetics we know 
today. However, by examining the scientific advances made following Waddington’s work, 
the link between these two schools of thought becomes clear.  
As the understanding of embryology improved into the 20th century, it became clear that 
development adheres to the model of epigenesis. One piece of evidence that seemed to support 
this was the fact that the complement of DNA in a fertilised egg is identical to that of every 
somatic cell arising from it. Watson and Crick’s model of semi-conservative replication 
provides the mechanism of how this level of genetic homology can arise during 
development48,49. However, this observation raised another challenge in the field: How could 
identical genetic material across cells produce such a wide diversity of cell types and tissues?45 
Stedman and Stedman provided the first explanation to this phenomena, understanding that 
the proteins bound to DNA in the nucleus could act for repressors for gene expression50. At 
the time, it was assumed that different cell types must have a different set of DNA binding 
proteins. It wasn’t until 1964 when Allfrey and Mirsky began describing how post-
translational modification of these proteins can impact on gene expression that epigenetics 
took the form we know of today51.  
The archaic form of term epigenetics was coined to further understand the role of genetics 
during development, aiming to answer one of the oldest questions in biology: “Does the 
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embryo contain all its parts in little from the beginning… or is there a true formation of new 
structures as it develops?” (Aristotle, 350BC)52,53. By examining the evidence supporting this 
hypothesis, scientists throughout the 20th century discovered that DNA can be altered without 
affecting the sequence itself, ushering in the new age of epigenetics. 
The core histones within a eukaryotic nucleus are capable of acquiring more than 100 different 
post-translational modifications: including acetylation, ubiquitination, acetylation, 
SUMOylation, and phosphorylation54. By altering how histones interact with DNA, these 
modifications make up a complex mosaic of changes commonly referred to as the “histone 
code55.” For example, methylation of histone lysines H3K4 is associated with transcriptional 
activation, while methylation of histone lysines H3K9 and H3K27 are both associated with 
transcriptional repression. In these cases, histone methylation acts to recruit activating enzyme 
complexes to chromatin56,57. On the other hand, acetylation of lysine residues impacts on gene 
expression by neutralising the ionic interaction between DNA and histones54. Histone 
deacetylation, a separate enzymatic process, complements this interaction, alluding to a 
complex system of biochemical switches that alter gene expression while leaving the DNA 
sequence intact58.  
Long non-coding RNAs (lncRNAs) are also considered to be an element of epigenetic 
regulation59. Once believed to be non-functional, now it is understood that lncRNAs regulate 
transcription by base-pairing with mRNAs in the cytoplasm. For example, a mouse lncRNA 
complementary to the gene Uchl1 can control UCHL1 synthesis at a post-transcriptional 
level60. Although a very promising area of research, the sheer abundance of lncRNAs is 
proving to be a significant challenge to overcome59. However, efforts are underway to 
categorise the structure-function dynamics of lncRNAs that regulate protein expression – 
including the identification of protein and RNA binding domains61. With such a wide diversity 
of individual transcripts yet to discerned, uncovering the “global landscape of elements in 
lcnRNAs” may bring the field closer to unravelling this complex epigenetic system59. 
There is a third type of epigenetic mechanism more extensively studied than those mentioned 
here: DNA methylation62. However, despite the huge volume of research being carried out to 
investigate the nature of this modification, many of its mechanisms and characteristics are still 
unknown. Nonetheless, with a wide range of health and biological implications, the study of 
DNA methylation is an incredibly promising field63.  
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1.4: DNA Methylation 
DNA methylation is a biochemical process where a DNA base, usually cytosine, is 
enzymatically methylated at the 5-carbon position64. An epigenetic modification associated 
with gene regulation, DNA methylation plays a key role in biological health and disease, 
acting through processes such as genomic imprinting, X-inactivation, and tissue specific gene 
expression with possible trans-generational effects65–67. Changes in DNA methylation patterns 
have also been implicated in the pathogenesis of human diseases such as cancer68. Although 
DNA methylation also occurs in prokaryotic cells, the purpose for which is fundamentally 
different to eukaryotic cells: bacteria methylate their own DNA in order to differentiate it from 
that of invading bacteriophages. Utilized as a restriction/modification mechanism, DNA 
methylation allows bacterial cells to protect their own DNA from the restriction enzymes used 
to digest incoming phage DNA69. 
Relatively little is known about the regulatory systems in place that influence DNA 
methylation patterns in vivo. The raw materials for all DNA methyltransferase reactions are 
derived from the “methylation cycle” of one-carbon metabolism in the form of S-
adenosylmethionine. The DNA methyltransferase family of enzymes catalyse the transfer of 
methyl moieties from S-adenosylmethionine, and are broadly categorised into two groups; 
maintenance and de novo methyltransferases. The maintenance methyltransferase, DNMT1, 
has a substrate preference for hemi-methylated DNA; methylated DNA that has undergone 
semi-conservative replication with one parent retaining its methylation mark70,71. The enzymes 
DNMT3a and DNMT3b are capable of methylating unmethylated DNA, and constitute de 
novo methylation70. DNMT2 was once believed to not have any DNA methyltransferase 
activity, localising to the cytoplasm in transfected mouse fibroblasts72. Now, however, 
evidence has emerged that this elusive enzyme targets RNA molecules for methylation73. 
It was previously believed that DNA demethylation only occurs passively; DNMT1 would 
switch off during DNA replication, eventually decreasing the number of hemi-methylated 
nascent strands after subsequent cycles74. Although this has been demonstrated to be the case 
in embryonic stems cells during development, evidence is emerging for an active DNA 
demethylation mechanism75,76. The enzyme TET1 has been demonstrated to oxidate 5-
methylcytosine to 5-hydroxymethylcytosine77. Although there were some proposals that 5-
hydroxymethylcytosine acts as a unique epigenetic mark involved in transcriptional 
regulation78, there is more coherent data in the literature to suggest that 5- 
hydroxymethylcytosine acts as an intermediate between 5-methylcytosine to unmethylated 
cytosine. Two possible enzymatic processes have been proposed to explain this, either through 
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further oxidation to 5-formylcytosine and 5-carboxycytosine, or by deamination of the 5-
hydroxymethylcytosine molecule to 5-hydroxymethyluracil. In both the oxidation and the 
deamination models, possible T:G mismatches are introduced which, when corrected by base-
excision repair machinery, produce unmethylated cytosines (Figure 1.4)79–82.  
However, the role of 5-hydroxycytosine may not be limited to passive demethylation. Indeed, 
5-methylcytosine is thought to have originated as an ancestral, protective agent in mammalian 
cells against invading retroviral elements, based on the high levels of methylation found in 
repeated and transposable regions of chromosome centromeres83. Although the DNMT 
enzymes are highly conserved across various organisms, other complex processes associated 
with DNA methylation have evolved beyond its ancient role, and are not common across all 
species84. For example, imprinted genes in mammals and plants and have been found to be 
methylated monoallelically based on their parent of origin – something now known to have 
emerged from convergent evolution85. Thus, it is possible that hydroxymethylation could have 
evolved beyond its role in active demethylation over the course of evolutionary history. For 
example, 5’hydroxymethylation is also known to inhibit methylation via DNMT1, possibly 
facilitating passive demethylation too86.   
In a recently published review, Hahn et al., (2014)87 describe how 5’ hydroxymethylation has 
been demonstrated to be stable in various cell and tissue types,  alluding to a function beyond 
demethylation. Even more recently, Bachman et al., (2014)88 found 5’hydroxycytosine to be 
stable in mouse tissues in vivo using isotopic labelling.  
These studies show that the paradigm dictating the role of 5’hydroxymethylation is constantly 
changing as new data emerges. There is much more to learn about the process of DNA 
methylation and demethylation. This thesis aims to add to the collective knowledge of the 
influences on these processes by examining the impact of maternal nutrition on health and 
disease during pregnancy. 
1.5: The Foetal Origin of Human Disease  
In the winter of 1944-1945, a devastating famine in The Netherlands caused by a German 
imposed food embargo claimed the lives of over 200,000 people. Due to the fact that this was 
a manmade famine enforced upon a developed country for a short period of time with excellent 
medical records kept throughout, the ‘Dutch Hunger Winter’ has gained considerable attention 
from the scientific community. Many studies have been carried out on birth cohorts recorded 
during the famine in order to learn about the effects of malnutrition on the in utero 
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environment89–92. In 1976, it was found that children exposed to the famine during early 
gestation were more susceptible to obesity later in life, compared those exposed to the famine 
during the latter stages of development93. In another study, it was found that although reduced 
glucose tolerance was associated with exposure to the famine during any point during 
gestation, those exposed to the famine during late gestation were more susceptible to coronary 
heart disease, atherogenic plasma lipid profiles, and increased risk of breast cancer94.   
The Dutch Hunger Winter provided data that adhered to the now well established ‘Barker 
Hypothesis’, which holds that various adult diseases originate from the in utero environment 
from which the foetus developed1. It has been hypothesised that these disease states arise due 
to the predicted post-natal environment being radically different than the pre-natal 
environment94. For example, epidemiological associations between poor foetal growth and 
development of type 2 diabetes later in life indicate that a developing child is capable of 
adapting a ‘thrifty phenotype’ in order to prepare for a possibly adverse environment upon 
birth. It is when a baby is born into an environment that does not reflect it gestational 
conditions – such as poor foetal nutrition during a short famine – that susceptibility to diseases 
like diabetes increases95,96. 
There seems to be an obvious, intricate, and complicated relationship between the in utero 
environment and adult health and disease. A rather elaborate and elusive molecular system, 
like the plasticity of the epigenome, may hold the biological explanation to what has been 
observed in these studies97.  
During the foetal development in mice, the parental genomes both undergo significant 
epigenetic reprogramming. At the very early stages, before blastocyst formation, genome-
wide DNA demethylation takes place74. After implantation, genome-wide levels of 
methylation increase, along with activity of the de novo methyltransferases, DNMT3a and 
DNMT3b98. Very little is known about the mechanisms that control this reprogramming, but 
researchers are beginning to speculate that Barker’s ‘thrifty phenotype’ may in fact be a 
‘thrifty epigenotype’99,100.   
1.6: DNA methylation and Nutrition 
Although it has been known for a long time that diseases like asthma, neurological disorders 
and some forms of cancer originate through an alteration in the DNA methylation status, 
evidence is now mounting that these changes occur through aberrant environmental 
conditions101–103. The sites that are subject to change are called differentially methylated 
regions (DMRs), and the variations themselves are called metastable epialleles104,105. A variety 
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of environmental influences have been observed that can bring about changes to DMRs, 
including diet, malnutrition, and exposure to chemicals such as tobacco smoke, alcohol, 
metals, and other sources of oxidative stress106–108. 
As a precursor to the methyl-donor S-adenosylmethionine, interest is growing around folate’s 
role in DNA methylation. In particular, a study on mice has yielded proof that genetically 
identical animals can have drastically different phenotypes due to observable changes in a 
particular DMR brought on by the diet of the mother109. In this case, a pregnant mouse with a 
diet supplemented with methyl donating vitamins, such as folic acid itself, exhibited a change 
in the DMR of the agouti gene, generating metastable epialleles with drastically differing 
phenotypes. When the retroelement Intracisternal A Particle (IAP) (a type of transposable 
element or ‘genetic parasite’ capable of reverse-transcribing to RNA and changing position in 
the genome110) upstream of the agouti gene is methylated, expression of the agouti signalling 
protein increases and produces the phenotype of yellow fur, obesity, Type II diabetes, and a 
predisposition to tumours. When IAP is silenced through DNA methylation, the agouti gene 
is expressed in its healthy, wild type form. Due to the variable levels of activity from IAP, a 
spectrum of colours from yellow to brown was observed in correlation with levels of upstream 
methylation. These changes persisted to the following generation, even without exposure to 
the same in utero environment (Figure 1.5)110. 
In humans, the effects of nutrition on particular DMRs in utero have been observed from the 
Dutch Hunger Winter. In a study tracing those that had been exposed to the famine prenatally, 
Heijmans et al. (2008) found a significant difference in the DNA methylation statuses of IGF2 
between same sex siblings; those prenatally exposed to the famine showed a significant 
decrease in DNA methylation at the imprinted locus compared to those who did not97. At the 
same time, other imprinted loci such as IL10, LEP, ABCA1 and MEG3 showed increased 
methylation in the same exposed individuals107. 
With respect to folate status, several studies have shown that folic acid supplementation has 
an effect on the methylation status of particular genes. For example, the IGF2 DMR of 
children whose mothers consumed 400μg of folic acid periconceptionally was shown to be 
highly methylated in comparison to those who had not108. In another study by Fryer et al. 
(2011)111, a genome-wide analysis correlating DNA methylation levels with homocysteine 
levels (a product of folate metabolism) found many more DMRs that can be affected by folate 
status111. This study was carried out on cord blood taken at the end of term, demonstrating that 
the effect of folate status on DNA methylation continues throughout the entire pregnancy.  
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More recently, Dominguez-Salas et al., (2014) demonstrated that variations in folate status, 
caused by seasonal influences, impacted on the methylation status of six metastable epialleles 
of children born in rural Gambia112. In another recent study, Amarasekera et al., (2014) 
examined the impact of folate status during the third trimester of pregnancy on neonatal DNA 
methylation. Seven FS-DMRs emerged from the analysis with one, the promoter region of 
ZFP57, significantly hypomethylated in response to high folate levels. With ZFP57 
expression levels found to increase as a result of hypomethylation, and its product known to 
be a regulator of imprinting-associated DNA methylation during development, Amarasekera 
and colleagues tentatively speculate that a compensatory mechanism may exist to regulate 
ZFP57 production in response to folate levels113.  
The studies listed above suggest that similar changes to DNA methylation status of these 
DMRs may also be observed in the FASSTT samples; the Steegers-Theunissen paper 
describes a study with individuals taking the same amount of folic acid, 400μg/day. The 
imprinted loci of IGF2 was found to be methylated in the lymphocytes of test subjects108. At 
the same time, data from the Fryer et al. (2011) study on homocysteine suggest that, although 
the beneficial effects of folic acid supplementation with respect to the prevention of neural 
tube defects is limited to the first few weeks of gestation, the relationship between folic acid 
supplementation and DNA methylation changes may be relevant throughout the second and 
third trimester111.  
In a review published in 2011, Parle-McDermott & Ozaki examined studies in the literature 
that identified nutrient sensitive DNA methylation sites in humans3. There is a wealth of 
information in the literature to suggest that factors affecting one-carbon metabolism can have 
a significant impact on DNA methylation throughout the genome. By examining DNA 
obtained from the FASSTT study, we aim to add to the growing list of FS-DMRs already 
established in this incredibly fast-moving field.  
1.7: Methods in DNA methylation analysis 
1.7.1: Genome-wide DNA methylation analysis 
Upon the completion of the Human Genome Project in 2001, it was clear that the full ‘Book 
of Man’ had yet to be elucidated. The inexplicable complexity of human biology could not be 
explained by genetics alone, as with only 30,000 protein-coding genes we possess just 33% 
more than the nematode, Caenorhabditis elegans, and approximately 6,000 less than the 
humble banana plant, Musa acuminate114–117. However, mounting evidence from the past few 
decades is pointing to a new set of variables that contribute to our individuality. The Human 
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Genome Project has already unveiled the genetic hardware needed to create a person, but the 
search for the biochemical software is still underway5. 
Methylated cytosine itself is very difficult to measure without further modification. Early 
genome-wide methylation analysis based on Reversed-Phase High Performance Liquid 
Chromatography relied on the separation of methylated cytosine from unmethylated cytosine, 
but was limited to only displaying the total level of methylation in a given sample, independent 
of the associated loci118. Methods of this nature elucidate very little about the epigenome on a 
practical scale, especially when aiming to eventually link specific DNA methylation 
alterations to changes in gene expression.  
Recent advances in Next Generation Sequencing (NGS) technology have yielded a variety of 
sophisticated and high-throughput, high-resolution methods for whole genome-wide 
epigenetic analysis119. At the moment, the gold-standard profiling method with the highest 
resolution is bisulfite sequencing coupled with NGS. Although this is a highly expensive 
approach120, cost is becoming less of an issue in recent years5. For example, Illumina unveiled 
its Infinium HumanMethylation450 BeadChip: a microarray capable of processing 480,000 of 
the 28 million CpG dinucleotides across the human genome without the use of NGS 
technology121,122. As comprehensive as this seems, the use of a DNA microarray to obtain data 
immediately introduces bias; only regions of the genome represented by the array itself can 
be probed for changes in DNA methylation.  
As part of a review in Frontiers in Genetics5, the available methods for DNA methylation 
analysis were examined. Table 1.2 outlines the features and differences between a selection 
of genome-wide methods. Of those that are based on NGS, whole bisulfite sequencing as 
described by Cokus et al., (2008) is the most comprehensive123. MeDIP-seq (Methylated DNA 
Immunoprecipitation Sequencing) and anti-5mC MBDiGS (Methyl-Binding Domain isolated 
Genome Sequencing) follow similar premises, with shearing of the whole genome followed 
by immunoprecipitation of methylated DNA fragments for the former, and 
immunoprecipitation of  methyl-binding proteins for the latter124,125. Unlike sodium bisulfite 
sequencing, however, these methods do not produce data at a single-base pair resolution, as 
NGS is utilised to identify the tags enriched for methylation rather than the individually 
methylated cytosines themselves.  
1.7.2: Modified Methylation Specific Digital Karyotyping 
It has been mentioned in Section 1.4 that DNA methylation exists in bacteria as a restriction 
modification system to differentiate between the organism’s own DNA and that of invading 
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phage69. In the context of mammalian DNA methylation, this characteristic is still of interest 
to researchers from a technical standpoint.  Of the restriction enzymes used by bacteria to fend 
off phage DNA, there are some that can differentiate between methylated and unmethylated 
DNA.  For example, the enzyme HpaII will only digest DNA at the site CCGG when 
unmethylated, but not when methylated. Exploiting the redundancy of the many palindromic 
motifs of restriction sites throughout the genome, Cedar et al., (1979) used a pair of 
‘isoschizomers’ to map the methylation patterns of calf thymus DNA126. Since both MspI and 
HpaII cut at the same site, and the latter will only cut unmethylated DNA, digesting DNA with 
both in tandem can be used to discriminate between methylated and unmethylated loci127. 
Since the publication of this MspI/HpaII assay in 1990, other groups began to experiment with 
similar enzymes to obtain DNA methylation data. Restriction landmark genomic scanning 
(RLGS) is a genomic scanning method that takes advantage of the specificity of restriction 
endonucleases and allows a low resolution comparison of genome-wide differences between 
individuals128. Radiolabelled DNA is digested with two restriction enzymes and separated in 
two dimensions. This produces a profile of thousands of spots spread through the gel, each 
representing a restriction site. This method was adapted for DNA methylation analysis 
(RLGS-M) by employing methylation-sensitive restriction enzymes to differentiate 
methylation differences between individuals129,130. Later, simpler and less expensive genome-
wide screening strategies came into practice. Using methylation-sensitive and insensitive 
restriction enzymes with two low-stringency annealing steps, Liang et al., (2002) found that 
methylation profiles could be obtained by digesting DNA with methylation-specific 
endonucleases followed by a PCR reaction with random primers131. This process is known as 
arbitrarily primed PCR (AP-PCR), and is based on a method developed by Welsh and 
McClelland in 1990, initially used to identify bacterial species132. AP-PCR was adapted in 
order to scour tumour genomes for new differential methylation sites, comparing the 
difference in product sizes and identifying the sites by cutting, cloning and sequencing the 
bands104,131. 
Today, there are many techniques in the literature that apply the same principles of the Singer-
Sam paper to Next-Generation Sequencing124,133,134. One is Methyl-sensitive restriction 
enzyme sequencing (MRE-seq), where genomic DNA samples are digested with restriction 
enzymes and the subsequent DNA fragments are size selected and sequenced. Differential 
DNA methylation may be identified by comparison of the fragments. In a similar manner, Li 
et al., (2009) developed a method called Modified Methylation Specific Digital Karyotyping 
(MMSDK)133,134. Here, methylated DNA is mapped with a methylation specific enzyme, and 
29 
 
 
oligonucleotide linkers are ligated to either side of the fragments, incorporating Illumina NGS 
adaptors into their sequences. This method allows high-throughput and low-cost genome-wide 
DNA methylation mapping with multiple samples.  
The MMSDK process, outlined in Figure 1.6, involves the tandem digestion of genomic DNA 
with a methylation sensitive restriction enzyme (AscI) and a frequent cutting fragmenting 
enzyme (NlaIII)133. The ligation of a biotinylated oligonucleotide linker to the overhangs 
generated by AscI allows for the separation of fragments flanked by two NlaIII sites from 
those with one AscI site and one NlaIII site. The latter are retained via streptavidin-bound 
magnetic beads, and ligated to a second oligonucleotide which contains a restriction site for 
the enzyme MmeI at its 5’ end. The enzyme MmeI recognises this sequence, and cuts 16-18bp 
into the downstream unknown genomic DNA. A final linker is ligated to the overhang 
generated by MmeI, resulting in the flanking of an unknown 16-18bp genomic sequence by 
two Illumina NGS adapters. Since AscI does not cut methylated fragments, the library 
obtained from these reactions represents areas adjacent to unmethylated AscI sites throughout 
the genome. By aligning these sequences back to a reference genome, an accurate map of CpG 
methylation can be obtained.  
1.7.3: Methylated DNA Immunoprecipitation 
The use of antibodies raised against 5’methylcytosine as an agent to discriminate between 
methylated and unmethylated DNA was first discussed in 1985135. Building on this work, 
Oakeley et al. (1997)136 devised an efficient method to study global changes in DNA 
methylation during tobacco pollen maturation with confocal microscopy and secondary 
antibodies bound to fluorescent isothiocyanate. Later, the dynamic epigenetic reprogramming 
associated with mammalian embryonic development was uncovered using a similar 
immunofluorescence-based technique137. However it would take several more years until 
DNA microarray and next generation sequencing technology would advance to a stage where  
methylated DNA could be immunoprecipitated and scrutinised at a single base-pair 
resolution14.  
Methylated DNA Immunoprecipitation (MeDIP) is a protocol that requires genomic DNA to 
be sheared and denatured prior to enrichment with anti-methylcytosine (Figure 1.7)138. This 
can be achieved through sonication or by digestion with a restriction endonuclease.  
1.7.4: Gene-specific DNA Methylation analysis  
As described previously, there are three main strategies for analysing DNA methylation at a 
gene-specific and genome-wide context: digestion with methylation-specific restriction 
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endonucleases, immunoprecipitation with anti-5’methylcytosine, and treatment with sodium 
bisulfite5. The use of methylation-specific restriction endonucleases and anti-
5’methylcytosine allow indirect analysis of DNA methylation patterns, though both lack the 
capacity to generate a significant amount of data at single-base resolution. The third approach, 
adapted here for high-throughput gene-specific analysis, achieves just this.  
It was first found in 1970 that treating DNA with sodium bisulfite deaminates cytosine 
residues to uracil129. Later, it was discovered that the same reaction, when applied to 
methylated cytosine, takes place at a much slower rate139. Frommer et al., (1992)140 exploited 
this property in a classic paper to demonstrate that sodium bisulfite treatment can be used in 
conjunction with PCR to change all unmethylated cytosines to thymidine, while all methylated 
cytosines deaminate to unmethylated cytosines. Although this method was used to establish a 
genome-sequencing based protocol at the time, sodium bisulfite treatment of DNA has now 
been applied to conventional genotyping techniques for gene-specific DNA methylation 
analysis5.  
For example, in Methylation-Sensitive Single Nucleotide Primer Extension (MS-SNuPE)141, 
a target sequence is treated with sodium bisulfite and amplified with conventional PCR. The 
product is separated and isolated via electrophoresis, and two SNuPE primers are annealed to 
the amplified fragment. These primers are designed to lie immediately upstream of the 
targeted nucleotide. From here, 32P-dCTP or 32P-TTP are incorporated into an amplified 
fragment of sodium bisulfite treated DNA, and the particular nucleotide incorporated can be 
visualised using autoradiographic film or phosphorimage quantitation. In a methylated target 
cytosine, the nucleotide would not undergo bisulfite conversion, and 32P-dCTP would be 
incorporated. In the case that the target cytosine is unmethylated, it would be converted to 
thymidine, and the incorporation of 32P-TTP would be observed at that locus. 
Based on a well-known PCR method for resolving single-base restriction fragment length 
polymorphisms142, Methylation-Sensitive Single-Strand Conformation Analysis (MS-SSCA) 
is another a technique used to screen and analyse DNA methylation in a gene-specific 
manner143. Genomic DNA is bisulfite treated and the gene of interest is amplified with PCR. 
The methylation differences, manifesting as a sequence change within the PCR product, can 
be discerned by digestion with a restriction enzyme. The digestion patterns of samples are 
compared to a methylation standard and variations in pattern imply changes in DNA 
methylation. Methylation differences are characterized using a gel stabbing technique and 
sequencing144.  
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Similarly to MS-SSCA, Methylation Specific PCR utilises PCR primers specific to a 
methylated, sodium bisulfite template145. Although incredibly sensitive, this method leaves no 
means to identify false positives following amplification – a common occurrence due to the 
decreased sequence complexity of sodium bisulfite treated DNA. In order to combat these 
pitfalls, MSP has been adapted for Sensitive Melting after Real Time Methylation Specific 
PCR (SMART-MSP)146. By carrying out a high-resolution melting analysis on the amplified 
PCR product, false positives obtained from non-specific amplification or incomplete bisulfite 
conversion can be eliminated based on the temperature of the melted PCR product. 
SMART-MSP was selected as our method for gene-specific DNA methylation analysis. The 
FASSTT samples require a reliable and high-throughput DNA methylation analysis; 
something that only SMART-MSP can provide with the resources accessible to us. This 
method can also be adapted to use on the Roche Lightcycler 480TM platform available in our 
laboratory.  
Although SMART-MSP does not yield the specific methylation tags on a particular locus at a 
single-base pair resolution like MS-SSCA and MSNuPE, it can be scaled easily for multiple 
samples on 96-well plates once the PCR assay has been optimised, making it a cheaper, 
efficient alternative to the other methods described here. The current ‘gold-standard’ method 
for DNA methylation analysis is Pyrosequencing following sodium bisulfite treatment5,147, but 
this platform was not available to us.  
1.8: Aims and Objectives 
Hypothesis 
Folic acid supplementation during pregnancy affects the methylation status of specific regions 
of the genome known as Folate Sensitive Differentially Methylated Regions (FS-DMRs). In 
folate-mediated one carbon metabolism, DHFR is controlled by competing post-translational 
modifications. 
Aim 
To identify differentially methylated regions of the genome which change their methylation 
status in response to folic acid supplementation, and to examine the potential of DHFR to 
acquire post-translational modifications. 
Objectives  
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 To conduct a review of the literature and determine what the most suitable methods 
of gene-specific and genome-wide DNA methylation analysis are, taking into 
consideration cost, efficiency, coverage, bias, specificity, and scalability.  
 To carry out genome-wide DNA methylation analysis on a subset of FASSTT samples 
to generate a short-list of candidate FS-DMRs. 
 To validate these FS-DMRs in the entire cohort using gene-specific DNA methylation 
analysis. 
 To examine the effect of altered DNA methylation patterns of these DMRs on gene 
expression in a cell culture model. 
 To produce recombinant GST-tagged DHFR and examine its susceptibility for post-
translational modifications in vitro.  
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Figure 1.1: FASSTT Study Overview 
All women were recruited at the beginning of their second trimester, after the known beneficial 
effects of folic acid have taken place. Those in the intervention group continued to take 400µg 
of folic acid daily, while those in the placebo group received a placebo. A total of 3 blood 
samples from each woman were taken during the FASSTT study. One before intervention, 
one after 36 weeks of pregnancy, and one more from the umbilical cord upon delivery. Out of 
119 total participants, 59 were recruited for the intervention group and 60 for the placebo. 
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Figure 1.2: Folate mediated one-carbon metabolism 
Taken from Tibbets and Appling, (2010)7. Folate mediated one carbon metabolism is 
compartmentalised between the nucleus, cytoplasm, and mitochondria. Dietary folate is 
reduced by DHFR and incorporated into either the DNA cycle, producing purines and 
thymidylate (dTMP), or the methylation cycle, producing S-adenosylmethionine (AdoMet).  
Figure legend: Red, end products; Blue, one-carbon donors; Green, activated one-carbon 
units; MTHFD1, methylenetetrahydrofolate dehydrogenase 1; MTHFD2, 
methylenetetrahydrofolate dehydrogenase 2; MTHFDL1, methylenetetrahydrofolate 
dehydrogenase 1-like; SHMT, serine hydroxymethyltransferase; GSC, glycine cleavage 
system; MTHFR, 5,10-methylene-THF reductase; MS, methionine synthase; DMGD, 
dimethylglycine dehydrogenase; SD, sarcosine dehydrogenase; TS, thymidylate synthase; 
FDS, 10-formyl-THF. MTFMT, methionyl-tRNA formyltransferase; DHFR, dihydrofolate 
reductase; BHMT, betaine-homocysteine methyltransferase. 
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Figure 1.3: Stages of Neural Tube Defect Development 
Cross-sections of the rostal end of the embryo before the neural tube has closed (A), and at 
the centre of the embryo after neurulation is complete (B). Two types of NTDs are depicted 
relative to where the neural tube fails to close along a dorsal view of the embryo (C). 
Anencephaly, inencephaly, and encephalocele are cranial defects, while both open and closed 
spina bifida are caudal defects. Cranioarchischisis is the most severe NTD, characterised by 
both cranial and caudal defects in neural tube formation. Image taken from Botto et al., 
(1999)10. 
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Figure 1.4: Passive and Active DNA Demethylation 
The enzyme Tet1 mediates the oxidation of 5’methylcytosine (5mC) to 
5’hydroxymethylcytosine (5hmC). With maintenance DNA methyltransferase unable to bind 
5hmC, successive replication cycles may dilute this epigenetic mark, leading to the 
incorporation of unmethylated cytosine (C) in its place (passive demethylation). 5hmC may 
also be further oxidated to 5’formylcytosine (5fC) and 5’carboxycytosine (5caC). Although 
passive methylation through replication may occur with these molecules too, they can also be 
removed by the DNA glycosylase Tdg. The abasic site left by this reaction can be replaced by 
cytosine through base-excision repair (BER). Another model has proposed that 5hmC may be 
modified by the deaminase enzymes Aid/Abobec to generate 5’hydroxymethyluracil. This in 
turn can also be excised by the DNA glycosylases Tgd or Smug1. Both pathways involving 
BER constitute active demethylation. Image taken from Piccolo et al., 201484.  
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Figure 1.5: Maternal methyl donor supplementation impacts on IAP methylation 
Five isogenic mice with varying coat colour as a result of maternal supplementation with 
methyl donors such as betaine, choline, and folic acid. This dietary intervention affects the 
methylation status of the Intracisternal A Particle transposable element, which regulates the 
agouti gene. All animals have identical agouti genotypes, but markedly different phenotypes. 
Image taken from Waterland and Jirtle, 2003109. 
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Figure 1.6:  Modified Methylation-Specific Digital Karyotyping (MMSDK)  
The MMSDK process uses three tandem enzyme digestion and linker ligation steps to generate 
a methylation-specific genomic library for next generation sequencing. The ligation of 
biotinylated oligonucleotide linkers to overhangs generated by AscI digestion allows for the 
separation of fragments flanked by two NlaIII sites from those with one AscI site and one 
NlaIII site. The latter are retained via streptavidin-bound magnetic beads, and ligated to a 
second oligonucleotide which contains a restriction site for the enzyme MmeI at its 5’ end. 
The enzyme MmeI recognises this sequence, and cuts 16-18bp into the downstream unknown 
genomic DNA. A final linker is ligated to the overhang generated by MmeI, resulting in the 
flanking of an unknown 16-18bp genomic sequence by two Illumina NGS adapters. Since 
AscI does not cut methylated fragments, the library obtained from these reactions represents 
areas adjacent to unmethylated AscI sites throughout the genome. Figure taken from Li et al., 
2009133.  
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Figure 1.7: Methylated DNA Immunoprecipitation 
Taken from Mohn et al., (2009)138. Genomic DNA is sheared prior to immunoprecipitation 
with anti-methylcytosine bound to magnetic beads. An Input fraction is also prepared in the 
same manner, with immunoprecipitation omitted. Both the Methylated and Input fractions can 
be compared using qPCR or traditional PCR and agarose electrophoresis. Differentially 
labelling both fractions with Cy3 and Cy5 and hybridising to an oligonucleotide microarray 
can create a complete picture of DNA methylation on a genome-wide or promoter-specific 
scale, depending on the platform used.  
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Table 1.1: Clinical and Biochemical data from FASSTT cohort, taken from McNulty et 
al., 20134 
Placebo group (n = 60)Treatment group (n = 59)P
General characteristics
 Age (y) 28.0 ± 4.3 29.2 ± 4.0 0.12
 Ethnicity (white) (%) 100 100 —
 BMI (kg/m) 24.3 ± 3.7 25.0 ± 5.0 0.39
 Smokers (%) 18.3 15.3 0.93
 Parity (n) 0.92 ± 1.06 0.98 ± 0.92 0.72
 Gestation at baseline (wk) 13.8 ± 2.2 14.0 ± 2.2 0.59
 Duration of folic acid supplement usage (wk)13.6 ± 9.6 11.9 ± 6.8 0.26
MTHFR 677C>T genotype (%)
 CC 36.7 45.8 —
 CT 45 44.1 —
 TT 18.3 10.2 0.37
Dietary intakes
 Energy (kcal/d) 1927 ± 475 1861 ± 361 0.46
 Total dietary folate (μg/d) 280 ± 110 298 ± 106 0.43
 Folic acid added to food (μg/d) 95 ± 78 112 ± 96 0.37
 Natural food folate (μg/d) 185 ± 57 186 ± 46 0.89
 Vitamin B-12 (μg/d) 4.1 ± 1.9 3.9 ± 1.8 0.69
B vitamin status
 Plasma homocysteine (μmol/L) 6.6 ± 2.4 6.3 ± 1.5 0.29
 Serum folate (nmol/L) 45.7 ± 21.3 47.0 ± 21.0 0.74
 Red blood cell folate (nmol/L) 1106 ± 746 1203 ± 639 0.45
 Serum vitamin B-12 (pmol/L) 211 ± 82 235 ± 94 0.13
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Table 1.2: Overview of whole-genome methods of DNA methylation analysis 
Method Platform Genomic Coverage Notes 
Bisulfite 
Sequencing123 
NGS Whole Genome Single-base pair resolution, 
full coverage. Considered to 
be the ‘gold standard’ 
technique. 
MeDIP-Seq124 NGS Enriched Methylated DNA Genome-wide analysis 
lacking single-base-pair 
resolution 
Anti-5mC 
MBDiGS125 
NGS Enriched Methylated DNA Genome-wide analysis 
lacking single-base-pair 
resolution 
MRE-Seq125 NGS Size selected fraction Low coverage, but capable 
of finding novel DMRs 
MMSDK133 NGS Representative genome tags  Low coverage, but capable 
of finding novel DMRs 
MRE133 CGI microarray CG islands  High coverage, but limited 
to array 
MeDIP133 SMRT array Whole Genome (low resolution) High coverage, but limited 
to array 
MeDIP133 Promoter Array All biologically relevant promoters High coverage, but limited 
to array 
Sodium Bisulfite 
Treatment133 
Illumina beadchip Whole genome (high resolution) Similar to Bisulfite 
Sequencing. High resolution 
coverage across genome. 
NGS: Next Generation Sequencing, MeDIP: Methylated DNA Immunoprecipitation, MBDiGS: Methyl-binding domain isolated genome 
sequencing, MRE: Methylation-sensitive Restriction Endonucleases, CGI: CpG Island, SMRT, Submegabase resolution tiling array 
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Materials and 
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2.1 Materials 
2.1.1 Biological Materials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Abcam: Rabbit polyclonal antibody to dihydrofolate reductase, (Cat. no. ab85056); Rabbit 
polyclonal antibody to GST, (Cat. no. ab19256); Mouse monoclonal antibody [33D3] to 5-
Methylcytosine ChIP Grade, (Cat. no. ab10805). 
ATCC: HEK293 cell line, (Cat. no. CRL-1573). 
Bioline: Alpha Gold Standard cells [Genotype: F- deoR endA1 recA1 relA1 gyrA96 hsdR17(rk 
-, mk +) supE44 thi-1 phoA Δ(lacZYA argF)U169 Φ80lacZΔM15λ], (Cat. no. Bio-85027); 
BioScript, (Cat. no. Bio-27036); Human Genomic DNA, (Cat. no. Bio-35025); Isolate II RNA 
Extraction kit, (Cat. no. Bio-52072); ISOLATE Plasmid Mini Kit, (Cat. no. Bio-52026); 
ISOLATE RNA Mini Kit, (Cat. no. Bio-52043); MyTaq DNA Polymerase 2500 Units, (Cat. 
no. Bio-21106); Oligo dT, (Cat. no. Bio-38029); Random Hexamers, (Cat. no. Bio-38028); 
SensiFast ROX Step Kit, (Cat. no. Bio-76001); Velocity DNA polymerase, (Cat. no. Bio-
21099). 
Biosera: Foetal Bovine Serum (FBS), (Cat. no. S1900). 
Gibco: Dulbecco’s Modified Eagle Medium (DMEM) 1X, (Cat. No. 41965). 
Greiner Bio-One: 25cm2 flasks, (Cat. no. 690175CI); 75cm3 flasks, (Cat. no. 658175CI); Cell 
Scrapers, (Cat. no. 541070G); 24-well plate, (Cat. no. 662160).     
Invitrogen: Dynabeads M-280 Sheep Anti-Mouse IgG, (Cat. no. 112-01D); Dynabeads M-280 
Streptavidin, (Cat. no. 112-05D); T4 DNA Ligase HC, (Cat. no. 15224-041); TA Cloning Kit, 
(Cat. no. k202020); UltraPure Phenol:Chloroform:Isoamyl Alcohol (PC8) (25:24:1, v/v), 
(Cat. no. 15593-03).   
New England Biolabs:  100bp Ladder, (Cat. no. N3231S); AscI with 10x NEBuffer 4, (Cat. 
no. R0558); BL21(DE3) Competent Cells [Genotype: fhuA2 [lon] ompT gal (λ DE3) [dcm] 
∆hsdS λ DE3= λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5], (Cat. no. 
C2527H); Mlul with 10x NEBuffer 3, (Cat. no. R0198); MmeI with 10x NEBuffer 4 & 32mM 
SAM, (Cat. no. R0637); MseI with 10x NEBuffer 4 & 100x BSA, (Cat. no. R0525S); NlaIII 
with 10x NEBuffer 4 & 100x BSA, (Cat. no. R0125); SOC Outgrowth Medium, (Cat. no. 
B9020S). 
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Promega: CellTiter 96 AQueous One Solution Cell Proliferation Assay (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; 
MTS), (Cat. no. G3581). 
Qiagen: EpiTect Fast Sodium Bisulfite Kit, (Cat. no. 59826); EpiTect PCR Control DNA Set, 
(Cat. no. 59695). MaXtract High Density Gel Column, (Cat. no. 129046); Qiaquick Gel 
Extraction Kit, (Cat. no. 28704); Qiagen Flexigene DNA kit, (Cat. no. 51204). 
Roche: Glycogen, (Cat. no. 901-393); Lightcycler 480 High Resolution Melting Master, (Cat. 
no. 04909631001); Proteinase K recombinant PCR grade solution, (Cat. no. 03115887001). 
Sigma: Acrylamide/Bis-acrylamide 30% Solution, 29:1, (Cat. no. A3574); Agarose, (Cat. no. 
A9539); Ammonium Acetate (7.5M), (Cat. no. A-2706); Carbenicillin disodium salt, (Cat. no. 
C1389); Dihydrofolate Reductase Assay Kit (Cat. no. CS0340); DL-Dithiothreitol, (Cat. no. 
D9779); DNase kit, (Cat. no. AMPD1); Ethanol, (Cat. no. E7023); Ethidium Bromide (Cat. 
no. E1385); Ethylenediaminetetraacetic acid, EDS; Formaldehyde (37%), (Cat. no. F-1268); 
Genomeplex Whole Genome Amplification kit, (Cat. no. WGA2); Glycerol, (Cat. no. G5516); 
Guanadine Hydrochloride, (Cat. no. G4505); Imprint DNA Modification Kit, (Cat. no. 
MOD50); L-Glutamine Solution, (Cat. no. 59202C); Magnesium Chloride, (Cat. no. M8787); 
N-lauroyl sarcosine, (Cat. no. L5125); Orange G, (Cat. no. O3756); PCR Buffer without 
Magnesium Chloride (10X), (Cat. no. P2317); Potassium Chloride, (Cat. no. P9541); 
Potassium Phosphate Dibasic, (Cat. no. P3786); Potassium Phosphate Monobasic, (Cat. no. 
P9791); Ribonuclease, (Cat. no. R4642); RNA Loading Buffer, (Cat. no. R1386); Sodium 
Pyruvate, (Cat. no. S8636); Taq Polymerase 5U/μl, (Cat. no. D4545); TEMED (Cat. no. 
T7024); Triethanolamine, (Cat. no. 90279); Tris, (Cat. no. T1503); Triton X, (Cat. no. X100); 
Trypan Blue, (Cat. no. T8154); Trypsin EDTA, (Cat. no. T4049). 
Thermo Scientific: 4-20% Precise Tris-Glycine gel, (Cat. no. 0025269); Acetic Acid Glacial, 
(Cat. no. A0360PB17); Filter paper; (Cat. no. 84783); Glutathione Agarose, (Cat. no. 16100); 
Glutathione Reduced, (Cat. no. BP25215); O'Range Ruler 10bp DNA ladder, (Cat. no. 
SM1313); Page Ruler Plus Pre-stained Protein Ladder, (Cat. no. 26619); Pierce 4-20% Tris-
Glycine Gel, (Cat. no. 0025269); Pierce Page Ruler Plus Pre-Stained Protein Ladder, (Cat. no. 
26619); Pierce Sugar-Signal West Femto Maximum Sensor, (Cat. no. 34096); PVC Film, (Cat. 
no. 88518). 
2.1.2: Stock Solutions and Reagents  
10x Digestion Buffer: 50mM Tris (pH 8.0), 10mM EDTA, 0.5% SDS 
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10x Immunoprecipitation Buffer: 100mM sodium phosphate (pH 7.0), 1.4M sodium chloride, 
0.5% Triton X100 
Bacteria Lysis Buffer: 50mM Potassium Phosphate, 400mM NaCl, 100mM KCl, 10% 
glycerol, 0.5% Triton X-100, 10mM Imidazole 
Coomassie Blue De-stain: 100ml Acetic Acid, 300ml Methanol, 600ml H20 
Coomassie Blue Stain: 2.5g Coomaisse, 100ml Acetic Acid, 300ml Methanol, 600ml H20 
Crush & Soak Elution Buffer: 0.5M ammonium acetate, 10mM magnesium acetate, 1mM 
EDTA (pH8.0), 0.1% SDS 
Lamelli Buffer (10X): 15.14g Tris-HCl, 5g 1% SDS, 71.3g Glycine, in 500ml dH2O  
LB Agar: 3.75g agar added to 250ml LB broth 
LB Broth: 250ml dH2O, 2.5g Butotrpytone, 2.5g NaCl, 1.25g yeast extract 
Low Tris Buffer (LoTE): 3mM tris-HCl pH 7.5, 0.2 mM EDTA, pH 7.5 
Methylated DNA Immunoprecipitation (MeDIP) Ethanol Precipitation Solution: 2 volumes of 
ice-cold ethanol (100%), 0.3M sodium acetate, and 2μl glycogen 
Modified Methylation Specific Digital Karyotyping (MMSDK) Ethanol Precipitation 
Solution: 2 volumes of ice-cold Ethanol (100%), 2.5M ammonium acetate, 2μl glycogen 
MMSDK Isopropanol Precipitation Solution: 0.75 volumes of isopropanol and 6.33M sodium 
perchlorate 
Orange G (10x): 20g Sucrose, 100mg Orange G in 50ml dH2O 
PBS-BSA (0.1%): 0.01g of BSA in 10ml of PBS 
Protein Purification GST Equilibration / Wash Buffer: 50mM Tris, 150mM NaCl, (pH 8.0) 
Protein Purification GST Elution Buffer: 50mM Tris, 150mM NaCl, 10mM Reduced 
Glutathione, (pH 8.0) 
Resolubilisation Buffer: 1mM EDTA (pH 8.0), 1.5% N-lauryl sarcosine, 25mM 
Triethanolamine. 
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Protein Unfolding Buffer: 20mM potassium phosphate buffer (pH 7.0), 0.1mM EDTA, 10mM 
DTT, 0.2M KCl, 6M guanidine HCl 
Protein Refolding Buffer: 20mM potassium phosphate buffer (pH 7.0), 0.1mM EDTA, 10mM 
DTT, 0.2M KCl, 20% Glycerol 
TBE (10x): 48.44g Tris-HCl, 12.37g, Boric Acid, 1.5g EDTA, in 500ml dH2O (pH 8.2) 
TBS (10x): 43.83g NaCl, 6.06g Tris, in 500ml dH2O (pH 8) 
TBST: 100ml TBS (10x), 900ml dH2O, 0.5ml Tween 
Wash Buffer D: 5 mM Tris, 0.5 mM EDTA, 1 M NaCl, 200 μg/ml BSA (pH 7.5) 
 
2.1.3 Oligonucleotide and primer sequence list  
Modified Methylation-Specific Digital Karyotyping*: 
Biotinylated Linker, 
Sense:  
5’Biotin-TTTGCAGAGGTTCGTAATCGAGTTGGGTGG 3’ 
Biotinylated Linker, 
Antisense:   
5’Phos-CGCGCCACCCAACTCGATTACGAACCTCTGC 3’ 
N-linker Sense:   5’ ACAGGTTCAGAGTTCTACAGTCCGACCATG 3’ 
N-linker Antisense:  5’ Phos-GTCGGACTGTAGAACTCTGAAC 3’ 
P7 Linker 
Sense:
  
5’ TCGTATGCCGTCTTCTGCTTG 3’ 
P7 Linker Anti-Sense:  5’ CAAGCAGAAGACGGCATACGANN 3’ 
P5 Long Primer:       5’AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA’3 
P7 Primer: 5’CAAGCAGAAGACGGCATACGA 3’ 
All sequences taken from Li et al., 2009 133 
Methylated DNA Immunoprecipitation: 
H19 Forward: 5’ GAGCCGCACCAGATCTTCAG 3’ 
H19 Reverse:  5’ TTGGTGGAACACACTGTGATCA 3’ 
H3b Forward:  5’ CCCACACTTCTTATGCGACA 3’ 
H3b Reverse:  5’ CTGTGCCTGGTTGCAGATTA 3’ 
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All sequences taken from Buckley et al., 2009148 
Sensitive Melting After Real Time Methylation-Specific PCR*: 
COL2A1 Forward   5’ GTAATGTTAGGAGTATTTTGTGGGTA 3’ 
COL2A1 Reverse  5’ CTACCCCAAAAAAACCCAATCCTA 3’ 
Chr9ORF44 Forward     5’ GGGATGTTTTTGAGAATGGCGG 3’                                                                                                                                                                                                                                                                                                                                                                                         
Chr9ORF44 Reverse 5’ ACCTCAAAACCCATCGTACTCT 3’ 
GPS2 Forward 5’ GTTAGGAGGTTTTTTAAGGGTAGC 3’ 
GPS2 Reverse 5’ TTTTTCTTATCTAACAAATTCCGAA 3’ 
IP6K1 Forward 5’ TGTTAGTAGGAAGTATTTTTTTTGGCG 3’ 
IP6K1 Reverse 5’ AACTACAAAAAACCCGCCCCCG 3’ 
RASA4 Forward 5’ TGTTTTTGTGGGTGGATTTCGG 3’ 
RASA4 Reverse 5’ GAAAATAAAAACCCCAACTTTCCG 3      
*All sequences designed using Methprime and Netprimer software, except for COL2A1 
Forward and Reverse. 
Reverse Transcriptase-Quantitative PCR 
IP6K1 Forward    5’ CAACAGTGGCTTGAGTTCTGA 3’ 
IPK1 Reverse 5’ TTCTCAAGCAGGAGGAACTTG 3’ 
RASA4 Forward 5’ CGTGGAGGGGAAGAACCT 3’ 
RASA4 Reverse  5’ TCCACCTTCACGATGCAGTA 3’ 
SURF1 Forward  5’ AACTCAGAGTGGGGCCTATG 3’ 
SURF 1 Reverse  5’ CCTGGGAACGAACCCTCTAT 3’ 
GPS2 Forward  5’ AGTCGGGCTTTGCAGCTA 3’ 
GPS2 Reverse       5’ GATGGTCACTTGTGGTAGAATCG 3’ 
All sequences designed using UPL design centre 
cDNA Genomic Contamination Assay 
MTHFDRQ Forward:  5’ CACTCCAGTGTTTGTCCATG 3’ 
MTHFDRQ Reverse 5’ GCATCTTGAGAGCCCTGA 3’ 
Primer sequences taken from Brody et al., 2002149. 
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2.2: Cell Culture Methods  
2.2.1: HEK293 Cell Culture  
Human Embryonic Kidney Cells 293 (HEK293) were cultured in GIBCO’s Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% (v/v) foetal bovine serum, 1% 
(v/v) L-glutamine (Sigma-Aldrich) and 1% (v/v) sodium pyruvate (Sigma-Aldrich). Cells 
were grown in a 5% CO2 incubator at 37oC in 10ml of media for 75cm2 flasks, 6ml of media 
in T25cm2 flasks, 500μl in 24-well plates, and 100μl in 96-well plates. Prior to each cell 
passage, the monolayer was rinsed with 2ml of Trypsin-EDTA (Sigma-Aldrich) before 
incubating with 3ml Trypsin-EDTA in 37oC for 10 minutes. Trypsin was inactivated with one 
volume of DMEM, and cells were centrifuged at 500 g for 5 minutes.  
2.2.2: HEK293 Cell Counts 
Cells were collected by centrifugation as described above (Section 2.2.1) prior to resuspension 
of the pellet in 6ml DMEM. A 1:6 dilution of cell-suspension was made in trypan blue (Sigma-
Aldrich) and left at room temperature for 5 minutes before loading into a haemocytometer. At 
100x magnification, viable cells were counted in four corners of the square grid. Average cell 
counts were calculated by multiplying the average across the four squares with the dilution 
factor and 104.  
2.2.3: HEK293 Cell Growth Curve 
Cells were counted as described above (Section 2.2.2) seeded at 1 x103, 2 x103, 4 x103, 8 x103, 
1.6 x104, 3.2 x104, 6.4 x104, 1 x105 cells per ml in a 96-well plate for 7 days (37oC, 0.5% CO2). 
Media was removed and 20μl MTS from Promega’s CellTiter 96 AQueous One Solution Cell 
Proliferation Assay kit was added to each well and incubated at 37oC for 3 hours. Absorbance 
readings were taken at A273nm on a Nanoquant Infinite M200 Tecan plate reader. 
2.2.4: Cytotoxicity assay of 5’Azacytidine for HEK293 Cells 
Using an optimal seeding density determined from a growth curve (Section 2.2.3), cells were 
grown in a 24-well plate with multiple concentrations of 5’azacytidine (5aC). Control wells 
were included on the plate containing no cells, cells below the optimal seeding density, and 
cells above the optimal seeding density. 5aC was prepared by making a 4mM solution in 1ml 
50% acetic acid:water. Concentrations of 5aC including 0.5μM, 3μM, 6μM, 12μM, and 25μM 
were made from this stock, diluting the 4mM 5aC in DMEM. The highest concentration of 
acetic acid – for 25μM 5aC – was made by diluting 62.5μl of the 4mM stock into 10ml 
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DMEM. Wells with cells growing in 62.5μl 50% acetic acid:water diluted into 10ml DMEM 
were also included to control for the effect of the maximum concentration of acetic acid on 
cell proliferation. Prior to crystal violet staining, cells were rinsed with 1x PBS and incubated 
with 500µl of 10% formalin for 10 minutes at room temperature. Formalin was removed and 
wells were dried before adding 500µl 0.25% crystal violet and incubating for 10 minutes at 
room temperature. The stain was eluted in 300µl 33% glacial acetic acid (Thermo Scientific) 
for 30 minutes at room temperature with gentle rocking. Eluted crystal violet stain was 
removed and added to a 96-well plate in 100µl triplicates and analysed on a Tecan plate reader 
at A620nm. 
2.3: Molecular Biological Laboratory Techniques  
2.3.1: Nucleic Acid Extraction from HEK293 Cells 
For RNA extraction, cells were centrifuged at 500 g for 5 minutes, then washed with 1x PBS. 
Cells were lysed using the Lysis Buffer RLY supplied by the Isolate II RNA Mini Kit 
(Bioline). The rest of the protocol adhered to the manufacturer’s instructions, with RNA eluted 
in 60μl RNase-free water. Although an on-column DNase I digestion step is included in the 
Isolate II RNA Mini Kit procedure, a second digestion was carried out using the DNase I Kit 
from Sigma-Aldrich. Briefly, 2μg of RNA was digested in 11μl reaction at room temperature 
for 15 minutes with 2 units of enzyme. The DNase I reaction was stopped using a Stop 
Solution supplied with the kit, incubated at 70oC for 10 minutes.  
DNA extraction was carried out using Qiagen’s Flexigene DNA kit. Cells were counted and 
2 x106 were used in the protocol outlined in the manufacturer’s instructions. Following this, 
samples were treated with Ribonuclease (Sigma-Aldrich) to remove any contaminating RNA. 
In a 200μl reaction, DNA was incubated for 1 hour at 37oC with 1 unit of enzyme. Residual 
enzyme was removed via isopropanol precipitation with 3M sodium acetate as described in 
Section 2.3.6. 
2.3.2 Non-denaturing Polyacrylamide Gel Electrophoresis 
The 12% PAGE gels for DNA analysis were made using 30% bis-acrylamide (Sigma-
Aldrich). With a total volume of 51.4ml, each gel contained 21.3ml bis-acrylamide, 6ml 
1xTBE, 25.7ml dH2O, 378μl 10% APS and 35μl TEMED (Sigma-Aldrich), added in that 
order. The gel was cast using glass plates and air-dried for over an hour as the gel polymerised. 
A GibcoBRL vertical electrophoresis rig (Model V15-17) with 1x TBE buffer was used to run 
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the gel for 90 minutes at 250 volts, with power supplied by an EC600-90 apparatus from 
Artisan Scientific. The gel was stained in an ethidium bromide bath of 1μg/ml for 30 minutes 
and visualised using a DNA Mini-Bis Pro Bio-imaging system.  
2.3.3: Agarose Gel Electrophoresis  
For a 1% agarose gels, 0.5g of agarose was dissolved in 50ml 1xTBE and heated in a 
microwave for one minute until the liquid began to boil. From here, the gel was cooled under 
a cold tap until it reached approximately 55oC and 1μl ethidium bromide (10mg/ml) was 
added. For each run, 5μl of DNA (typically ranging from 100ng/μl to 500ng/μl) was mixed 
with 2μl with Orange G (Section 2.1.2). DNA fragments were separated at 90 volts for 30 
minutes on a Watman Horizon S8 electrophoresis rig, with power supplied from an EC600-
90 apparatus from Artisan Scientific.  
2.3.4: SDS PAGE and Western Blot  
Prior to electrophoresis, a solution containing 18μl of protein extract and 6μl 4X NuPage LDS 
was denatured for 10 minutes at 99oC. On a 4-20% Precise Tris-Glycine gel (Thermo 
Scientific), 5μl Page Ruler Plus Pre-stained Protein Ladder (Thermo Scientific) and 24μl of 
the protein samples were added and run for 1 hour at 130 volts. Gels were stained overnight 
in coomassie blue, and de-stained with de-staining buffer at room temperature until the 
background colour was removed.  
Protein transfer was carried out using the Pierce G2 Fast Blotter following the manufacturer’s 
instructions. Briefly, gels were sandwiched with a sheet of PVC pre-deionised membrane 
(achieved by incubation for 30 seconds in methanol) between the cathode and anode, with 
four sheets of pre-wet filter paper separating gel and film from the electrodes. Transfer was 
carried out at 25V for 7 minutes. Once this was complete, the membrane was blocked with 
5% fat-free milk in TBST for 2 hours. The primary antibody was added to the membrane in 
5% fat-free milk (ratio variable depending on antibody used) and left to incubate overnight at 
4oC with gentle shaking. The film was washed three times with TBST for 10 minutes before 
adding the secondary anti-rabbit HRP-conjugated antibody at a ratio of 1:50,000 in TBST for 
1 hour at room temperature.  Membranes were washed three times again with TBST before 
imaging with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific) 
on a Gene Gnome SynGene Bio Imaging System. 
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2.3.5: Estimation of nucleic acid concentration 
Concentrations of both DNA and RNA were determined using a nanodrop ND-1000 
spectrophotometer from Mason Technology measuring at A260nm. For each sample, 1μl was 
used. Quality of nucleic acid was determined by measurement of the A260:280 ratios, with 
pure DNA falling between 1.8 and 2.   
2.3.6: Phenol Extraction and Precipitation of DNA 
This protocol used to extract and precipitate DNA was derived from Sambrook’s molecular 
cloning150. DNA was mixed with one volume of UltraPure Phenol:Chloroform:Isoamyl 
Alcohol and spun down at 19,000 g in a Qiagen Maxtract gel extraction-tube, separating the 
aqueous nucleic acid phase from the organic phase. The former, upper phase was removed 
mixed with one of the three precipitation mixes listed in Section 2.1.2, made up fresh each 
time. Incubated on ice for 30 minutes and spun at 19,000 g at 4oC for 30 minutes, the pellet 
produced was ready for resuspending in the appropriate solution after two washing steps with 
70% ethanol. The centrifuge used was a Hettich Mikro 200R Zentrifugen machine. 
2.3.7: TA Cloning and Transformation of Competent Cells   
MMSDK PCR products were ligated into PCR 2.1 plasmid in a 10μl ligation reaction with 
10x ligation buffer, 4.0 Weiss units of T4 ligase, and 50ng plasmid DNA. The concentration 
of PCR product used — in each case, 1.15ng — was determined by the calculation given in 
Invitrogen’s TA Cloning manual, taking into account the length of the PCR product (90bp) 
and the size of the empty vector (3,900bp). This ligation reaction took place overnight at 14ºC. 
Competent alpha-gold standard E. coli cells from Bioline were transformed with the pCR 2.1 
plasmid by heat shocking the cells as follows: For each 50μl vial of competent cells, 2μl of 
ligation was added and incubated on ice for 30 minutes. Immediately following this, the cells 
were incubated at 42oC for 30 seconds then briefly placed back on ice. These cells were then 
added to 250μl LB media with no antibiotics and incubated at 37oC for 1 hour while shaking. 
Each transformation was then spread onto LB plates containing ampicillin (100μg/ml in agar), 
X-gal (40μl of 40mg/ml) and IPTG (40μl of 100mM). After an overnight incubation, white 
colonies indicated positive recombinant clones and were analysed further and confirmed.  
Transformation of DHFR recombinant clones followed a similar transformation procedure as 
above, but OneShot BL21A1 cells were transformed with 100ng of the GST-tagged plasmid 
previously prepared by Dr. Mari Ozaki. Agar plates and overnight cultures contained both 
contained 50μg/ml of carbenicillin.  
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2.3.8: Recombinant Protein Production 
Once transformation was confirmed on carbenicillin plates, a single colony was removed and 
incubated in 120ml of carbenicillin broth (50μg/ml) overnight. Afterwards, a 1/20 dilution of 
the bacteria was made in LB broth with carbenicillin (50μg/ml) up to 2L. This was split into 
two 1L flasks (400ml in each) and six 500ml flasks (200ml each) and incubated at 37oC until 
the OD of each flask reached 0.4 at A600nm. At this point, the temperature was brought down 
to 30oC for 1 hour. All incubations involving broth were set to shake at 220 RPM. Cells were 
centrifuged at 4,000 g at 4oC for 5 minutes and the supernatant was removed. Pellets were 
weighed and stored at -20oC. 
2.3.9: Recombinant Protein Fractionation 
Pellets were thawed and lysed in bacterial lysis buffer at 8ml per 0.4g cells. A homogenous 
mixture was obtained by pipetting cells up and down and passing the fluid through a 27-gauge 
needle. Cells were then put through three freeze-thaw cycles in liquid nitrogen and a 42oC 
water-bath. Lysed cells were centrifuged at 4,000 g for 15 minutes at 4oC. Both the soluble 
and insoluble fractions were retained and stored at -20oC. 
2.3.10: Concentration of DHFR soluble fraction 
Protein lysates were concentrated using 30 kDa centrifugal filter unites (Millipore), spinning 
at 4,000 g for 1 hour at 4oC. These were then diluted 1 in 5 in bacterial lysis buffer and 
syringed-filtered through 0.45μM filters.  
2.3.11: Resolubilisation of DHFR insoluble fraction via Folding and Refolding 
To remove DHFR from the insoluble fraction, it was necessary to denature the enzyme with 
an Unfolding Buffer (20mM potassium phosphate buffer  (pH 7.0), 0.1mM EDTA, 10mM 
DTT, 0.2M KCl, 6M guanidine HCl), and return it to its active state with a Refolding Buffer 
(20mM potassium phosphate buffer (pH 7.0), 0.1mM EDTA, 10mM DTT, 0.2M KCl, 20% 
glycerol). Pellets were resuspended in 10ml of the former, and stirred slowly at 4oC for 1 hour. 
The protein was then added drop-wise to a 20 fold dilution of the Refolding Buffer. 
Aggregates began forming after storing samples overnight at 4oC. This method was carried 
out according to Sirawaraporn et al., (1993)151. 
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2.3.12: Resolubilisation of DHFR insoluble fraction via Resuspension with N-lauroyl-
sarcosine and triethanolamine 
Another method for resuspending the insoluble fraction of DHFR was taken from Molecular 
Probe’s product insert for their product, Glutathione Agarose Linked through Sulfur (G2879). 
Recommended by the manufactures of the GST system if the protein of interest was found in 
the insoluble fraction, this method involved a single resuspension step in a buffer containing 
1.5% N-lauroyl-sarcosine, 25mM triethanolamine, and 1mM EDTA (pH 8.0) and mixing for 
ten minutes before centrifugation for 10 minutes at 4oC.  
2.3.13: Gravity-Flow Column Purification of GST-tagged Protein 
Protein purification was carried out using Pierce Glutathione Agarose (Thermo Scientific). 
Prior to this, the column was washed with 1x PBS and packed with an appropriate volume 
glutathione beads. The storage buffer was drained slowly from the beads, reducing the volume 
inside the column by half. The column was then equilibrated with 10 volumes 
Equilibration/Wash Buffer (50mM Tris, 150mM NaCl, pH 8.0). The protein sample was put 
through the column twice, ensuring the resin remained wet and undisturbed. The beads were 
then washed with 10 volumes of Equilibration/Wash Buffer, until the absorbance the wash 
fraction reached baseline at A280nm. The targeted protein – tagged with GST – was then eluted 
with 2 volumes of Elution Buffer (50mM Tris, 150mM NaCl, and 10mM Reduced 
Glutathione, pH 8.0). Multiple fractions were taken at this point, and the absorbance at A280nm 
was tested. Protein purification manifested as a spike in absorbance in a particular fraction 
(usually the fourth of fifth). Purified fractions were pooled and concentrated as 
aforementioned, and analysed by SDS-PAGE and Western Blot analysis.     
2.3.14: Batch Purification of GST-tagged Protein 
For smaller batches of lysate, binding to the glutathione column was carried out in a 15ml 
tube. Tubes were centrifuged with 2ml of glutathione-beads inside to reduce the resin volume 
to 1ml. Washing and preparation of the column from this step forward was similar as above, 
with the beads washed with 10ml of Equilibration/Wash Buffer. Binding took place overnight 
shaking at 4oC. Afterwards, the resin was washed twice with the same volume of 
Equilibration/Wash Buffer. Elution was carried out multiple times with 1ml Elution Buffer. 
Absorbance was observed at A280nm with each elution, and analysed by SDS-PAGE and 
Western Blotting.   
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2.3.15: Bradford Protein Assay 
Bovine Serum Albumin standards from 0mg/ml to 1.25mg/ml were prepared in distilled water. 
On a 96-well plate, 5µl of each standard was added to 250µl Bradford reagent in triplicate. 
Samples were prepared in the same way, with the relevant background medium used as a 
blank. The plate was shaken for 30 seconds and incubated for 10 minutes at room temperature. 
Absorbance was read at A595nm on a Tecan plate-reader. 
2.3.16: DHFR Kit assay for enzyme activity  
Enzyme activity of DHFR was determined using Sigma-Aldrich’s Dihydrofolate Reductase 
Assay kit with minor changes to the manufacturer’s protocol. Each 500µl reaction was set up 
in a cuvette with the 1x Assay Buffer, DHFR enzyme (variable), 60µM NADPH, and 50µM 
DHF, added in that order. At a concentration of 0.044µg/µl, 500ng of DHFR was used in these 
reactions. Absorbance was measured on a bench-top Biochrom Libra S12 spectrophotometer 
at A340nm under a kinetic programme reading every 15 seconds for 2.5 minutes. Inhibition 
assays were carried out with 0.2µM methotrexate under the same conditions to ensure NADPH 
depletion was cause by DHFR activity alone.  
2.3.17: In vitro SUMOylation assay 
SUMOylation assays were carried out using the SUMO-1 link from Active Motif according 
to the manufacturer’s instructions. A total of seven reactions were carried out per experiment, 
with tubes blocked with 50ng/ml BSA (Sigma-Aldrich) for 1 hour at 37oC before starting.  
Each 20µl reaction contained 5x SUMOylation Buffer, 20x Protein Buffer, and 1µl each of 
E1 and E2 conjugating enzymes. To assess the SUMOylating capacity of the kit, supplied p53 
protein was used as a control, with the protein known to contain a SUMOylation site. As a 
negative control, a reaction containing no protein of interest was set up to control for self-
SUMOylation of the conjugating and activating enzyme complex. For each protein assessed, 
a second reaction containing a mutant SUMO1 protein was included — this is a protein 
incapable of being conjugated to the peptide of interest.  
Reactions were incubated at 30oC for 3 hours and stopped with 2X SDS-PAGE Loading 
Buffer (130mM Tris, pH 6.8%, 4% SDS, 0.02% Bromophenol blue, 20% glycerol, 100mM 
DTT). Samples were analysed via PAGE and Western blotting with supplied anti-SUMO and 
anti-p53 antibodies at ratios of 1:4000 and 1:5000 respectively. Probing with anti-DHFR, was 
carried out a ratio of 1:10,000. Anti-rabbit HRP conjugated secondary antibody was used at 
1:25,000.  
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2.3.18: Plasmid DNA Preparation from Bacterial Cells 
Using the ISOLATE plasmid mini-kit from Bioline, plasmids from transformed cells were 
extracted and analysed. Cells in the 15ml tubes were pelleted by spinning at 19,000 g for 1 
minute and as much supernatant as possible was removed. The pellet was resuspended in 
250μl resuspension buffer and mixed thoroughly. To this, 250μl lysis buffer was added and 
mixed by inversion. Then, 350μl neutralisation buffer was added to the sample and mixed 
carefully again by inversion. Afterwards, the samples were centrifuged for 10 minutes at full 
speed. This was all transferred to spin column P with a collection tube and centrifuged at full 
speed for 1 minute. The filtrate was discarded while the spin column was reused and washed 
with 500μl wash buffer AP with full speed spinning for 1 minute. Removing the filtrate, the 
same spin column was washed again with 700μl wash buffer BP and centrifuged at full speed 
for 1 minute. With the filtrate removed, the column was centrifuged at full speed for 2 minutes 
to remove any residual liquid. Finally, the column was placed into a fresh collection tube and 
the DNA was eluted with Elution Buffer by centrifugation for 1 minute. Isolated DNA was 
quantified via the ND-1000 nanodrop spectrophotometry from Mason Technology. 
2.3.19: Sodium Bisulfite Treatment of DNA 
For each Qiagen FAST DNA Bisulfite reaction, 1μg of DNA was used—whether obtained 
from the FASSTT (Folic Acid Supplementation during the Second and Third Trimester) 
cohort or from HEK293 cells. Following the manufacturer’s instructions, samples were eluted 
in 100μl H2O. Due to the nature of sodium bisulfite treated DNA, converted samples could 
not be quantified or qualified through agarose gel electrophoresis or through nanodropping. 
The COL2A1 SMART-MSP assay (Section 2.3.20) was used to confirm that converted DNA 
was obtained.  
2.3.20: Sensitive Melting After Real Time Methylation Specific PCR 
For each SMART-MSP assay, primers were designed to preferentially amplify methylated 
DNA that has been treated with sodium bisulfite. The COL2A1 assay, however, acted as a 
measure of the total amplifiable DNA in each sample. With primers containing no CpG sites 
in their sequence or in their product, all converted DNA — methylated or not — would be 
targeted. Primers were designed using MethPrime and NetPrimer, following the criteria listed 
by146. Secondary structure formation was kept to a minimum where possible.  A melting 
analysis was carried out after each qPCR run, which was used to determine if the targeted 
product did indeed amplify. Each 10μl reaction contained 25ng DNA, 1mM MgCl, and 5x 
HRM Master Mix from Roche. Primer concentrations and Tm values varied from assay to 
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assay (described in more detail in Chapter 5). All runs were carried out on 96-well plates 
designed to be used by the Roche Lightcycler 480TM Instrument.   
2.3.21: cDNA Synthesis of HEK293 extracted RNA 
For each reverse transcription reaction, 5.5μl of DNase-treated RNA was used—half of the 
11μl of the DNase I reaction outlined in Section 2.3.1. Following the manufacturer’s 
instructions for the Bioline SuperScript Kit, 5.5µl DNase-treated RNA (1µg) was transferred 
to a fresh 0.2µl tube containing a mix of 2µl random hexamers (50ng/µl) and 4µl oligo-DT 
(270ng/µl). After incubation for 70oC for 5 minutes, samples were cooled on ice and added to 
a reaction containing 4µl Reaction Buffer (5x), 1µl RiboSafe RNase inhibitor (40u/µl) 1µl 
Bioline Bioscript reverse transcriptase enzyme (200u/µl), 1µl dNTPs (10mM), and 1.5µl 
nuclease-free water. Samples were incubated under the following programme: 10 minutes, 
25oC; 60 minutes, 42 oC; and 15 minutes, 70 oC.  
2.3.22: Genomic DNA Contamination Test 
Although two DNase-treatment steps are included in the cDNA synthesis process, it was 
imperative to ensure that no genomic DNA was contaminating the RT qPCR reactions. A 
simple PCR assay was designed to flank an intron, generating a larger fragment for genomic 
DNA than for cDNA. The genomic region chosen, within the coding region of the MTHFD1 
gene, yielded a 232bp band for cDNA, and 330bp for genomic DNA. This difference can be 
easily visualised on an agarose gel. Only samples containing no contaminating DNA were 
brought forward to RT qPCR analysis. The 50μl PCR reaction containing 1x PCR buffer, 
0.3µM forward primer, 0.4µM reverse primer (sequences in Section 2.1.3), 0.2mM dNTPs, 
and 1.5mM MgCl was carried out using the following programme: 95oC for 3 minutes; 35 
cycles of 94oC for 30 seconds, 58oC for 1 minute, 72oC for 1 minute; and 72oC for 1 minute. 
2.3.23: Reverse Transcriptase-Quantitative PCR 
All RT qPCR reactions were carried out on the Roche 480 Lightcycler machine with assays 
designed by the Universal ProbeLibrary Design Centre. Each reaction contained a 1/10 
dilution of the supplied and recommended probe, 2x Probe Master, 2.5mM MgCl2, and 1μl 
cDNA produced from Section 2.3.21. 
2.3.24 Data Analysis and Statistics 
All data analysis was carried out using Microsoft Excel 2013. Macro and sub macro codes for 
DNA microarray analysis were written in Visual Basic 8 (more detail in Section 3.3). 
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Significance values in Chapter 4 were obtained using single-factor ANOVA analysis from 
Excel’s Analysis Toolpack add-in (Section 4.2.8). 
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Chapter 3:          
DNA Methylation Method 
Development and 
Identification of Folate 
Sensitive Differential 
Methylation Regions (FS-
DMRs) 
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3.1 Introduction 
3.1.1: The Human DNA Methylome 
Cytosine methylation is known to occur primarily at CpG sites in mammals: a dinucleotide 
typically underrepresented in their genomes. In general, about 60-80% of these CpGs are 
methylated152. A smaller fraction are located in dense regions called CpG islands (CGIs), and 
are classically associated with transcription start sites of housekeeping, developmental, or 
regulatory genes, and thus are mainly devoid of DNA methylation153.  
However, as technology improved and the field of epigenetics progressed, many cases have 
been found that violate this traditional model.  For example, half of all CGIs are known to 
occur outside annotated promoter regions154. These ‘orphan’ CGIs show similar epigenetic 
features to promoter CGIs, and are both intergenic and intragenic in mammalian 
genomes154,155. At the same time, some tissue-specific and cancer-related differentially 
methylated regions have been found to occur more frequently in CGI ‘shores’ – regions 
flanking CGIs with relatively low CpG levels156,157. Recently, gene-body methylation has been 
associated with increased levels of expression in many tissue and cell-types; something that 
was once thought to be restricted to specific cases such as the active X-linked human 
chromosome and the genome of Aradopsis thaliana158–160.  
The role of DNA methylation at a tissue-specific and disease-specific context still remains 
elusive. With variations in DNA methylation appearing between different cells, tissues, and 
individuals, mapping all of these changes is proving to be a significant challenge. Still, 
building on a collective understanding of DNA methylation distribution, projects like 
“DiseaseMeth” and “mPod” are striving towards the identification of how aberrant 
methylation changes can have such a negative impact on a healthy individual, all while 
shedding light on the nature of DNA methylation itself161,162.   
There is still much to be learned, even outside the context of DNA methylation distribution in 
disease. In a review published by this research group, nutrient sensitive differentially 
methylated regions were identified from the literature, several of which were observed in 
response to folic acid supplementation in humans3.  
Using a genome-wide method of DNA methylation analysis, the work presented here will 
expand on this list by examining regions that alter their methylation status in response to folic 
acid supplementation in pregnant women.  
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3.1.2: Selection of a genome-wide method of DNA methylation analysis  
The first step of the project was to select a method for genome-wide methylation analysis of 
the FASSTT samples (Folic Acid Supplementation during the Second and Third Trimester), 
described in Section 1.2.2. It was imperative that the method selected would be of adequate 
efficiency and sensitivity with respect to the aims of the project. It was also essential that the 
method undergo vigorous testing in the laboratory before processing the FASSTT samples, 
due to the precious nature of the DNA. In 2011, we published a review in Frontiers in Genetics 
outlining the major differences between various strategies of DNA methylation analysis in a 
historical context5. This was used as a framework for selecting the appropriate protocol 
Various methods of genome-wide DNA methylation analysis have been discussed in Section 
1.7. Two that were considered for our initial analysis were modified methylation-specific 
digital karyotyping (MMSDK) and methylated DNA immunoprecipitation (MeDIP).  
MMSDK uses methylation-specific restriction enzymes to differentiate between unmethylated 
and methylated DNA, with the regions themselves being identified using Next Generation 
Sequencing. On the other hand, MeDIP uses antibodies raised against 5’methylcystosine to 
precipitate methylated DNA, which is then hybridised to a promoter microarray to measure 
enrichment levels across the genome. MeDIP will not yield single-base-pair resolution data, 
as the hybridisation process will only be used to identify CGIs that have been enriched during 
precipitation. Although it could be argued that this shouldn’t be an issue – with CpG islands 
spanning hundreds of base-pairs co-methylated in human cells anyway163 – our analysis of the 
FASSTT cohort aims to find novel FS-DMRs; some of which may lie outside traditional CpG 
islands. As a result, MMSDK was given precedence over MeDIP as a method of genome-wide 
methylation analysis.  
Two pilot studies were carried out on MMSDK. First, it was found that this method was 
capable of generating a genomic library for lambda DNA. However, when this was scaled up 
for human genomic DNA, no products could be obtained. After extensive optimisation, 
MMSDK could not be applied to the FASSTT samples, and the second method, MeDIP, was 
considered instead.   
The MeDIP protocol requires genomic DNA to be sheared and denatured prior to enrichment 
with anti-methylcytosine138. Although many protocols use sonication for the former, we used 
the restriction enzyme MseI to generate fragments of DNA between 200bp to 1000bp in size. 
This approach was favoured over sonication as the restriction digestion approach does not 
require excessive optimisation and testing to achieve the desired outcome. Also, with MseI 
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digestion being specific to a particular sequence motif, the sizes and contexts of fragments 
generated could be determined ahead of time. 
Following immunoprecipitation, quality control analysis was carried out after enrichment to 
demonstrate that MeDIP successfully separated methylated DNA from unmethylated DNA. 
This analysis demonstrated that MeDIP had successfully enriched for methylated DNA from 
the FASSTT cohort – something that could not be achieved from MMSDK. As a result, 
MeDIP was chosen for the genome-wide methylation analysis.  
MeDIP DNA was hybridised on a Nimblegen Delux 2.1M Promoter Array and compared 
against “Input DNA” – DNA prepared in the same manner as the MeDIP samples, but without 
immunoprecipitation.  
Based on the selection criteria outlined in Section 3.2.10, DNA from 6 participants who 
exhibited a typical response to folic acid supplementation based on circulating folate levels 
were precipitated through MeDIP and hybridised to a DNA microarray covering every 
biologically relevant promoter region of the human genome known at the time of the 
experiment. The vast amount of data received from this analysis provided a significant 
challenge in the data analysis outlined in Section 3.3. Once potential FS-DMRs are identified, 
they’ll be analysed further in a gene-specific context, as described in Figure 3.1.  
3.1.3: Aims and Objectives   
Aim:  
To carry out an assessment of the feasibility of applying the genome-wide DNA methylation 
analysis methods MMSDK and MeDIP to the FASSTT cohort (n=119). Following this, the 
most suitable method will be used to find potential FS-DMRs from a subset of the FASSTT 
cohort (n = 6).  
Objectives: 
 To carry out a pilot study on lambda DNA using MMSDK to see if it is capable of 
generating a genomic library at a small scale. 
 To carry out a second pilot study on human genomic DNA using MMSDK to see if it 
is capable of generating a genomic library at a larger scale. 
 To assess the precipitation of methylated DNA via MeDIP using qPCR. 
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 To carry out a genome-wide method of DNA methylation analysis (MMSDK or 
MeDIP) on suitable subset of the FASSTT cohort (n=6), selected to represent a typical 
response to folic acid supplementation based on serum and red-cell folate levels. 
3.2: Methods 
3.2.1: The FASSTT Study 
In an intervention study carried out by the University of Ulster, 119 pregnant women were 
recruited and given either a folic acid supplement or a placebo during their second and third 
trimesters. The study, called Folic Acid Supplementation during the Second and Third 
Trimester (FASSTT), aimed to analyse the effect of folic acid supplementation on circulating 
folate and homocysteine levels in mother and child without interfering with the beneficial 
effects of supplementation in the first trimester4.  
Blood samples were taken from women before intervention, after 36 weeks gestation, and 
from the umbilical cord of the child upon delivery (Chapter 1, Figure 1.1). From these samples, 
plasma homocysteine, serum folate, and red-cell folate levels were determined using 
immunological and microbiological assays, carried out by Dr. Breige McNulty in the 
University of Ulster. DNA was extracted from the buffy coats of the blood in our laboratory 
by Dr. Mari Ozaki using the Flexigene DNA extraction kit (Qiagen).  
3.2.2: Annealing of MMSDK Ligation linkers 
The MMSDK protocol requires double-stranded ligation linkers. Individual strands were 
synthesised by Integrated DNA Technologies [http://eu.idtdna.com/site] and annealed via 
incubation at 95oC for 5 minutes on an Applied Biosystems GeneAmp PCR 9700 thermal 
cycler. The samples were cooled slowly to room temperature with the following incubations: 
65oC for 20 minutes, 37oC for 20 minutes, and 25oC for 20 minutes. Linkers were stored at -
20oC once annealed. 
3.2.3: Modified methylation specific digital karyotyping 
The MMSDK process involves three restriction enzyme digestions and three linker ligation 
steps133,134. In the first reaction, 5μg of DNA (lambda or human) was digested with 120 units 
of AscI and 1x NEB buffer in a 200μl reaction containing LoTE for 90 minutes at 37oC.  
Afterwards, the reaction was placed in a Maxtract gel tube (Qiagen) with 200μl UltraPure 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and centrifuged for 5 minutes. The 200μl 
64 
 
 
nucleic acid phase (top) was extracted and ethanol precipitated as described in Section 2.3.6, 
and the pellet was resuspended in 5μl LoTE. Overnight, 2.5μl of 1μM annealed biotinylated 
linker was ligated to the AscI fragments with 5 units of T4 DNA ligase and the supplied ligase 
buffer in a 12μl reaction. Before adding the enzyme, the reaction was heated to 50oC for 2 
minutes and cooled to room temperature for 10 minutes. Ligation took place overnight at 16oC. 
Afterwards, 188μl LoTE was added to the ligation reaction, followed by phenol extraction and 
isopropanol precipitation (Section 2.3.6). The pellet was then resuspended in 172μl LoTE. A 
200μl NlaIII digestion was carried out for 1 hour at 37oC containing 1x NEB buffer 4, 1x BSA 
and 60 units of NlaIII. Before binding the NlaIII fragments to streptavidin Dynabeads, the 
beads were isolated from suspension using a magnetic stand. The isolated beads were washed 
with 400μl Wash Buffer D. The 200μl NlaIII digest was added directly to the beads and made 
up to a further 600μl with more Wash Buffer D. The beads and DNA fragments were incubated 
at room temperature for 20 minutes with gentle mixing to ensure that the mixture remained 
homogenous. After this binding step, the beads were washed with 600μl wash buffer D three 
times, and once with 300μl 1x ligation buffer. Next, 2.5μl of 2μM Annealed N-linkers were 
ligated directly onto the DNA-bound beads at 16oC overnight with gentle mixing. This 
reaction was 40μl in volume made up with LoTE and 1x ligation buffer. As before, the mix 
was incubated at 50oC for 2 minutes and cooled to room temperature for 10 minutes before 
adding the enzyme, in this case 12.5 units. Afterwards, the beads were washed three times 
with 600μl wash buffer D and transferred into another tube. Here, they were washed once 
more with 600μl wash buffer D and 200μl 1x NEBuffer 4. Tags were then released from the 
streptavidin Dynabeads through MmeI digestion. This was a 150μl reaction with 30 units of 
enzyme, 15μl of 500μM SAM (S-adenosylmethionine) and 10x NEBuffer 4 in LoTE. The 
tube was incubated for 1 hour and 10 minutes with gentle mixing at 37oC. Samples were 
centrifuged for 2 minutes at full speed and made up to 300μl with LoTE. This was added to a 
pre-spun Maxtract tube as before with 300μl Phenol:Chloroform:Isoamyl and then centrifuged 
for 5 minutes (full speed) at room temperature. A final ethanol precipitation step was carried 
out, similarly to before, but at 2ml total volume. This contained 300μl of the tags, 4μl 
glycogen, 200μl 7.5M ammonium acetate and 1.5ml 100% pre-chilled 100% ethanol. The 
pellet was resuspended in 12μl LoTE. The final ligation step had the same conditions as the 
previous reactions, with 0.13µM linker P7. A reaction without the ligase enzyme was included 
to control for downstream amplification of templates without P7 linkers.  
3.2.4: PCR amplification of MMSDK products 
Once obtained, the MMSDK final product from lambda DNA was amplified using the MyTaq 
polymerase from Bioline and 1μM each of P5 and P7 primers (Section 2.1.3)133. The reaction 
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was as follows: 98oC for 30 seconds; 25 cycles of 98oC for 10 seconds, 60oC for 30 seconds, 
75oC for 15 seconds; 75oC for 10 minutes and cooling at 4oC. Products were run on a 12% 
PAGE gel, with an expected product size of 88bp. For human genomic DNA, Velocity 
polymerase was used in a 50µl reaction containing 1mM dNTPs, 1μM of each P5 and P7 
primers, 3% DMSO, and 2 units of enzyme.  
3.2.5: DNA extraction form PAGE gel 
DNA from bands on PAGE gels were extracted using an adapted version of the Crush and 
Soak method described in Molecular Cloning by Sambrook et al., (1989)150. The bands were 
cut out using a sterile scalpel, transferred to micro-centrifuge tubes, and crushed using pipette 
tips. From here, two volumes of Crush and Soak elution buffer were added to the gel slices 
and incubated at 37oC while rotating for 3 hours. At 4oC, the gel extracts were centrifuged for 
1 minute, with the supernatant removed afterwards. From the Qiaquick Gel Extraction Kit 
from Qiagen, 3 volumes of Buffer QG were added to this supernatant. This was applied to 
QIAquick Spin columns in provided 2ml collection tubes and centrifuged for 60 seconds at 
room temperature at full speed. Discarding the flow-through, the columns were washed with 
750μl Buffer PE and centrifuged again for 60 seconds. After discarding this flow-through, the 
empty column was spun again at full speed to remove any residual ethanol from the tube 
(contained in buffer PE). DNA was eluted using 50μl of water and quantified using the 
nanodrop spectrophotometer (Section 2.3.5).  
3.2.6: Methylated DNA Immunoprecipitation  
For each DNA sample analysed, 2μg was sheared using the enzyme MseI in a 100μl reaction 
containing BSA and 10x NEBuffer 4 at 37oC for 1 hour. After this, the reaction volume was 
brought to 225μl using 1x TE Buffer. The samples were denatured at 95oC for 10 minutes in 
order to increase the affinity of the anti-5’methylcytosine antibody (Abcam) to the fragmented 
DNA. Before immunoprecipitation, 25μl of 10x IP Buffer was added to the samples. 
Overnight, 4μg of anti-5’methylcytosine was incubated at 4oC with the fragmented DNA. 
After immuno-capturing, the samples were enriched using a secondary antibody pre-bound to 
magnetic sheep anti-mouse Dynabeads (4×108 beads/ml, Invitrogen). The anti-mouse sheep 
monoclonal antibodies have an affinity to the mouse anti-5’methylcytosine, and the beads can 
be purified quickly and efficiently using a magnetic stand. Dynabeads were pre-blocked before 
this process with 800μl PBS-BSA (0.1%) by rotation for 5 minutes at room temperature and 
eluted in 20μl 1X IP buffer. This elution was added directly to the immuno-captured DNA, 
and incubated for 2 hours at room temperature while shaking. While methylated DNA was 
bound to the beads via an antibody-antibody complex, the beads were washed three times by 
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gentle shaking for 5 minutes at room temperature with 700μl 1x IP buffer to remove the 
unmethylated fragments. The beads were then suspended in 250μl digestion buffer and 
incubated at 95oC for 5 minutes. Following this, 315μg Proteinase K (Roche) was added and 
digestion occurred at 55oC overnight while rotating. The DNA was precipitated from here to 
remove residual proteins, including the proteinase K enzyme itself. In accordance to the 
manufacturer’s instructions, 50μl Phenol:Chloroform:Isoamyl Alcohol and 250μl of the 
sample and mixed in a Maxtract tube (Qiagen) and the organic phase was extracted. The 250μl 
of DNA removed from this was brought to 500μl with 0.2M NaCl. Finally, 2 volumes of ice-
cold ethanol and 3μl glycogen were added to the sample and precipitated at -20oC for 1-2 
hours. The DNA pellet was formed by spinning at 19,000 g for 30 minutes at 4oC, and this 
was washed twice with 70% ethanol with 15 minute spinning in between. The final DNA 
pellet was resuspended in 30μl of molecular grade H2O, and the final concentration was 
determined using the ND-100 nanodrop spectrophotometer (Mason).  
3.2.7: Whole genome-wide amplification of MeDIP DNA 
The precipitated DNA was then whole-genome-amplified using Sigma-Aldrich’s 
Genomeplex Whole Genome Amplification kit. As the DNA here has already been 
fragmented by the MseI enzyme, the shearing step in the manufacturer’s instructions was left 
out. The genomic library was prepared from a 1ng/μl solution of DNA by adding 2μl of 
Library Preparation Buffer and 1μl of Stabilisation Solution. The samples were vortexed and 
centrifuged before incubating at 95oC for 2 minutes. After cooling on ice, 1μl of Library 
Preparation Enzyme was added and the following reaction took place in the Applied 
Biosystems GeneAmp PCR 9700 thermal cycler: 16oC for 20 minutes, 24oC for 20 minutes, 
37oC for 20 minutes, 75oC for 20 minutes, and 4oC hold. Whole genome-wide amplification 
was carried out by adding the following solution to the 15μl library: 7.5μl of 10x Amplification 
Master Mix, 47.5μl dH2O, and 5μl WGA DNA polymerase. The PCR programme was as 
follows: 95oC for 3 minutes; 94oC for 15 seconds and 65oC for 5 minutes over 14 cycles. 
Amplified DNA was analysed on a 1% agarose gel, quantified on a nanodrop 
spectrophotometer and qualified using the qPCR assays described below.   
3.2.8: Quality Control Analysis of Immunoprecipitated DNA 
After the methylated fragments were precipitated, the quality of the assay was assessed. Two 
qPCR assays were carried out on the MeDIP DNA using primers directed at regions that are 
known to be methylated and unmethylated. The long non-coding RNA gene H19 was selected 
to represent the former, while the histone gene H3B was chosen to select for the latter148. Both 
assays were run on the following programme: 95oC 10 minutes; 95oC for 10 seconds, 56oC for 
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15 seconds, 72oC for 15 seconds for 45 cycles; and 40oC for 10 seconds. Primer concentrations 
were at 0.2µM per reaction 
For qPCR, DNA amplification is quantified as CP values: the number of cycles taken for 
fluorescence to reach a defined threshold. When comparing the CP levels of MeDIP against 
Input DNA, given that both samples will have the same concentration, positive enrichment of 
methylated DNA would manifest as a lower CP value in H19, and diminishment of the 
unmethylated portion manifest as an increase in CP values for H3B. 
Over the twelve FASSTT samples in each QC assay, a mean value was taken and compared 
to the CP of each Input. With the following formula, the mean CP value and the mean Input CP 
value were used to separately calculate the fold change for the assays: 
 Fold Change = 2 ^ (Input – FASSTT) 
DNA quality was assessed on a 1% agarose gel (Section 2.3.3).  A thick smear from 200 – 
1000bp in length is representative of successfully precipitated DNA.  
3.2.9: Nimblegen Microarray Analysis 
The following was carried out by Nimblegen: MeDIP samples were labelled using Cy5 
random nanomers, while Input DNA was labelled with Cy3 nanomers. Input and MeDIP 
fractions were mixed and hybridised to the array using a Precision Mixer Alignment Tool 
(PMAT). Each PMAT was washed and incubated at 42oC in a Roche Hybridisation system 
for 16 hours. All 12 samples were loaded into a NimbleGen MS 200 Microarray Scanner in 
one Slide Magazine. Image files were extracted and processed using DEVA software. 
Data was returned in the form of pair files, processed peak files, Signal Map GFF files, and 
promoter reports. The data analysis discussed here is based on the promoter reports, which 
contain annotated information for each peak, along with the log2 ratios for the corresponding 
probes. Raw data analysis on the peak-probe relationship is based on the Signal Map GFF 
files. 
3.2.10: Selection of samples for genome-wide analysis 
From the entire FASSTT cohort, 12 samples were selected from 6 women to reflect the most 
dramatic responses to intervention. As the variation of  DNA methylation between individuals 
is unknown (either caused by genetic diversity or environmental differences)164, the pre-
intervention samples of each of the 6 participants was paired with their respective post-
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intervention samples. MeDIP analysis was used to investigate the effect of intervention on 
DNA methylation for the same individuals first, reducing the amount of DNA methylation 
'noise' that is likely to exist between individuals. 
One limit of the FASSTT study itself is the fact that intervention occurred during the second 
trimester, after the known beneficial effects of folic acid supplementation have taken place. 
As it would have been highly unethical to recruit participants at the periconceptional stage of 
pregnancy, women from both groups who displayed low baseline levels of red cell and serum 
folate before intervention were considered for MeDIP analysis. Selection was also based on 
response to folic acid supplementation: those from the supplementation group who had high 
levels of red cell and serum folate after intervention were chosen, along with those from the 
placebo group who exhibited the typical decline in red cell and serum folate during pregnancy 
(Table 3.1). All women were taking folic acid before recruitment to this trial. The aim of this 
selection process was to find that would represent the entire cohort in terms of response to 
intervention. Although bias may be introduced as a result of this selection – ruling out women 
who may not have a dramatic response to folic acid – the purpose of our genome-wide analysis 
is not to find definitive FS-DMRs, but to find potential FS-DMRs for further examination in 
Chapter 4. This selection process was carried out in consultation with Dr. Kristina Pentieva in 
the University of Ulster, Coleraine.  
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3.3: DNA Microarray Data Analysis 
3.3.1: Introduction 
DNA Microarray data was received in several raw and processed file formats, including Excel 
files containing annotated information for each “peak” — groups of probes across a genomic 
region reaching a significant level of enrichment. These were used to obtain our initial FS-
DMR lists, while the raw data was used to narrow down the candidates further. 
Using Visual Basic 6.0, three looping macros and several sub macros were written in-lab to 
sort through the Excel data and compare the peak scores of each processed locus over all the 
samples. The aim of this analysis was to generate a list of genes that significantly changed 
their DNA methylation signature in response to intervention 
First, fold change values were compared between each of the 12 samples (6 participants, pre- 
and post-intervention) and a “peak change” score in response to intervention was obtained 
(Section 3.3.2). After this, the recurring genes between the three folic acid group participants 
were compared with those from the placebo group (Section 3.3.3). Those that also appeared 
in both groups were removed, leaving only FS-DMRs. Figure 3.2 illustrates this process.  
In order to examine the most dramatic differences between both groups—i.e. regions that 
either completely lost or gained methylation in response to intervention—a similar approach 
was taken. Genomic regions that were found to be enriched pre-intervention while not being 
present in the post-intervention dataset for a particular individual were placed in an “ON/OFF” 
group. Those that did not appear in the pre-intervention dataset and found to be enriched post-
intervention were placed in an “OFF/ON” group (Section 3.3.4). Further analysis was carried 
out as described above. Figure 3.3 illustrates this process 
Methylation changes common in both the folic acid and the placebo groups were then 
implemented in a separate list of pregnancy related DMRs.  
Focusing on the FS-DMRs obtained from these steps, two further stages of analysis were 
carried out, eliminating hits less significant than others. First, the levels of enrichment for 
every region were examined for each participant, and any outliers were removed – those that 
did not exhibit changes represented by the mean value, discussed in further detail in Section 
3.3.6. Then, a thorough evaluation of the probe distribution within each peak was carried out, 
correlating each peak value used in the above analysis to CpG methylation at a much higher 
resolution (Section 3.3.7).    
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3.3.2: Comparison of Pre- versus Post-intervention for each Individual 
From Nimblegen, a gene list with peak values representing levels of methylation was supplied. 
There was a cut-off of 2 for peak scores, so any gene that had less than a four-fold change in 
methylation against the input fraction has been omitted. It was necessary to write macros in 
Visual Basic 6 in order to sort through the data, separating genes with peak scores in both 
groups from those that only reached the cut-off in one. The aim of this step was to compare 
the peak scores of every genomic region pre- and post-intervention for each of the 6 FASSTT 
participants.  
Excel data was arranged in a manner similar to Figure 3.4. Here, the rows were sorted based 
on their accession numbers and chromosomal regions so the loci line up as close as possible. 
In the first few rows, the data from “pre” (red) and “post” (blue) matched up evenly. However, 
a frame shift was introduced at B000007 in the “pre” set. To cut and paste an entry like this 
away from the dataset to be analysed later, two sub macros were written (full scripts and 
descriptions are included in Appendix A.1 and A.2). NuRedCut was written to remove a row 
of the “before” set, with NuBlueCut removing data from “after.” The three lines of instructions 
on each dictate where Excel should copy, paste, and delete the necessary data.  
As a result, the macro matches together all entries on the array that reach the threshold for 
enrichment before and after intervention. Those that only have an entry pre-intervention are 
put aside, as are ones that only have an entry post-intervention. These are brought back into 
the analysis in Section 3.3.4 for the ON/OFF lists. Using the fold enrichment observed in the 
pre-intervention group as a normaliser, fold changes in response to intervention were 
calculated for each locus. 
3.3.3: FS-DMR Comparison between folic acid intervention and placebo groups  
After the data was sorted by the looping macro described in Section 3.3.2, all of the genes that 
remained were arranged by their accession number for each sample (Figure 3.5), and the 
looping macro “RemoveRow” was written to remove every entry but those common across 
all three (Appendix A.3, Appendix A.4).  
This approach was used to generate two separate lists of genes that exhibited an increase or a 
decrease in methylation in both the placebo and intervention groups. The submacros and 
looping macro “PlaceboCompare” (Appendices A.5 and A.6) were used to compare the two 
lists, removing entries that were common in both.   
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3.3.4: Obtaining lists for complete DNA methylation responses to folic acid 
supplementation 
The final analysis for finding genes that completely gained or lost methylation in response to 
intervention was similar to that in Section 3.3.2. The entries initially removed by NuBlueCut 
and NuRedCut were selected because they did not appear in the opposing group. Instead of 
focusing on the matching rows that were left behind –as Section 3.3.2 did – the new lists 
generated by the cutting process were the focus for this part of the analysis. For the ON/OFF 
groups, genes present pre-intervention and not post-intervention in the folic acid 
supplementation group were compared to those of the placebo group. The selection criteria 
here was focused on genes that went from ON to OFF in the folic acid group, but remained 
ON pre- and post-intervention in placebo group. For the OFF/ON list, genes that went from 
unmethylated to methylated in the folic acid group and those that also stayed OFF both sides 
of the intervention in the placebo group were retained.  
3.3.5: Pregnancy related Differential Methylated Regions 
Finally, by applying these macros to the dataset without discriminating between the 
intervention and placebo groups, a list of genes that changed their methylation status in 
response to pregnancy alone was obtained. 
3.3.6: In-depth analysis of FS-DMRs:  Individual Enrichment Levels across the Subset 
When comparing the enrichment scores for the initial FS-DMR list, an average value for the 
fold change across the three individual folic acid supplementation groups was used to find the 
most dramatic changes. However, with such a wide range of fold changes for each loci across 
the six participants, it was necessary to examine each individual fold change to determine if 
the mean change was being influenced by a single sample.  
For loci found with positive enrichment, all three participants from the folic acid 
supplementation group needed to have a fold change greater than or equal to 1.20 to be 
considered for the final FS-DMR list, while all three in the placebo group needed to display 
either a decline or no change in methylation. Likewise, those in the negative enrichment group 
needed to be diminished by a factor of 0.8 or more, while having no change or an increase in 
all three placebo samples. Values between 0.8 and 1.2 enrichment were deemed to have no 
change. For example, for the DMR Solute carrier family 38, member 3, the mean enrichment 
across the three folic acid samples was 0.51. However, one sample was found to have an 
enrichment of 0.88, or “no change” under these criteria. As a result, this DMR would be 
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removed from the dataset. The limits of 0.8 and 1.2 are quite stringent, and led to the removal 
of many samples from the dataset, but these numbers were chosen to ensure that only the 
highest scoring FS-DMRs – those with the most dramatic change in response to intervention 
– would be brought forward for the gene-specific screening across the rest of the cohort 
(n=119).  
For the ON/OFF samples, no genes were removed from this shorter list, as the selection criteria 
outlined in Section 3.3.4 had already taken individual scores into account.  
3.3.7: In depth analysis of FS-DMRs: Probe distribution across remaining peaks 
In calculating the initial peak values used in this analysis, groups of four or more probes 
reaching a significant threshold of enrichment on the microarray were combined and mapped 
back to a reference genome (Figure 3.6). One limit of this approach is that in many cases, the 
group of probes mapped back to a particular gene in one sample may not necessarily overlap 
with the group of probes mapped to the same gene in another sample i.e., the original software 
(DEVA) can call different sets of probes by the same gene name. By going back to the raw 
data, this next step aimed to eliminate any false positives found due to this limitation.  
3.4: Results 
3.4.1: MMSDK Pilot Study 1, Lambda Phage DNA 
Two pilot studies were carried out to assess the feasibility of applying the MMSDK method 
to the precious FASSTT samples. First, an MMSDK library was generated from lambda phage 
DNA in order to test the efficiency of the process. Lambda genomic DNA contains 2 AscI 
sites, generating three fragments of 31853, 13127, and 3522 base pairs in length when cut with 
enzyme. The simplicity of the library that MMSDK generated from lambda DNA meant that 
direct Sanger sequencing could be used to determine the methylation status of the AscI sites. 
A PAGE gel (Figure 3.7) revealed that the PCR stage of the pilot study was successful, as 
indicated by a band at 88bp, representative of the desired MMSDK PCR product.  
This band were cut from the gel (Section 3.2.5), cloned using the TA cloning system (Section 
2.3.7), and sequenced using Sanger sequencing. Three MMSDK products were sequenced 
from this band. Each was found to have identical upstream and downstream P5 and P7 adapter 
sequences with different 16bp genomic sequences in between. Two of the three 16bp 
sequences were of reverse complement to one another, and both derived from the same AscI 
site in the genome. The third was matched back to the other AscI site, indicating that both 
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were unmethylated upon initial digestion (Figure 3.8). In Table 3.2, the MMSDK product 
starts at the highlighted portion, with blue representing the sequence of the P5 primer, green 
from the P7 primer, and yellow as the unique MMSDK read. Comparing this to the lambda 
genome, it was found that the first two MMSDK products were derived from the NlaIII site at 
approximately position 16400 of the genome, with the third from the NlaIII site at position 
3500.  
3.4.2: MMSDK Pilot Study 2, Human Genomic DNA 
With proof that MMSDK can be used to obtain a full genomic library form a simple genome, 
our next goal was to demonstrate that this could be scaled up for human DNA. The human 
genome contains 4675 AscI sites, and will generate fragments of approximately 600,000bp 
after digestion133. The second pilot study aimed to generate MMSDK tags of human genomic 
DNA using the same process as the first pilot study.  
Not only did amplification of human genomic DNA introduce a significant challenge based 
on its increased template size, but also for the processes downstream from amplification. The 
P5 and P7 sequences integrated into the MMSDK product are based on the adapters used for 
Illumina NGS. While using a conventional Taq polymerase to introduce A-overhangs to these 
products for TA-cloning was a valid option for Sanger Sequencing, the increased complexity 
of an MMSDK library derived from human genomic DNA required a high-fidelity polymerase 
for the PCR stage.  
Velocity DNA Polymerase (Bioline) is capable of generating PCR products with a low number 
of cycles. Too many PCR cycles can cause long concatemers of DNA to form as multiple 
products are integrated into one another. This is phenomenon is evident on the PAGE gel in 
Figure 3.9. When the recommended concentration of 0.13µM P7 linker was used in the final 
MMSDK ligation reaction, no 88bp product was formed from the PCR step (lane 2), possibly 
from the linker forming self-dimers during ligation and preventing PCR amplification from 
taking place. When the ligase enzyme was omitted from this reaction (lane 4), a smear of non-
specific amplification occurred, with separate DNA fragments containing sequences 
complementary to both primers now present in the reaction. When the concentration of P7 
linker was reduced to 0.06 µM (lane 3, with ligase; lane 5, without ligase), concatemers over 
100bp formed, along with more non-specific products.  
All reactions on the PAGE gel from Figure 3.9 were carried out with 25 PCR cycles. Due to 
concatemer formation, the number of reactions carried out was decreased to 12, 15, 18 and 20 
74 
 
 
cycles under the same conditions (with 0.06µM P7 linker). This, however, resulted in no 
amplification (Figure 3.10).  
After rigorous optimisation of the previous MMSDK steps and the final PCR steps, no 
amplification other than non-specific smears or high molecular weight concatemers could be 
obtained. A high-quality product is required for Illumina Sequencing, but this could not be 
obtained from MMSDK using human genomic DNA under the conditions described above. It 
was decided not to pursue this method on our FASSTT samples, given that the protocol could 
not be successfully executed on control human DNA.    
3.4.3: Methylated DNA Immunoprecipitation, another method for genome-wide 
methylation Analysis 
Returning to the literature, other methods for genome-wide methylation analysis were 
examined. Amongst these were promoter DNA microarrays by Roche Nimblegen, designed 
to analyse DNA fragments obtained from methylated DNA immunoprecipitation (MeDIP). 
Initially, there was concern that using a DNA microarray would limit the study and introduce 
bias. However, combined with the MeDIP technique, the Nimblegen Delux 2.1M promoter 
array can assess the DNA methylation status of up to 28,266 CpG islands in close proximity 
to gene and miRNA promoters165. In comparison, the enzyme AscI, when used in MMSDK, 
will only asses the methylation status of 4,675 sites; 3,028 of which lie in CpG islands134. 
Although MMSDK did have the advantage of finding completely new FS-DMRs outside of 
already annotated CGIs, MeDIP has a higher chance of linking changes in DNA methylation 
patterns to gene expression.  
3.4.4: Quality Control of MeDIP DNA 
To test the quality of the DNA obtained from the MeDIP process (Section 3.2.6), each of the 
twelve samples were run on a 1% agarose gel via electrophoresis. Each lane contained a smear 
of DNA running from 200bp to 1000bp in length, as expected from the initial MseI digestion. 
The difference in smearing patterns across each individual indicates that there is a variance in 
DNA quality across each sample. Although these also passed an independent QA step carried 
out by Nimblegen (based on similar criteria described here), special attention will be paid the 
sample “FASSTT 1 Methylated” and the data that arises from it (Figure 3.11). 
Using qPCR and the assays described in Section 3.2.8, the extent of which the MeDIP process 
enriched for methylated DNA was determined to be 3.41 fold compared to the Input fraction. 
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For unmethylated DNA, the histone H3B assay exhibited a 25 fold diminishment for MeDIP 
versus Input (Figure 3.12). Raw data is included in Appendix B.   
Once confirmed that enriched DNA was of adequate quality, the 12 MeDIP samples along 
with their corresponding untreated Input fractions were sent to Roche to be hybridised on a 
Nimblegen 2.1M Deluxe Promoter Array. Prior to labelling and hybridisation, Nimblegen 
carried out their own QC analysis on the samples and confirmed that all 12 DNA samples had 
concentrations between 250ng/μl and 1000ng/μl, with A260/A280 and A260/230 ratios 
greater than 1.7 and 1.6, respectively. 
3.4.5: Novel FS-DMRs  
Following the data analysis process described in Section 3.3, a total of 19 preliminary FS-
DMRs have been identified, as depicted in Tables 3.3-3.5. None of these genomic regions 
have been implicated to change their methylation status in response to environmental factors 
before. Before finalising this list, however, it was necessary to narrow down the candidates 
down further, given the wide variety of variations introduced with these FASSTT samples 
(genetic, environmental, etc.). With such a large number of genes probed by the microarray to 
begin with, and DNA methylation itself capable of being affected by a wide range of factors 
— many of which the field hasn’t fully elucidated — only the candidate regions that remained 
after the two-pronged approach described in Section 3.3.6 and Section 3.3.7 can be considered 
as novel folate sensitive-DMRs. The list of 19 FS-DMRS were reduced to 5 after taking into 
account their individual fold changes (Tables 3.5 – 3.7). In this analysis, individuals from the 
folic acid supplementation group (represented by the numbers (1085, 1156, and 1099) were 
compared to those of the placebo group (represented by the numbers 1061, 1010, and 1074).  
However, on analysing the raw data for each of these 5 regions (Figures 3.13 – 3.17), none 
were found to significantly and consistently change their methylation status in response to 
folic acid supplementation when examined at this resolution. Each is discussed individually 
below. The main issue arose from peaks being compared between samples that did not overlap. 
All peak positions are listed in Table 3.8. 
IP6K1, Figure 3.13: There is no single area covered by all twelve peaks in this locus. Thus, 
the changes in methylation observed here cannot be pinned down to a single probe. In samples 
1085A and 1085B (four-digit numbers refer to the FASSTT participant, letters A and B refer 
to pre-and post-intervention samples, respectively) for example, the probes grouped together 
as a peak all lie in the same region, so their scores may be compared accurately. On the other 
hand, the regions compared between samples 1099A and 1099B do not overlap, though their 
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peaks were scored as 4.62 and 25.50, respectively. These figures are inflated due to the region 
for 1099B being further down the chromosome. At this point, the correlating region for 1099A 
actually has a similar level of enrichment, higher than what was called as a peak in the initial 
analysis. If this particular region was examined in both samples instead, IP6K1 may not have 
been found to be significant at all. The region 3:49824013-49824101 was chosen for further 
analysis in Chapter4. 
Chr9ORF44, Figure 3.14: Here, there are only two samples, 1061A and 1061B, that lie 
outside the region Chr9:94904005-94904144 covered by every other peak. These two 
probes—marked as a full peak for sample 1099B—fail to hold the same trends as the other 
scored peaks for each sample. The goal of this phase of the project was to take the peak scores 
for each gene and narrow their corresponding methylation changes to a smaller group of CpGs. 
Given how the data has been presented, this approach would render Chr9ORF44 as a void 
entry. The region 9:94905691-94905940 was chosen for further analysis in Chapter 4. 
RASA4, Figure 3.15: As a gene found in the ON/OFF list, RASA4 was not subjected to the 
same setbacks as the other potential DMRs. It is clear that the region Chr7:102156300-
102156800 in samples 1099A and 1099B does not necessarily exhibit a complete loss of 
methylation, as suggested by no peak being scored for 1099B. The region 7:10215800-
102158200 was chosen for further analysis in Chapter 4. 
SGPL1, Figure 3.16: Following a similar trend to the others, there is no single probe that has 
a common trend across the dataset. Although 1085B was called for having no peaks, the 
enrichment levels of the probes at the region Chr10:72575627-72576074 are too similar to 
draw any further conclusions from.  
Chr19ORF75, Figure 3.17: With only 3 out of the 12 samples tested showing a peak, finding 
a single region to represent the enrichment scores given to Chr19ORF75 proved more difficult 
than anticipated. No probe in the region Chr19:51767100-51769200 was found to reflect this 
relationship. 
3.5: Discussion  
The method initially selected for genome-wide methylation analysis was Modified 
Methylation Specific Digital Karyotyping (MMSDK) which has been successfully applied in 
a number of studies. Steenbergen et al., (2013) used MSDK (the parent method of MMSDK) 
to identify 34 genes with increased methylation in response to human papillomavirus-induced 
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transformation166. Likewise, Li et al.,, (2013) found significant genome-wide changes using 
MMSDK on breast cancer cell line models resistant to the therapeutic agent tamoxifen167.  
However, after a series of pilot studies, MMSDK was not found to be reliable and consistent 
enough to use on the FASSTT samples. While MMSDK was successfully applied to a simple 
genome i.e., lambda, applying the method to human DNA did not yield the desired PCR 
product that would have been subject to NGS. MMSDK was considered for the initial genome-
wide analysis for our samples due to it being an economical, reliable, and non-biased 
approach.  Moreover, a related method had been implemented in the lab previously and thus, 
previous experience was considered an additional advantage for choosing this method.   From 
the lambda DNA pilot study, it was found that MMSDK succeeded in generating sequencing 
tags for both of the possible sequencing sites in the genome, adjacent to the two AscI 
sequences in its genome. However, scaling this up to the size of the human genome proved 
problematic.  
The technical challenges that MMSDK imposed meant that other methods needed to be 
considered. A perfect, gold standard method of DNA methylation analysis has yet to appear 
in the literature.  The best method would be whole genome bisulfite sequencing (although with 
reduced complexity, reassembling the genome is proving challenging168), but the cost 
implications even at the beginning of this project prevented this as a viable option. As a result, 
many different approaches to genome-wide and gene-specific methylation analysis were 
examined, each with their own pros and cons.  
It was at this point that MeDIP and DNA microarray analysis was found to be an alternative 
method to MMSDK given its technical challenges. Although the microarray analysis approach 
was considered and rejected during the early stages of the project due to the large amount of 
bias introduced by the array along with its inability to find completely novel sites or those 
outside CGIs, it was re-evaluated and found that it can potentially cover far more CGIs than 
MMSDK, although limited to promoter regions. This method has been successfully applied to 
several studies investigating DNA methylation changes arising from tumourigenisis169–171, 
Alzheimer’s disease172, and across different species of primates173,174. Methylated DNA 
Immunoprecipitation (MeDIP) coupled with microarray analysis was subsequently applied to 
a subset of the FASSTT samples to generate a list of potential FS-DMRs.   
In a literature review published by this research group3, a list of genomic regions known to 
alter their methylation status in response to nutritional factors such as methyl-donor  
availability was put together to address our initial hypothesis: does folic acid supplementation 
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have an impact on DNA methylation in pregnant women. Because the supplementation 
strategy employed in the FASSTT study closely resembles the national medicinal guidelines4, 
these samples provide a unique insight to what is happening on a molecular level to the DNA 
of women taking folic acid supplements. The data obtained here brings the field one step closer 
to linking folate availability to health and disease through epigenetic mechanisms. 
This approach is not without its limits, however. Throughout the literature, methods to detect 
DNA methylation have been employed to learn more about tumourigeneis, disease states, and 
differences between related species, but rarely applied to healthy individuals170,172,173. MeDIP 
results found under these conditions tend to be far more dramatic, with larger gene lists 
obtained exhibiting more prominent changes in methylation levels169,171,175. 
When the initial list of 19 FS-DMRs was narrowed down based on the individual peak scores 
for each participant in the study, only 5 loci remained. On examining these regions further, 
comparing the enrichment values for the individual probes within each peak, it was clear that 
the analysis falls short in finding any novel FS-DMRs at this point in the study. Had the DNA 
methylation changes observed here been as significant as what has been reported in the 
literature, the seemingly contradictory nature of the peak-probe relationship would not have 
been so detrimental.  
Most studies looking at DNA methylation using MeDIP take a qualitative approach; genomic 
regions are reported to be either hypomethylated or hypermethylated based on the microarray 
data169,174. In other words, all analysis in the literature either has taken the same approach as 
our ON/OFF and OFF/ON lists. From our own qualitative analysis, the number of FS-DMRs 
we identified is far lower than what has been found in other studies. Of the papers cited here, 
none have examined the peak-probe relationship at the same level of detail we have.  
Throughout the literature, thousands of DMRs have been found by examining MeDIP data 
from experiments comparing disease states or different species. In most cases, a separate gene-
specific method of analysis has been used to confirm these findings169,171,173,174. However, 
MeDIP results in some cases have been published without confirmation with a different 
method of analysis at all170,172,175. Nonetheless, further confirmation of our candidate FS-
DMRs will be carried out in the next chapter, aiming to expand on our dataset and confirm 
that the methylation changes observed here are consistent with folic acid supplementation, as 
opposed to confirming what has been already found across the same samples already tested.  
For example, Morris et al., (2011)171 combined a MeDIP and a whole-genome methylation 
array with high-density expression array analysis to find genes that were methylated and 
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transcriptionally silenced in renal cell carcinoma. For confirming methylation, both sodium 
bisulfite sequencing and combined bisulfite restriction analysis were carried out on the regions 
of interest, but the sample set was not expanded from n = 11. In this case, validation was 
carried out to confirm the findings of the MeDIP analysis, rather than investigating if these 
changes persist in other samples under the same conditions. The other approach was taken by 
Zhang et al., (2013)169, who discovered 2654 DMRs over 351 genes in 9 patients with tongue 
squamous cell carcinoma. Validation was carried out on an expanded sample set of 20 patients 
on three candidate genes found from the MeDIP analysis, with results consistent with the 
microarray study.   
However, dramatic changes in DNA methylation status are known to occur during 
tumourigenesis. In contrast to the above studies, a similar magnitude of change was not 
observed for the FASSTT study which carried out over a relatively short period of time with 
just a nutritional intervention.  Thus, confirming methylation changes at a more subtle level 
using this approach has not been reported in the literature. 
Validation of these MeDIP results will follow the same course as Zhang et al., (2013)169. The 
number of FASSTT samples examined for methylation changes will be expanded from 6 to 
119 for gene-specific methylation analysis.  Three of the final 5 FS-DMRs will be examined 
in this manner: IP6K1, Chr9ORF44 and RASA4.  
Inositol hexakisphosphate kinase I (IP6K1) is a gene encoding for one of three kinase enzymes 
involved in synthesising inositol pyrophosphates, signalling molecules involved in multiple 
cellular processes such as chromatin remodelling and cell aging176,177. IP6K1 itself has been 
implicated in a variety of roles associated with insulin sensitivity, homologous DNA 
recombination repair, and spermatogenesis178–180. More recently, IP6K1 has been found to 
mediate the assembly and disassembly of the CRL4-signalosome: a complex of ubiquitin 
ligases involved in cell cycle regulation and DNA repair181. To our knowledge, aberrant DNA 
methylation in the regulatory region of IP6K1 has not yet been reported in the literature.  
The gene encoding Ras p21 protein activator 4 (RASA4) has been found to be deleted in 
primary effusion lymphoma cell lines, along with two well-established tumour suppressor 
genes182. The gene’s product is involved in regulating Ras, a small GTP-binding signalling 
molecule involved in gene expression and cell cycle control183. Hypermethylation of RASA4 
has been recently found to be a characteristic juvenile myelomonocytic leukemia, correlated 
with poor prognosis184. 
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The approach taken by this chapter has been limited by the nature of the FASSTT study; 
healthy women divided into two groups were either given folic acid or a placebo over the 
course of several weeks. In comparison to reported DMRs arising from cancer or other disease 
states, it is no surprise that the changes in methylation observed so far have not been as 
significant. Unlike the other studies cited here, however, these experiments did not aim to find 
a list of FS-DMRs from MeDIP and microarray analysis alone. By concentrating on a subset 
of women from the FASSTT cohort who had the most pronounced response to folic acid 
supplementation, the work presented here has highlighted regions of the genome that may 
alter their methylation status in response to folic acid supplementation. Despite the negative 
finding of this microarray analysis, the highest scoring FS-DMRs will still be carried on to the 
gene-specific analysis over the entire FASSTT cohort in Chapter 4. With a more specific 
method of analysis, analysing DNA methylation patterns in an entirely different manner than 
MeDIP, these potential sites may still be confirmed as FS-DMRs.  
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Figure 3.1: Project Overview 
A genome-wide analysis will be carried out on a subset (n=6) of the FASSTT cohort to find 
potential folate sensitive differential methylation regions (FS-DMRs). These samples were 
selected from the full FASSTT cohort (n=114) based on the criteria listed in Table 3.1. 
Confirmation of these FS-DMRs across the rest of the FASSTT cohort (n=114) will be carried 
out using a gene-specific method of analysis (Chapter 4). Finally, changes in DNA expression 
patterns in response to these FS-DMRs will be analysed in a cell culture model (Chapter 4). 
In this Chapter, the method for genome-wide analysis will be selected based on evidence from 
a literature review and experimental data.  
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Figure 3.2: Analysis overview of Microarray Data: Quantitative Methylation Changes  
The data analysis process was divided into three steps. Changes in enrichment levels of genes 
within the same individual (FASSTT 1, FASSTT 2, etc.) were first assessed (Step 1), 
generating a list of loci with changes in methylation calculated as a fold change of post-
intervention against pre-intervention (FASSTT 1 Change, FASSTT 2 Change, etc.). Following 
this, the three participants from each group were compared to one another, and loci that were 
common amongst all three were examined further (Step 2). Finally, FS-DMRs were obtained 
by comparing those common in the folic acid group against those in the placebo group i.e., a 
region was identified as a FS-DMR if it only showed a change in the intervention group and 
not the placebo. 
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Figure 3.3: Analysis overview of Microarray Data: Complete Methylation Changes 
The data analysis process for complete DNA Methylation changes was divided into three 
steps. Complete changes (from ON to OFF and from OFF to ON) in enrichment levels of 
genes within the same individual (FASSTT 1, FASSTT 2, etc.) were first assessed (Step 1), 
generating a list of loci that either completely lose (ON/OFF) or gain (OFF/ON) methylation 
in response to intervention. Following this, the three participants from each group were 
compared to one another, and loci that were common amongst all three were examined further 
(Step 2). Finally, FS-DMRs were obtained by comparing DMRs common in the folic acid 
group against those in the placebo group i.e., a region was identified as a FS-DMR if it only 
showed a change in the intervention group and not the placebo. 
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Figure 3.4: Sample dataset for pre- and post-intervention comparison 
Genes were sorted by their accession number and chromosomal location. Red represents the 
loci pre-intervention, and blue, post-intervention. Where the rows matched (rows 2 and 3), the 
“fold change” score from the post-intervention column was divided by that of the pre-
intervention column to obtain a “fold difference” score. Whenever a frame-shift was 
introduced (like at BC000007, in row 4) the appropriate macro was called to remove and re-
align the dataset. In this example, the looping macro would call a sub-macro to remove entry 
for BC000007 in red, aligning both red and blue entries for BC000008.  
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Figure 3.5: Sample dataset for comparison between three participants 
Along the top row, the macro described in Section 3.3.2 was designed to delete any four-
column rows in the green, purple, or black sections that did not have a match (each colour 
representing a different FASSTT participant). Those that did were removed and pasted 
elsewhere for further analysis. In cases were the three samples did not match up (like in row 
8), the appropriate submacro was called to adjust the dataset accordingly, creating more three-
way matches for further analysis. 
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Figure 3.6: Sample illustration between probe and peak enrichment scores 
Each 100bp probe is represented by a green line, with enrichment scores on the Y axis, and 
chromosomal position on the X axis. Adjacent probes that reach a significant threshold are 
grouped together and identified as a “peak” (blue rectangle), with the “peak score” given as 
the average enrichment value for the probes. Peak scores were converted to fold change 
differences for the initial analysis on the dataset to generate an initial list of FS-DMRs. In the 
process of narrowing these down to the final list, raw probe enrichment values making up each 
peak were re-examined to ensure that the relationship between a participants peak score pre- 
and post-intervention reflected that of their probe scores. 
87 
 
 
 
Figure 3.7: MMSDK Pilot Test on Lambda DNA: PCR amplification step 
After the PCR step of MMSDK, the final product was visualised on a 12% polyacrylamide 
gel. Lane 1 contains a 10bp O’Range Ruler (Thermo Scientific). Lanes 2-6 contain PCR 
products after 8, 12, 16, 20 and 25 cycles, respectively. Lane 7 contains an MMSDK PCR 
product after 25 cycles, but with the ligase enzyme from the final ligation step omitted to 
control for amplification of templates without P7 linkers. Lane 8 contains a no template 
negative control. Lanes 9 contains another 10bp O’Range Ruler. In lane 6, two bands at ~88bp 
and ~65bp appear together. The former is equal to the expected size of the MMSDK product, 
and was cut out from the gel. The latter is an amplified product of DNA unligated to the P7 
linker, equal to the only band to appear in lane 7, i.e., the non-desirable PCR product. The 
largest band here, at over 100bp in length, is possible the result of concatemer formation, 
resulting from extensive amplification of a short product.  
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Figure 3.8: Restriction sequences of the Lambda Genome.  
MMSDK is designed to target the NlaIII sites that flank the AscI sites of the input DNA. Image 
A depicts a map of the entire lambda genome, with two regions circled in red. Image B shows 
these two regions in more detail. The four-base-pair recognition sequence of NlaIII is far more 
numerous than the eight-base-pair recognition sequence of AscI. With only two AscI sites, 
marked here, MMSDK can only generate four possible tags from lambda genomic DNA, in 
comparison to approximately 9,000 of that in human DNA. It was the simplicity of lambda 
DNA resulted in the success of the first pilot study. 
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Figure 3.9: MMSDK PCR Products on Human Genomic DNA 
Products of MMSDK PCR carried out on human genomic DNA. Two concentrations of P7 
linker were used in the final ligation step, (0.13µM, lanes 2 and 3; 0.06µM, lanes 4 and 5), 
with no ligase negative controls for both (lane 3 and lane 5). When ligase was included in the 
reactions, this PCR only produced products for 0.06µM P7, with a very weak band visible at 
~88bp. Omitting the ligase enzyme generated more non-specific products, including high 
molecular-weight concatemers greater than 100bp in length.  
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Figure 3.10: MMSDK PCR Products on Human Genomic DNA 
With a P7 linker concentration of 0.06µM, the cycle number of the final MMSDK PCR was 
reduced to 12 (lane 2), 15 (lane 3), 18 (lane 4) and 20 (lane 5). No amplification occurred in 
either reaction.  
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Figure 3.11: Quality Control analysis of MeDIP DNA, gel electrophoresis 
All 12 MeDIP samples were run on a 1% agarose gel for 45 minutes alongside a 1kb ladder. 
A smear for each sample between 200bp and 2000bp in length represents DNA digested with 
the MseI enzyme. The MeDIP process yielded a Methylated and Input Fraction of the 6 
FASSTT participants, each of which were loaded in numerical order on the gel, from left to 
right (Lane 1, FASSTT 1 Input; Lane 2, FASSTT 2 Methylated; Lane 3, FASSTT 2 Input, 
etc.) 
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Figure 3.12: Quality Control analysis of Immunoprecipitated DNA by qPCR 
Using qPCR, the methylated lncRNA H19 gene was found to be enriched 3.41 fold, while the 
unmethylated histone gene H3b decreased by 25 fold during the enrichment process. The mean 
CP values over all FASSTT samples for each assay were compared with that of the Input 
samples using the formula: Fold Change = 2 ^ (Input – FASSTT). 
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Figure 3.13: IP6K1 MeDIP probe positions 
Complete peak overlap is evident in sample 1085A and 1085B (green). Although the peak 
scores for 1099A and 1099B (red) exhibited a significant increase after intervention, there is 
little difference between the actual probe enrichment values. In fact, a decrease in enrichment 
is evident at the region marked by the peak in 1099A. The region 3:49824013-49824101 
(orange square) was chosen for further analysis in Chapter 4, as this site has the most overlap 
in probes that represent the trend originally depicted by the peaks.  
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Figure 3.14: Chr9ORF44 MeDIP probe positions 
Only the probes for the peak of sample 1099B (red) are present in 10 out of the 12 samples 
here. At this region, however, the trends of enrichment do not follow that of the full peak 
scores allocated to the samples in the first stage of analysis. The region 9:94905691-94905940 
(orange square) was chosen for further analysis in Chapter 4, as the single probes there exhibit 
the decline in enrichment observed in the initial analysis. 
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Figure 3.15: RASA4 MeDIP Probe positions  
As a gene from the ON/OFF list, RASA4 does not suffer from the same setbacks as IP6K1 and 
Chr9ORF44 did. The region 7:10215800-102158200 (orange rectangle) was chosen for 
further analysis in Chapter 4, as the peaks at this region reflect the ON/OFF trend observed in 
the initial peak values. 
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Figure 3.16: SGPL1 MeDIP probe positions 
Similarly to RASA4, SGPL1’s peak-probe distributions mirrored what was depicted by the 
peak score values used in the initial analysis. However, region at 1085B (green) expected to 
have no peak had enrichment at the region scored as a peak for 1085A. As a result, no 
conclusions from SGPL1 can be drawn, and no further analysis was not carried out on this 
locus. 
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Figure 3.17: Chr19ORF75 MeDIP probe positions 
It appears that there was not a significant OFF/ON relationship between the probe values here, 
despite what the peak data had shown in the initial analysis. Although many of the samples 
here were scored with no peaks, there is a significant level of enrichment towards the right-
hand side of the region. Further analysis was not carried out on Chr19ORF75. 
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Table 3.1: Criteria for selecting FASSTT samples for MeDIP analysis. 
Folic Acid Intervention group Placebo Group 
Participants taking folic acid 
supplementation for less than 6 weeks 
before recruitment 
Participants taking folic acid 
supplementation for less than 6 weeks 
before recruitment 
Participants with lowest red cell folate at 
baseline 
Participants with lowest red cell folate at 
baseline 
Participants with highest red cell folate and 
serum folate response  
Participants with typical decline of red cell 
folate and serum folate response 
Participants with matching cord blood red 
cell folate and serum folate levels 
Participants with matching cord blood red 
cell folate and serum folate levels 
Participants age-matched to Placebo group Participants age-matched to Folic Acid 
Supplemented group 
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Table 3.2: Sequences of Sanger reads obtained for MMSDK. 
MMSDK 
Lambda  
Product 1  
NNNNNNNNAGGGCGANTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCA
GTGTGATGGATATCTGCAGAATTCGGCTTAATGATACGGCGACCACCGAC
AGGTTCAGAGTTCTACAGTCCGACCATGGGGAAACGTCTTGGTGCTCG
TATGCCGTCTTCTGCTTGAAGCCGAATTCCAGCACACTGGCGGCCGTTAC
TAGTGGATCCGAGCTCGGTACCAAGCTTGGCGTAATCATGGTCATAGCTGT
TTCCTGTGTGAAATT… 
 
MMSDK 
Lambda  
Product 2 
NNNNNNNNNNNNGGCGATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGC
CAGTGTGATGGATATCTGCAGAATTCGGCTTCAAGCAGAAGACGGCATAC
GAGCACCAAGACGTTTCCCCATGGTCGGACTGTAGAACTCTGAACCTG
TCGGTGGTCGCCGTATCATTAAGCCGAATTCCAGCACACTGGCGGCCGTT
ACTAGTGGATCCGAGCTCGGTACCAAGCTTGGCGTAATCATGGTCATAGCT
GTTTCCTGTGTGAAATT… 
 
MMSDK 
Product 3 
NNNNNNNNNGGCGATTGGGCCNCTAGATGCATGCTCGAGCGGCCGCCAGT
GTGATGGATATCTGCAGAATTCGGCTTAATGATACGGCGACCACCGACA
GGTTCAGAGTTCTACAGTCCGACCATGCTGGCAATATGCGGGATCGTA
TGCCGTCTTCTGCTTGAAGCCGAATTCCAGACACTGGCGGCCGTTACTAG
TGGATCCGAGCTCGGTACCAAGCTTGGCGTAATCATGGTCATAGCTGTTTC
CTGTGTGAAATT… 
 
Blue, P5 primer sequence; Yellow, Unique MMSDK read from genomic DNA; Green, P7 primer sequence 
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Table 3.3: Genes that exhibited changes in methylation at their promoter regions in all 
individuals tested 
  Folic Acid 
Mean1 
Folic Acid 
Standard2 
Placebo 
Mean1 
Placebo 
Standard2 
Inositol hexakisphosphate kinase 1 
[NM_001006115]  
2.79 2.3637 0.48 0.1347 
Macrophage stimulating 1 [BC048330] 3.04 1.2897 0.98 0.6907 
Lipocalin 15 [NM_203347] 2.02 0.9968 1.01 0.3202 
Chromosome 22 open reading frame 34 
[NR_026997] 
2.29 1.2985 1.06 0.2880 
Lymphocyte-specific protein 1 pseudogene 
[NR_027238] 
2.15 1.3780 1.12 0.2588 
Ubiquitin-conjugating enzyme E2M pseudogene 
1 [NR_002837] 
2.02 0.6113 1.00 0.2219 
          
Solute carrier family 38, member 3 [NM_006841] 0.51 0.3293 0.78 0.0945 
Chromosome 9 open reading frame 44 
[NR_027341] 
0.49 0.0579 1.50 0.7752 
Amiloride binding protein 1 [BC014093] 0.47 0.0531 1.33 0.6466 
Ciliary rootlet coiled-coil, rootletin-like 1 
[NR_026752] 
0.44 0.1381 1.17 0.8183 
Death-domain associated protein [BC109073] 0.60 0.2900 1.76 1.1806 
G protein pathway suppressor 2 [BC103901] 0.45 0.1488 0.98 0.3883 
Melanoma antigen family A, 4 [NM_001011549] 0.59 0.0915 1.05 0.2911 
Surfeit 1 [BC028314] 0.46 0.1159 0.91 0.2550 
Transmembrane protein 145 [NM_173633] 0.49 0.1127 0.90 0.3264 
Hypothetical LOC149134 [NR_015422] 0.50 0.2944 0.87 0.2287 
1: average fold change across 3 samples in either group; 2: standard deviation of fold changes 
across 3 samples in either group. 
Green: Increased enrichment. Red: decreased enrichment. 
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Table 3.4: Genes that changed their methylation status from ON to OFF across all three 
individuals 
  Folic Acid 
Mean1 
Folic Acid 
Standard2 
Placebo 
Mean1 
Placebo 
Standard2 
RAS p21 protein activator 4 [NM_001079877]  7.27* 1.486 0.96 0.2648 
sphingosine-1-phosphate lyase 1 [BC052991] 7.17* 0.517 1.10 0.1601 
1: average fold change across 3 samples in either group; 2: standard deviation of fold changes 
across 3 samples in either group. 
* mean value taken from “before” samples only, as no peak values was scored for the “after” 
group 
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Table 3.5: Genes that changed their methylation status from OFF to ON across all three 
individuals 
  Folic Acid 
Mean1 
Folic Acid 
Standard2 
Placebo 
Mean1 
Placebo 
Standard2 
Chromosome 19 open reading frame 75 
[NM_001079877]  
9.97* 1.2433 0.00 0.00 
1: average fold change across 3 samples in either group; 2: standard deviation of fold changes 
across 3 samples in either group. 
*mean value taken from “after” samples only, as no peak values was scored for the “before” 
group. Also, no peaks were scored in any placebo samples. 
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Table 3.6: Narrowing down of FS-DMRs based on individual peak scores 
  
1085 
(FA1) 
1156 
(FA) 
1099 
(FA) 
Mean 
(FA) 
Standard 
(FA)  
1061 
(P2) 
1010 
(P) 
1074 
(P) 
Mean 
(P) 
Standard 
(P)  
Verdict 
 
Inositol 
hexakisphosphate 
kinase 1   1.36 1.49 5.52 2.79 2.3637   0.60 0.50 0.33 0.48 0.1347   Pass 
Macrophage 
Stimulating 1  2.07 4.50 2.54 3.04 1.2897   1.77 0.51 0.66 0.98 0.6907   Fail 
Lipocalin 15  1.19 3.12 1.75 2.02 0.9968   0.68 1.02 1.32 1.01 0.3202   Fail 
Chromosome 22 
open reading frame 
34  1.32 3.77 1.79 2.29 1.2985   1.14 1.29 0.73 1.06 0.2880   Fail 
Lymphocyte-specific 
protein 1 
pseudogene  1.45 3.74 1.27 2.15 1.3780   1.26 0.82 1.27 1.12 0.2588   Fail 
Ubiquitin-
conjugating enzyme 
E2M pseudogene 1 2.71 1.56 1.79 2.02 0.6113   0.79 1.23 0.98 1.00 0.2219   Fail 
                            
Solute carrier family 
38, member 3  0.88 0.42 0.24 0.51 0.3293   0.79 0.69 0.88 0.78 0.0945   Fail 
Chromosome 9 open 
reading frame 44  0.56 0.47 0.45 0.49 0.0579   2.38 0.95 1.15 1.50 0.7752   Pass 
Amiloride binding 
protein  0.53 0.45 0.42 0.47 0.0531   1.81 0.59 1.59 1.33 0.6466   Fail 
Ciliary rootlet coiled-
coil, rootletin-like 1  0.60 0.35 0.37 0.44 0.1381   0.88 0.54 2.10 1.17 0.8183   Fail 
Death-domain 
associated protein  0.86 0.66 0.29 0.60 0.2900   3.12 1.12 1.03 1.76 1.1806   Fail 
G protein pathway 
suppressor 2  0.44 0.60 0.30 0.45 0.1488   0.62 1.39 0.92 0.98 0.3883   Fail 
Melanoma antigen 
family A,  0.63 0.49 0.66 0.59 0.0915   1.21 1.24 0.72 1.05 0.2911   Fail 
Surfeit 1 Fold Change 0.50 0.32 0.54 0.46 0.1159   0.84 0.69 1.19 0.91 0.2550   Fail 
Transmembrane 
protein 145  0.57 0.53 0.36 0.49 0.1127   0.77 0.67 1.28 0.90 0.3264   Fail 
Hypothetical 
LOC149134  0.33 0.84 0.33 0.50 0.2944   0.62 0.93 1.07 0.87 0.2287   Fail 
1: folic acid intervention group; 2, placebo group. Figures with strikethroughs have been 
removed from the dataset for not adhering to the criteria listed in Section 3.3.6 
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Table 3.7: Final List of FS-DMRs 
  
1085 
(FA1) 
1156 
(FA) 
1099 
(FA) 
Mean 
(FA) 
Standard 
(FA)  
1061 
(P2) 
1010 
(P) 
1074 
(P) 
Mean 
(P) 
Standard 
(P) 
Inositol hexakisphosphate kinase 1   1.36 1.49 5.52 2.79 2.3637   0.60 0.50 0.33 0.48 0.1347 
Chromosome 9 open reading frame 44  0.56 0.47 0.45 0.49 0.0579   2.38 0.95 1.15 1.50 0.7752 
                        
RAS p21 protein activator 4 6.76 6.10 8.94 7.27 1.4860   0.65 1.08 1.14 0.96 0.2673 
sphingosine-1-phosphate lyase 1 7.08 7.73 6.71 7.17 0.5168   1.09 0.96 1.27 1.11 0.1557 
chromosome 19 open reading frame 75 8.82 11.29 9.80 9.97 1.2433   N/A N/A N/A N/A N/A 
1: folic acid intervention group; 2, placebo group 
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Table 3.8: Probe positions of FS-DMR Peaks 
RASA4 Peak Start Peak End  SGPL1 Peak Start Peak End 
1085A Chr7:102155177 Chr7:102158474  1085A Chr10:72575627 Chr10:72576074 
1085B - -  1085B - - 
1156A Chr7:102157905 Chr7:102158474  1156A Chr10:72575703 Chr10:72576174 
1156B  - -  1156B  - - 
1099A Chr7:102155177 Chr7:102158160  1099A Chr10:72575823 Chr10:72576476 
1099B - -  1099B - - 
1061A Chr7:102157726 Chr7:102158474  1061A Chr10:72575823 Chr10:72576074 
1061B Chr7:102157905 Chr7:102158160  1061B Chr10:72575909 Chr10:72576174 
1010A Chr7:102155177 Chr7:102158371  1010A Chr10:72575403 Chr10:72576174 
1010B Chr7:102156289 Chr7:102157575  1010B Chr10:72574322 Chr10:72574573 
1074A Chr7:102156289 Chr7:102158474  1074A Chr10:72575823 Chr10:72576174 
1074B Chr7:102156401 Chr7:102158474  1074B Chr10:72575315 Chr10:72576074 
       
IP6K1 Peak Start Peak End  Chr9ORF44 Peak Start Peak End 
1085A Chr3:49823693 Chr3:49824138  1085A Chr9:94903907 Chr9:94906773 
1085B Chr3:49823779 Chr3:49824236  1085B Chr9:94904005 Chr9:94904952 
1156A Chr3:49828748 Chr3:49831097  1156A Chr9:94904005 Chr9:94906773 
1156B  Chr3:49828548 Chr3:49831381  1156B  Chr9:94903615 Chr9:94904952 
1099A Chr3:49823779 Chr3:49824138  1099A Chr9:94903907 Chr9:94906773 
1099B Chr3:49828626 Chr3:49830779  1099B Chr9:94904005 Chr9:94904144 
1061A Chr3:49828626 Chr3:49831097  1061A Chr9:94904393 Chr9:94904764 
1061B Chr3:49828626 Chr3:49831097  1061B Chr9:94895004 Chr9:94901361 
1010A Chr3:49823693 Chr3:49824464  1010A Chr9:94894792 Chr9:94906644 
1010B Chr3:49828924 Chr3:49829073  1010B Chr9:94903907 Chr9:94906773 
1074A Chr3:49828548 Chr3:49831473  1074A Chr9:94903715 Chr9:94904952 
1074B Chr3:49823779 Chr3:49824138  1074B Chr9:94903615 Chr9:94905046 
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Table 3.8: Probe positions of FS-DMR Peaks (continued) 
Chr19ORF75 Peak Start Peak End 
1085A - - 
1085B Chr19:51767838 Chr19:51769287 
1156A - - 
1156B  Chr19:51767838 Chr19:51769287 
1099A - - 
1099B Chr19:51755588 Chr19:51756034 
1061A - - 
1061B - - 
1010A - - 
1010B - - 
1074A - - 
1074B - - 
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Chapter 4: 
Confirmation of candidate 
FS-DMR sites and 
assessment of their impact 
on gene expression 
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4.1: Introduction 
4.1.1: Overview 
The Methylated DNA Immunoprecipitation (MeDIP) and promoter microarray analysis 
described in Chapter 3 has yielded three potential folate sensitive differentially methylated 
regions (FS-DMRs): IP6K1, Chr9ORF44, and RASA4. Although five preliminary FS-DMRs 
have been found, none have passed the data qualification steps outlined in Section 3.3.7. 
However, these three exhibited the most dramatic change in response to folic acid 
supplementation.   
The genome-wide analysis has not been carried out on a sample-set large enough to make any 
valid conclusions, nor do they contain any quantitative data regarding the extent of DNA 
methylation at these regions. For these reasons, it was necessary to design a set of experiments 
to confirm these findings using a gene-specific DNA methylation analysis on an expanded 
dataset.  
In this chapter, three assays for gene-specific analysis of IP6K1, Chr9ORF44, and RASA4 
were designed, optimised, and validated (Section 4.3.1), then used to screen the entire 
FASSTT cohort for changes in DNA methylation (Section 4.3.3). Following this, a cell culture 
model treated with a demethylating agent was prepared (Section 4.3.5) to assess the effect of 
DNA methylation at these loci on gene expression (Section 4.3.7).  
Confirmation of these FS-DMRs and aligning the dataset with gene expression data concludes 
the investigation of the impact of folic acid supplementation on DNA methylation levels 
during pregnancy. 
4.1.2: The impact of DNA methylation changes on gene expression  
Promoter DNA methylation is classically associated with silencing of associated genes185. 
Although recent advancements in the field regarding gene-body and non-CpG complicate this 
simplified model159,186, its implications are still relevant to this study. All of the regions to be 
analysed in this chapter lie within or near the promoter region of their respective genes. In 
order to make the statement that these methylation changes are of biological relevance, 
aberrant methylation in these regions will need to be associated with gene expression.   
For this analysis, a cell culture model based on HEK293 cells treated with 5-azacytidine (5aC) 
was designed. As a chemical analogue of cytosine, 5aC severely inhibits the action of the 
DNA methyltransferase (DNMT) enzymes, leading to global passive demethylation187. 
Previous studies have examined the effect 5aC (trade name Vidaza) exposure to mammalian 
109 
 
 
cells, measuring gene expression and DNA methylation up to several days of treatment188–191, 
with concentrations varying depending on the cell lines used. Falck et al., (2012)190 observed 
a decrease of global DNA methylation in HEK293 cells treated with 1µM 5aC for 72 hours, 
from 4.61% before treatment to 1.38% after treatment, measured with micellular electrokinetic 
chromatography combined with laser-induced fluorescence detection.  On the other hand, 
Komashko  et al., (2010)191 treated HEK293 cells with 5µM 5aC for 8 days, confirming 
demethylation at selected loci with MeDIP PCR. Interestingly, Komashko and colleagues 
found that most genes that altered their gene expression in response to 5aC were not regulated 
by promoters displaying DNA methylation prior to treatment. This implies that 5aC treatment 
of HEK293 cells can have an effect on gene expression independent of its demethylating 
capabilities.  
Another demethylating agent and analogue of cytidine is 5-aza-2'-deoxycytidine (trade name 
Decitibine)192. Today, both drugs are used for the treatment of myelodysplastic syndrome 
(MDS)193. Although both appear to be very similar in functionality, 5aC has a stronger 
cytotoxic affect194. Moreover, while 5-aza-2’deoxycytidine integrates 100% into DNA, 5aC is 
also capable of integrating into RNA, possibly affecting gene expression without impacting 
on DNA methylation195.  
In order to examine the effect of DNA methylation on gene expression, the growth of HEK293 
cells exposed to 5aC was optimised to retain them in the log stage for 7 days, which is 
especially important due to its strong cytotoxic affect. This process is outlined in Section 4.2.4. 
By ensuring cells are exposed to the highest concentration of 5aC for a prolonged amount of 
time, significant loss of DNA methylation is expected at their promoter regions. It is 
imperative that any change in gene expression is mirrored by a loss of methylation, due to the 
potential for 5aC to interfere with mRNA. A loss in methylation should cause a symmetrical 
increase in gene expression, but as these studies indicate, the impact of DNA methylation on 
gene expression may not be as straightforward as previously understood.  
4.1.3 Aims and Objectives  
Aim 
To validate the FS-DMRs found in Chapter 4 with a gene-specific method of DNA analysis 
and examine the effect of DNA demethylation on gene expression in vitro in these regions. 
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Objectives  
 To design and optimise SMART-MSP assays for the candidate FS-DMRs identified 
from the MeDIP analysis. 
 To screen the FASSTT dataset across said SMART-MSP assays and confirm/refute 
the findings of Chapter 3. 
 To design a HEK293 cell-culture model to assess the effect of demethylating agent 
5’azacytidine on gene expression at these loci. 
 To confirm DNA demethylation of HEK293 DNA has occurred as a result of exposure 
to 5’azacytidine.  
 To carry out a gene expression analysis on RNA extracted from cells treated with 
5’azacytidine using RT-qPCR. 
4.2: Methods 
4.2.1: SMART MSP assay design 
Primers for SMART MSP analysis were designed based on the criteria outlined in Kristensen 
et al. (2008)146. Briefly, two CpGs were included in the primer sequences wherever possible, 
with one placed close to the 3` end of the oligonucleotide. In order to control for incomplete 
bisulfite conversion, the amplification region of each assay was designed to contain non-CpG 
Cs. With unmethylated Cs deaminating to Ts after sodium bisulfite treatment, a lower melting 
temperature would be expected in unmethylated DNA compared to that of the fully methylated 
standard. This is due to the fact that the base pair G-C is held together by three hydrogen bonds 
while A-T contains two; the former requires more energy to break than the latter. 
Primers were designed to keep both annealing temperatures as similar to one another as 
possible. Sometimes not all of these guidelines could be adhered by, due to the decrease in 
sequence complexity as a result of sodium bisulfite treatment and the limited regions being 
analysed from Chapter 3.   
MethPrimer (http://www.urogene.org/methprimer/) was used to sodium bisulfite treat the 
sequence of interest in silico. Primers with matching annealing temperatures were found using 
NetPrimer (http://www.premierbiosoft.com/netprimer/), with as little primer-dimer and self-
dimer forming capabilities as possible.  
111 
 
 
4.2.2: Rationale for FS-DMR selection for Confirmation in the FASSTT cohort and gene 
expression analysis 
 The following FS-DMRs were selected for confirmation in the FASSTT cohort as they each 
represented a different FS-DMR from the three groups presented in Chapter 3: Increase, 
Decrease, and On/Off: IP6K1, Chr9ORF44, and RASA4.  IP6K1 and RASA4 were chosen for 
the gene expression experiments, as the FS-DMR occurs within or near the regulatory region 
of these genes and therefore will inform on whether methylation changes in the promoter 
regions of these genes equals changes in gene expression. Since the Chr9ORF44 FS-DMR is 
not known to occur within a regulatory region of a given gene, another gene from the 
preliminary Decrease in methylation group was chosen for the gene expression analysis: 
GPS2.  
All assays were carried out using the Roche LightcyclerTM 480 system in 10µl reactions 
containing 2X Lightcycler 480 High Resolution Melting Master, 2.5mM magnesium chloride, 
and variable concentrations of forward and reverse primer (Table 4.1). For each reaction, the 
following programme was used: Pre-incubation, 95oC for 10 seconds; Amplification (45 
cycles), 95oC for 10 seconds, variable annealing temperature (Table 4.1) for 15 seconds, and 
72oC for 15 seconds; Melting, 95oC for 1 minute, 40oC for 1 minute, 70oC for 5 seconds, and 
95oC continuous with a ramp-rate of 0.02oC/s and 25 acquisitions every 1oC; Cooling, 40oC 
for 10 seconds.   
4.2.3: SMART MSP Optimisation 
The optimisation of the SMART-MSP assays followed a three-pronged approach. First, using 
100% and 0% DNA methylation standards (Qiagen), an appropriate annealing temperature 
that caused the reaction to preferentially amplify the methylated template was determined. 
Increasing the temperature by 1oC increments was found to slowly increase CP values (i.e. 
inhibiting amplification) while eliminating primer-dimer formation. When a suitable 
annealing temperature was found, a 9-reaction primer curve containing every combination of 
forward and reverse primer concentrations of 0.2µM. 0.3µM, and 0.4µM was used. Primer 
concentrations that produced a single product favouring methylated DNA and producing as 
little non-specific amplification were chosen. 
To confirm that the assays were working as expected, two standard curves were run on each: 
one with a decreasing quantity of DNA to determine the PCR efficiency of the reactions, and 
another serial dilution of the 100% standard against the 0% standard. After each assay was 
optimised, it was apparent that each was behaving differently and would require a unique 
approach in the subsequent analysis, discussed further in Section 4.3.1.  
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4.2.4: SMART MSP FASSTT Screening 
Prior to screening, each FASSTT sample was sodium bisulfite treated using the Qiagen 
EpiTect kit according to the manufacturer’s instructions with one alteration: 1µg DNA was 
used in each reaction and eluted in 100µl dH2O. Levels of amplifiable DNA were determined 
using the COL2A1 assay described by Kristenisn et al., (2008)146. This is an assay with no 
CpGs in its primer or product region, and therefore does not differentiate between methylated 
and unmethylated DNA. For the ΔΔCT calculations described later, COL2A1 was treated like 
an endogenous control. This assay was also optimised and tested for performance based on 
the criteria outlined in Section 4.2.3. Each assay was performed in duplicate. Standards of 
100% and 0% methylation were included on each plate, along with a negative no-template 
control. Melting peak data was used to confirm that the correct product had amplified for each 
sample, while methylation percentages were calculated from the CP data using the following 
formula: 
100 * 2^ - (Sample [Cp Target – Cp COL2A1] – 100% [ Cp Target – Cp COL2A1]) 
Here, ‘Target’ refers to the gene of interest, and ‘Calibrator’ refers to the COL2A1 assay. This 
formula is accurate where PCR efficiencies for both the gene of interest and the COLA1 assay 
are approximately identical146. Where PCR efficiencies were not similar, some calculations 
yielded a value greater than 100%. To address this, the CP and Tm values of each of these 
samples were examined to determine if the methylation percentage should be adjusted to 
100%, or discarded from the dataset entirely.  
4.2.5: HEK293 5’Azacytidine cytotoxicity assay  
The toxicity assay for HEK293 cells treated with 5aC was carried out on a 24-well plate (6 
x103 cells per well). A 40µM stock of 5’azacytidine was made in 50% acetic acid, which was 
then diluted down to various concentrations in DMEM (0.5μM, 3μM, 6μM, 12μM and 25μM). 
Media containing acetic acid was added after the cells attached to the flask. Every day, each 
well containing 5aC had its media changed. To control for the effect of acetic acid, wells 
containing acetic acid alone – proportional to the amount used in the 25µM 5aC sample – were 
included on the plate. Control-wells with cells seeded below and above 6x103 cells per well 
were also included to ensure cells grew correctly over the 7 day period. Cell density was 
measured using the crystal violet assay described in Section 2.2.4. 
For the 5aC experiments themselves, cells were grown in T75 flasks for 7 days with the media 
being changed every 24 hours due to the short half-life of the drug191. Control flasks containing 
acetic acid and no drug were maintained in parallel to the 5aC flasks. Once the time-course 
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was complete, DNA and RNA were extracted from cells treated with both 5aC and acetic acid 
in biological duplicates.  
4.2.6:  Reverse-Transcription Quantitative-PCR  
RNA was extracted from HEK293 cells using Bioline’s Isolate II RNA mini kit as described 
in Chapter 2, Section 2.3.1 and reverse-transcribed as described in Section 2.3.21. cDNA was 
analysed using a genomic contamination assay already established in the lab (Section 2.3.22).  
Once a band at 232bp was observed for amplified cDNA without genomic DNA 
contamination, gene-expression levels were analysed using the UPL RT-qPCR assays 
described in Section 2.3.23. All samples were run in duplicate, with negative-RT and no 
template negative controls on each plate. 
4.2.7: DNA Extraction from HEK293 cells  
DNA was extracted from the HEK293 cells using Qiagen’s Flexigene kit (Section 2.3.1), and 
quantified on the ND-1000 spectrophotometer from Mason Technology measuring at A260nm 
(Section 2.3.5). Quality was assessed by agarose gel electrophoresis, with a thick high 
molecular weight band representing genomic DNA (Section 2.3.3).  
Prior to sodium bisulfite treatment, DNA was RNase-treated with 25 µg Ribonuclease (Sigma-
Aldrich) for 30 minutes at 37oC. DNA was then ethanol precipitated with 0.3M sodium acetate 
and two volumes of isopropanol. DNA was quantified and checked for quality again after 
RNase treatment. Since RNase is an incredibly formidable enzyme, it was necessary to carry 
this out in another lab, followed by an ethanol precipitation step to ensure the DNA was clean 
of any of the contaminating enzyme. Sodium bisulfite treatment of DNA was carried out as 
described in Section 2.3.19. 
4.2.8: Data analysis and statistics 
P-values from FASSTT cohort methylation screening were obtained using single factor 
ANOVA. Values for methylation changes were placed in three bins: Up (>10%), Down (<-
10%), and No Change (-10% ≤x ≤10%). The spread of data across these three bins was tested 
for significance. Net changes across the cohort were analysed by combining values from the 
Up and Down bins together, with single-factor ANOVA testing for significance. ANOVA was 
selected to test for significance due to there being three independent groups in this analysis.  
All HEK293 experiments were carried out with technical and biological duplicates. Mean and 
standard deviation values for both RT-qPCR and DNA methylation analysis were obtained 
from four datapoints for each experiment. Single-factor ANOVA was used to test for 
significance. RT-qPCR analysis was carried out on the Roche LightcyclerTM.  
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4.3: Results 
4.3.1: Design and Optimisation of SMART-MSP assays 
SMART MSP assay sequences are described in Section 2.1.3, with their relative genomic 
position detailed in Appendix D, Figure D.1-D.4. Each of the four SMART MSP assays—
IP6K1, Chr9ORF44, RASA4, and GPS2—were optimised against methylated and 
unmethylated standards, with optimum conditions listed in Table 4.1. In each case, a standard 
curve of methylated DNA diluted into unmethylated DNA was obtained to evaluate how the 
assays worked on a heterogeneous mix of DNA; typical of the samples in the FASSTT study. 
After this, a second standard curve was found for methylated DNA diluted into water, in order 
to obtain a PCR efficiency for each assay (Appendix D, Figure D.5-D10). As described below, 
each assay had its own unique qualities which needed to be taken into account during the 
screening process.  Some assays amplified methylated DNA only, while others amplified both 
methylated and unmethylated DNA. A third type of peak is also sometimes observed: a 
primer-dimer peak which is identifiable from the negative control. A careful examination of 
the melting curves (which shows the different types of PCR products that are being amplified) 
was required to assess which was the case for each assay before the CP data could be 
interpreted accurately.  
IP6K1: The melting curve data for the IP6K1 assay indicates that there are just two types of 
peaks amplified for this assay (Figure 4.1). A methylated peak (Tm approx. 76.6oC), and a 
primer-dimer peak (Tm approx. 74.7 oC).  CP values arising only from the methylated peak 
were used in subsequent calculations.  
Chr9ORF44: The melting curve data for the Chr9ORF44 assay indicates that there are just 
two types of peaks amplified for this assay (Figure 4.2). A methylated peak (Tm approx. 
78.4oC) and an umethylated peak (Tm approx. 77.4oC). CP values arising only from the 
methylated peak were used in subsequent calculations. No amplification was observed for no-
template negative controls. Samples containing methylated DNA as low as 10% manifest as a 
methylated peak for this assay, with those at 1% generating a peak consistent with no 
methylation. As a result, this assay cannot differentiate between 1% and 0% DNA 
methylation, but can be used to determine methylation percentages above 10%. 
RASA4:  The melting curve data for the RASA4 assay indicates that there are just two types 
of peaks amplified for this assay (Figure 4.3). A methylated peak (Tm approx. 77.8oC) and a 
primer-dimer peak (Tm approx. 71.5oC). The SMART MSP calculation will be used only in 
products that exhibit methylated peaks. 
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GPS2: The melting curve data for the GPS2 assay indicates that there are just two types of 
peaks amplified for this assay (Figure 4.4). A methylated peak (Tm approx. 81oC) an 
unmethylated peak (Tm approx. 78.5oC). At 10%, methylation, a double-peak with both 
products forms. No amplification was evident in the no-template negative control. The 
SMART MSP calculation will be used only in products that exhibit methylated peaks. 
4.3.2: Assessment of the control Col2A1 assay in the FASSTT cohort 
The level of amplifiable DNA in each of the sodium bisulfite-treated FASSTT samples was 
determined using the COL2A1 assay described by Kristentisen et al146. With no CpGs in either 
primer sequence, this assay does not discriminate between methylated and unmethylated 
DNA. Also, with no CpGs present in the PCR product itself, the Tm for both methylated and 
unmethylated products are the same. As a result, no CpG methylation can occur between the 
COL2A1 primers. The only variable in the COL2A1 assay is the amount of amplifiable, 
bisulfite-treated DNA present in the sample.  
Of all the samples treated, 10 out of 238 did not amplify with this assay indicating that they 
did not contain enough amplifiable DNA following bisulfite conversion. Of these, some had 
low concentrations of DNA before treatment, but even those with high concentrations initially 
failed to amplify after treatment. Repeated conversions of these samples failed to produce 
DNA capable of being amplified by the COL2A1 assay.  
As each methylation assay would be normalised to the COL2A1 data, it was vital that the 
consistency of this data was verified. To this end, the COL2A1 assay was run in duplicate for 
each sample from the FASSTT study and run on two separate occasions with different batches 
of reagents.  Relative ratios of the result of the first run was compared to the second run, and 
those outside the range 0.8 – 1.20 were considered inconsistent and discarded. A second 
screening of COL2A1 across the cohort was carried out, and values were compared to the 
first. Of the 230 samples remaining, 28 produced inconsistent results and were also excluded 
from the analysis (Table 4.2. Raw data supplied in Appendix E.1). 
4.3.3: Methylation analysis of the FASSTT cohort 
Methylation percentage values were calculated for each sample based on the calculation 
described in Section 4.2.4. Similarly to how we identified FS-DMRs in Chapter 3, differences 
in methylation were assessed for each sample individually first, comparing methylation levels 
either side of intervention for each participant.  The methylation change determined by 
subtracting the percentage methylation in the pre-intervention sample from the post-
intervention sample.  This percentage difference value was then placed into one of three 
groups: Increased methylation, decreased methylation, and no change. These groups were 
116 
 
 
further subdivided as to whether they were from the folic acid intervention group or placebo. 
Having assessed the sensitivity of each assay using the standard curves, it was deemed that 
samples exhibiting a difference of less than 10% had no change in methylation.  
Inositol hexakisphosphate kinase 1: MeDIP Group: Increased methylation. The majority of 
samples analysed with the IP6K1 assay showed no change in DNA methylation before and 
after intervention (Figures 4.5-4.6). Differences that were observed failed to reach statistical 
significance (p = 0.95). Samples from the Up and Down bins were divided into their respective 
groups, folic acid (n=6), and placebo (n=4), and net methylation change was measured for 
each. Differences observed here failed to reach statistical significance, (p=0.19). Raw data 
supplied in Appendix E.2. 
Chromosome 9 Open Reading Frame 44: MeDIP Group: Decreased methylation. Although 
more variance in the data was observed overall for Chr9ORFF44 than IP6K1 (Figure 4.7), 
most samples exhibited no change in methylation in response to intervention (Figure 4.8). 
Those in the placebo group did respond more dramatically than the intervention group for both 
an increase and decrease in methylation, but this difference did not reach statistical 
significance (p = 0.74). Net changes were measured from samples showing increased or 
decreased methylation, but when divided into their respective groups, folic acid (n=20) and 
placebo (n=28), the differences observed failed to reach statistical significance (p=0.33). Raw 
data supplied in Appendix E.3. 
RAS p21 protein activator 4: MeDIP Group: ON/OFF methylation. Across the majority of 
the cohort, no DNA methylation was observed for RASA4 (Figure 4.9). Similarly to the two 
examples above, the differences that were observed did not reach statistical significance 
(Figure 4.10 A, p = 0.9). For the folic acid (n=6) and placebo (n=7) groups, net methylation 
changes were calculated, but failed to reach statistical significance (p=0.67). Raw data 
supplied in Appendix E.4. 
Along with examining differences in methylation between the folic acid and placebo group, 
the clinical data of samples that exhibited the most dramatic changes were compared to one 
another. For IP6K1, the single sample with the greatest decline in methylation was found to 
have low B12 levels when compared to the rest of the cohort. Likewise, the sample showing 
the second-largest decline in methylation for Chr9ORF44 was also found to have low levels 
of B12. However, the sample with the largest decline in methylation for this region did not 
match the emerging trend. For RASA4, two samples showed a considerable increase in DNA 
methylation. One of these two individuals was homozygous for the rare TT variant of the 
MTHFR polymorphism, while the other had the wild type CC variant. 
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4.3.4: Assessment of HEK293 Growth Curve in the presence of varying concentrations 
of 5’Azacytidine  
On a 24-well plate, a crystal violet assay was carried out to -find the optimum concentration 
of 5aC that maintained cells in the log phase of growth. At a concentration of 5µM, the drug 
was found to have the most significant effect on growing cells while keeping them in the 
exponential phase by Day 7. Higher concentrations lead to significant cell death, while lower 
concentrations arrested growth before the 7 day time-course was complete (Figures 4.11-
4.12). 
4.3.5: Nucleic Acid Extraction and Integrity 
After extractions were carried out based on the protocols outlined in Section 2.3.1, the 
concentrations of nucleic acid was assessed using the nanodrop ND-1000 spectrophotometer 
from Mason Technology measuring at A260nm, and integrity was assessed via gel 
electrophoresis. Figure 4.13 shows intact, undegraded RNA on a 1% gel, while a 
demonstration that the resulting cDNA was free from contaminating genomic DNA was 
shown using an intron flanking PCR based assay, (Figure 4.14).  
4.3.6: Gene Expression Analysis of HEK293 Cells treated with 5’Azacytidine by RT-
qPCR 
 RT-qPCR assays for IP6K1, RASA4, and GPS2 were designed using the UPL assay design 
centre website from Roche (http://lifescience.roche.com/shop/products/universal-
probelibrary-system-assay-design). An assay designed for GUS was used as an endogenous 
control, with a relative ratio between both experimental conditions established to be 0.92 
(Appendix G.1). Standard curves and PCR efficiencies were obtained for each assay 
(Appendix G.2-G.4), which were incorporated into the Lightcycler 480’s E Calculations.  
Data is displayed from Figures 4.15 to 4.17. Experiments were carried out in biological and 
technical duplicates, with mean and standard deviations derived from four data-points. All 
assays showed the same results, with 5’Azacytidine increasing expression levels of each gene. 
Experiments for IP6K1 exhibited an increase in expression exceeding 10-fold (p=0.007). The 
increases in gene expression of RASA4 were not as dramatic as that for IP6K1, but was 
significantly increased (p=0.015). For GPS2, an increase in gene expression was also observed 
(p=0.003). The results indicate that 5aC treatment of HEK293 cells has a significant and 
consistent impact on gene expression at these particular loci.  
4.3.7: Gene specific DNA methylation analysis of 5’Azacytidine treated HEK293 cells 
The gene expression results from Section 4.3.6 cannot be concluded to be caused by changes 
in methylation alone, however. As described by Komashko et al., (2010)191, treatment of 
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HEK293 cells with 5aC results in a genome-wide impact on expression, altering the 
transcription of genes regardless of their methylation status. Indeed, as demonstrated by the 
cytotoxicity assay in Section 4.3.4, exposure to the drug alone results in cell death. Given the 
plasticity of the transcriptome and its capacity to adapt to changes in the environment, more 
evidence that changes in gene expression observed through RT-qPCR were caused by 
demethylation of their promoter regions is required. 
SMART-MSP assays IP6K1, RASA4, and GPS2 were carried out on each DNA sample 
extracted from HEK293 cells treated with 5aC. Results were obtained using the standard 
SMART MSP calculations outlined in Section 4.2.4. In each case, 5aC treatment of HEK293 
cells successfully resulted in a decrease in DNA methylation (Figures 4.18-4.20).  
In cells treated with 5µM 5aC for 7 days, methylation at the IP6K1 locus decreased 
significantly (p = 2.23E-05). For RASA4, the decrease in methylation was less pronounced, 
but still statistically significant (p = 0.009). For GPS2, the loss of methylation was also 
statistically significant (p=0.019). In each of these cases, a decrease in DNA methylation at a 
promoter region is mirrored by an increase in gene expression. 
It is clear that 5’azacytidine treatment did not completely eliminate DNA methylation across 
the genome, as predicted by Falck et al., (2012)190. Only the region analysed by the IP6K1 
assay reached levels lower than 10% when exposed to the drug. Nonetheless, high levels of 
demethylation were found in each region, each consistent with an increase in gene expression 
for their associated genes.  
4.4: Discussion 
The primary aim of this project was to assess the effect of folic acid supplementation on DNA 
methylation during pregnancy. As a methyl donor for DNA methyltransferase reactions, folic 
acid and its folate derivatives have been hypothesised and demonstrated to influence DNA 
methylation on both a genome-wide and gene-specific level3,111,196,197. With the beneficial 
effects of folic acid during pregnancy being well established but poorly understood, DNA 
methylation has been considered to be a candidate for linking the cause and effect of 
periconceptional supplementation.  
The FASSTT study was designed to study the effects of folic acid supplementation after week 
12 of pregnancy4. During pregnancy, higher levels of circulating homocysteine have been 
associated with an increased risk of conditions including NTDs, preeclampsia, and recurrent 
early pregnancy loss198–200 relative to unaffected pregnancies198–200. Folate status is a major 
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determinant of homocysteine levels, as it is required for the methylation of homocysteine to 
methionine201. Accelerated folate catabolism has been reported to occur during a typical 
pregnancy202, which may contribute to the decrease in circulating folate levels found in other 
studies26. Recommended folic acid supplementation procedures during the first trimester aim 
to prevent this decline, but little has been known about its past week 12 of pregnancy. The 
FASSTT study has found that folic acid supplementation can prevent the decline in serum and 
red cell folate levels and the increase in homocysteine levels that occurs otherwise during 
pregnancy4.  
In order to examine the methylation levels of DNA extracted from the blood samples used in 
this study, a literature survey was first carried out to examine the different methods of genome-
wide and gene-specific DNA methylation analysis used in the field5. Although successful in 
finding methods suitable for the scope and scale of this project, it was clear from the review 
that the vast majority of methods established for DNA methylation analysis were conceived 
for the purpose of finding aberrant methylation patterns in cancer134,138,146. For each of the 
three methods discussed in this thesis – MMSDK, MeDIP, and SMART MSP – the “proof-
of-concept” experiments carried out in all of their respective publications were on DNA 
derived from cancerous tissue where dramatic DNA methylation differences are known to 
occur.  
From the subset of the FASSTT cohort subjected to MeDIP and promoter DNA microarray 
hybridisation, a preliminary list of FS-DMRs was obtained. Using highly astringent selection 
criteria, this list was narrowed down to five; far fewer than what is typically reported in studies 
using MeDIP to find DMRs between cancerous and healthy cell-lines170,203,204. In the 
subsequent analysis, when three of these FS-DMRs were examined over an extended cohort 
using a different, gene-specific method, no significant difference was observed. Some 
individual samples exhibited major changes in DNA methylation levels for these sites in 
comparison to the rest of the cohort, and clinical data for each was examined. Of the five 
individuals examined, 2 were found to have lower B12 levels when compared to the rest of the 
cohort, while 1 was a TT homozygote for the MTHFR 677 C>T polymorphism. Without a 
consistent trend amongst these samples, however, no conclusion can be made from these 
findings. 
Although these methods were not specific for examining tumourigeneis, the changes in 
methylation observed in the FASSTT study were not as significant as those presented in the 
cancer case-studies used to demonstrate their efficiency and specificity. The difficulty lies in 
the nature of the FASSTT samples themselves: the differences in DNA methylation levels 
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affected by supplementation in a healthy individual over a short period of time would never 
be as dramatic as those reported from tumourgenesis32,169,171,175. This, along with the 
differences in DNA methylation patterns that exist between individuals prior to intervention, 
has made analysing the effect of folic acid supplementation on DNA methylation particularly 
challenging.  
The cell culture analysis did yield conclusive results, however. When the promoter regions of 
IP6K1, RASA4, and GPS2 are subjected to demethylation in vitro, a consistent increase in 
gene expression is observed demonstrating that DNA methylation changes have a direct 
impact on the gene expression of these genes.  
The DNA methylation analysis on the FASSTT cohort did not find measurable changes in 
DNA methylation in response to folic acid supplementation, but if those differences did exist 
on a smaller scale, other methods of genome-wide methylation analysis using next generation 
sequencing and sodium bisulfite treatment to generate data at a single-base-pair resolution 
could be used to elucidate them. With evidence here that DNA methylation does in fact affect 
the expression of these genes, there is potential for a follow-up study to re-examine these 
proposed FS-DMRs using more sophisticated technology, such as sodium bisulfite 
pyrosequencing.  
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  Cp Cp  Average  STDEV Tm  Tm Average  STDEV 
100% 26.10 26.19 26.15 0.0636 76.63 76.64 76.64 0.0071 
50% 27.30 27.09 27.20 0.1485 76.62 76.49 76.56 0.0919 
10% 29.73 29.61 29.67 0.0849 76.49 76.42 76.46 0.0495 
1% 32.09 33.52 32.81 1.0112 76.65 76.56 76.61 0.0636 
0% 35.62 36.09 35.86 0.3323 74.79 74.50 74.65 0.2051 
neg 35.50 35.85 35.68 0.2475 74.99 74.96 74.98 0.0212 
 
Figure 4.1: Melting profile of IP6K1 SMART MSP Assay 
Melting peaks of products from IP6K1 assay. Blue Peak = methylated DNA (~76.6oC); Red 
peak = unmethylated DNA (74.7oC); Grey peak = no-template negative control (~74.7oC). 
Methylated and unmethylated DNA PCR products generate distinct melting peaks. The 
product of the no-template negative control has a peak similar to that of the unmethylated 
standard, both arising from primer-dimer formation. Only Cp values from the methylated peak 
(~76.6oC) were considered for the SMART-MSP methylation percentage calculation.  
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  Cp Cp  Average  STDEV Tm  Tm Average  STDEV 
100% 27.43 27.90 27.67 0.3323 78.41 78.35 78.38 0.0424 
50% 28.64 29.19 28.92 0.3889 78.32 78.30 78.31 0.0141 
10% 30.22 30.74 30.48 0.3677 78.17 78.22 78.20 0.0354 
1% 31.08 31.12 31.10 0.0283 77.51 77.31 77.41 0.1414 
0% 30.28 30.33 30.31 0.0354 77.37 77.32 77.35 0.0354 
neg N/A N/A N/A N/A N/A N/A N/A N/A 
 
Figure 4.2: Melting profile of Chr9ORF44 SMART MSP Assay 
Melting peaks of products from Chr9ORF44 assay. Blue Peak = methylated DNA (~78.3oC); 
Grey peak = unmethylated DNA (77.5oC); Yellow peak = no-template negative control (no 
amplification). Methylated and unmethylated DNA PCR products generate distinct melting 
peaks. Tm scores indicate that samples with 100% to 10% methylated DNA will generate a 
product at ~78.3oC, while those from 1% to 0% produced a peak at 77.5oC. Only Cp values 
from the methylated peak (~78.3oC) were considered for the SMART-MSP methylation 
percentage calculation.  
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  Cp Cp  Average  STDEV Tm  Tm Average  STDEV 
100% 24.54 24.8 24.67 0.1838 76.96 76.8 76.88 0.1131 
50% 26.47 26.21 26.34 0.1838 76.77 76.69 76.73 0.0566 
10% 27.48 27.36 27.42 0.0849 76.02 76.08 76.05 0.0425 
1% 28.86 28.22 28.54 0.4526 Early 
Peak 
Early 
Peak 
Early 
Peak 
Early Peak 
0% 35.65 35.91 35.78 0.1838  Early 
Peak 
Early 
Peak 
Early 
Peak 
Early Peak 
neg 34.83 33.50 34.165 0.9405 Early 
Peak 
Early 
Peak 
Early 
Peak 
Early Peak 
 
Figure 4.3: Melting profile of RASA4 SMART MSP Assay 
Melting peaks of products from RASA4 assay. Blue Peak = methylated DNA (~77.8oC, with 
a shoulder of ~71.5oC); Red peak = unmethylated DNA and no template negative controls 
(71.5oC); Orange peak = 10% methylated DNA, (peaks at 76.8oC and 71.5oC). Only Cp values 
from the methylated peak (~76.8oC) were considered for the SMART-MSP methylation 
percentage calculation.  
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  Cp Cp  Average  STDEV Tm  Tm Average  STDEV 
100% 31.67 31.79 31.73 0.0849 80.86 80.83 80.85 0.0212 
50% 32.56 32.52 32.54 0.0283 80.71 80.66 80.69 0.0354 
10% 35.72 35.53 35.63 0.1344 79.97 79.98 79.98 0.0071 
1% 35.32 37.14 36.23 1.2869 78.98 78.92 78.95 0.0424 
0% 35.02 35.71 35.37 0.4879 78.83 78.89 78.86 0.0424 
neg N/A N/A N/A N/A N/A N/A N/A N/A 
 
Figure 4.4: Melting profile of GPS2 SMART MSP Assay 
Melting peaks of products from GPS2 assay. Blue Peak = methylated DNA (~80.8oC); Red 
peak = unmethylated DNA (78.5oC); Grey peak = 10% methylated DNA, (peaks at 81oC and 
78.5oC). Only Cp values from the methylated peak (~81oC) were considered for the SMART-
MSP methylation percentage calculation. No template negative controls exhibit zero 
amplification. 
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Figure 4.5: Scatterplot of IP6K1 methylation changes for all FASSTT samples 
Regardless of their grouping, the change in methylation at the IP6K1 locus before and after 
intervention (Y-axis) was plotted for each participant of the FASSTT cohort. Changes of 10% 
increase or decrease (red lines) were deemed no change due to the insensitivity of the assay to 
detect consistent changes in this range. The single patient that showed the greatest decline in 
methylation was found to also have low B12 levels when compared to the rest of the cohort. 
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Distribution of methylation changes for IP6K1 across FASSTT cohort  
Intervention Up Down No Change Total 
FA 2 4 42 48 
Placebo 3 1 48 52 
Total 5 6 96 107 
B 
 
 
Figure 4.6: FASSTT cohort methylation changes for IP6K1 
A: All methylation % changes for IP6K1 across the FASSTT cohort were divided into three 
groups. Up (>10%), Down (<-10%) and No Change (-10 ≤x ≤10). The vast majorty of these 
samples fall into the No Change group. Differences observed between the FA and Placebo 
group failed to reach statistical significance (p=0.95) according to single-factor ANOVA 
analysis. B: All samples excluding those exhibiting no change were divided into either their 
respective groups, folic acid (n=6), and placebo (n=4), and mean net methylation levels were 
measured, with the range represented by error bars. Differences observed here failed to reach 
statistical significance, (p=0.19) according to single-factor ANOVA analysis. 
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Figure 4.7: Scatterplot of Chr9ORF44 methylation changes for all FASSTT samples 
Regardless of their grouping, the change in methylation at the Chr9ORF44 locus before and 
after intervention (Y-axis) was plotted for each participant of the FASSTT cohort. Changes 
below 10% (red lines) were deemed to exhibit no change. The single sample with the second-
largest decline in methylation was found to have low levels of B12.  
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A  
Distribution of methylation changes for Chr9ORF44 across FASSTT cohort  
Intervention Up Down No Change Total 
FA 11 9 30 50 
Placebo 13 15 31 59 
Total 27 25 63 115 
B 
 
Figure 4.8: FASSTT cohort methylation changes for Chr9ORF44 
A: All methylation percentage changes for Chr9ORF44 across the FASSTT cohort were 
divided into three groups. Up (>10%), Down (<-10%) and No Change (-10 ≤x ≤10). Again, 
the majorty of these samples fall into the No Change group. For the placebo group, more 
individuals exhibited measurable changes in methylation percentages than those taking folic 
acid, though these numnbers failed to reach statistical significance (p=0.75) according to 
single-factor ANOVA analysis. B: All samples excluding those exhibiting no change were 
divided into either their respective groups, folic acid (n=20), and placebo (n=28), and mean 
net methylation levels were measured, with the range represented by error bars.. Differences 
observed here failed to reach statistical significance, (p=0.33) according to single-factor 
ANOVA analysis. 
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Figure 4.9: Scatterplot of RASA4 methylation changes for all FASSTT samples 
Regardless of their grouping, the change in methylation at the RASA4 locus before and after 
intervention (Y-axis) was plotted for each participant of the FASSTT cohort. Changes below 
10% (red lines) were deemed to exhibit no change. Two samples exhibited a greater increase 
in methylation in comparison to the rest of the cohort. One of these samples was TT 
homozygous for the MTHFR C>T polymorphism, while the other was found to have low 
levels of serum folate when compared to the rest of the cohort.  
 
 
 
 
 
 
 
-20
-10
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80 100
C
h
an
ge
 in
 M
e
th
yl
at
o
n
 %
FASSTT Participents
130 
 
 
A 
Distribution of methylation changes for RASA4 across FASSTT cohort  
Intervention Up Down No Change Total 
FA 4 2 43 49 
Placebo 6 1 50 57 
Total 10 4 98 112 
 
B 
 
Figure 4.10: FASSTT cohort methylation changes for RASA4 
A: All methylation % changes for RASA4 across the FASSTT cohort were divided into three 
groups. Up (>10%), Down (<-10%) and No Change (-10 ≤x ≤10). Again, the majorty of these 
samples fall into the No Change group. No changes here reached statistical significance 
(p=0.9) according to single-factor ANOVA analysis. B: All samples excluding those 
exhibiting no change were divided into either their respective groups, folic acid (n=6), and 
placebo (n=7) and mean net methylation levels were measured, with the range represented by 
error bars.  Differences observed here failed to reach statistical significance, (p=0.67) 
according to single-factor ANOVA analysis. 
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Figure 4.11: HEK293 Cytotoxcity Assay with 5’Azacytidine Treatment 
Cells were seeded in a 24-well plate at  a seeding denstiy of 3 x105 with varying 
concentreations of 5aC for 7 days. Control wells containing cells above and below seeding 
density were included to ensure uniform cell proliferation throughout the timecourse. Baseline 
readings were taken from cells grown in acetic acid, the vehical for 5aC.  This data suggests 
a uniform death at concentrations above 6µM, and little effect below 3µM. As a result, DNA 
and RNA will be extracted from cells grown in 5µM 5aC over 7 days. Raw data included in 
Appendix F.1. 
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Figure 4.12: HEK293 Percentage Cell Death with 5’Azacytidine 
Data from cytotoxicity assay represented as a percentage of overall cell death. Although 
absolute cell death was not observed in the higher concentrations of 5aC, it was necessary to 
maintain cells in the log phase of growth over the 7-day timecourse to ensure passive 
demethylation occurred with each successive cell cycle. For this reason, 5µM 5aC was chosen 
for the DNA methylation and gene expression experiments.  
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Figure 4.13: RNA extracted from 5aC-treated HEK293 Cells 
RNA extracted from HEK293 cells on a 1% agarose gel. Two subunites of ribosomal RNA 
(28s and 18s) are visible along with mRNA (smear) and tRNA. Samples in lane 1 and 2 are 
denatured RNA extracted from HEK293 cells treated with 5’azcytidine.  
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Figure 4.14: cDNA Genomic Contamination test  
Products of a PCR that flanks an intron in the MTHFD1 gene separated on a 1% agarose gel. 
With primers spanning an intron, cDNA fragments amplified at 232bp, while contaminating 
genomic DNA manifests as a band at 330bp. Lanes 1 to 4 were loaded with cDNA samples 
from HEK293 cells treated with 5’azacytidine (samples A0, A5, B0, and B5 respectively). A 
positive control (lane 6) was included with HEK293 genomic DNA amplified with the same 
primers. The former products appear on the gel at 232bp, with the latter at 330bp. There is no 
genomic contamination in these cDNA samples. The 100bp ladder from New England Biolabs 
was loaded in lane 1. 
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Figure 4.15: IP6K1 Gene Expression in response to 5aC Treatment 
IP6K1 expression was found to increase when cells were treated with 5’azacytidine. Cells 
treated with acetic acid and no 5aC, as described in Section 4.3.4, were used as a baseline. 
Data taken from two biological replicates. Results reached statistical significance according 
to single-factor ANOVA analysis (p = 0.007). Raw data presented in Appendix G.5 
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Figure 4.16: RASA4 Gene Expression in response to 5aC Treatment 
RASA4 expression was found to increase when cells were treated with 5’azacytidine. Control 
cells (0µM) treated with acetic acid and no 5aC, as described in Section 4.3.4, were used as a 
baseline. Data taken from two biological replicates. Results reached statistical significance 
according to single-factor ANOVA analysis (p = 0.015). Raw data presented in Appendix G.6. 
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Figure 4.17: GPS2 Gene Expression in response to 5aC Treatment  
GPS2 expression was found to increase when cells were treated with 5’azacytidine (5µM). 
Control cells (0µM) treated with acetic acid and no 5aC, as described in Section 4.3.4, were 
used as a baseline. Data taken from two biological replicates. Results reached statistical 
significance according to single-factor ANOVA analysis (p = 0.003). Raw data presented in 
Appendix C, Table C.6.2. 
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Figure 4.18: IP6K1 DNA Methylation in response to 5aC Treatment 
IP6K1 SMART MSP assay confirms that HEK293 treatment with 5’azacytidine resulted in 
passive demethylation in biological replicates A and B. DNA was extracted from cells treated 
with 5µM 5’azacytidine (A5 and B5) and acetic acid (A0 and B0) for 7 days and sodium 
bisulfite treated using Qiagen’s Epitect Fast kit. Results reached statistical significance 
according to single-factor ANOVA analysis (p= 2.23E-05).  
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Figure 4.19: RASA4 DNA Methylation in response to 5aC Treatment 
RASA4 SMART MSP assay confirms that HEK293 treatment with 5’azacytidine resulted in 
passive demethylation. DNA was extracted from cells treated with 5µM 5’azacytidine (5µM) 
and acetic acid (0µM) for 7 days and sodium bisulfite treated using Qiagen’s Epitect Fast kit. 
Results reached statistical significance according to single-factor ANOVA analysis (p= 
0.009). 
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Figure 4.20: GPS2 DNA Methylation in response to 5aC Treatment 
GPS2 SMART MSP assay confirms that HEK293 treatment with 5’azacytidine resulted in 
passive demethylation in biological replicates A and B. DNA was extracted from cells treated 
with 5µM 5’azacytidine (A5 and B5) and acetic acid (A0 and B0) for 7 days and sodium 
bisulfite treated using Qiagen’s Epitect Fast kit. Results reached statistical according to single-
factor ANOVA analysis significance (p=0.019). 
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Table 4.1: SMART MSP Assay Conditions 
 Forward Primer  Reverse 
Primer 
Annealing Temp 
IP6K1  0.4µM 0.3 µM 63oC 
Chr9ORF44 0.4 µM 0.4 µM 59oC 
RASA4 0.4 µM 0.4 µM 56oC 
GPS2 0.4 µM 0.4 µM 56oC 
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Table 4.2: COL2A1 Consistency check across the FASSTT cohort 
Verdict   Number of Samples Percentage 
Pass  200 84.03 
Fail  28 11.76 
N/A  10 4.20 
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Chapter 5:  
Investigation of 
Dihydrofolate Reductase 
Post-Translational 
Modifications 
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5.1: Introduction 
5.1.1: The Epigenome beyond DNA methylation 
DNA methylation is not the only epigenetic modification capable of altering gene expression 
without affecting the sequence itself. Although DNA methylation is the most stable and 
heritable epigenetic modification, the word ‘epigenetics’ is now typically used in a broader 
sense than Waddington’s original definition of what he called the Epigenetic Landscape in 
1942: “the interaction between genes and their products to bring the phenotype into being205.” 
Today, epigenetics has become a loose term referring to any modification made to DNA or 
chromatin structure that impacts gene expression206. As a result, many cellular processes such 
as histones modification (including acetylation, methylation, ubiquitination and 
SUMOylation)103,207, nucleosome positioning208,209 and non-coding RNA localisation210,211 
have all been defined as ‘epigenetic modifications119,’ despite their lack of heritability in both 
a trans-generational and mitotic context.  
There is some controversy in the field regarding histone modifications, as a clear molecular 
mechanism to illustrate the self-propagation of these marks has yet to be elucidated212. To 
further complicate the issue, some cases have been reported where histone methylation has 
been found to be unstable from generation to generation, while the transcriptional effects 
established by it remain heritable213. A bimodal ‘buffer’ model has been proposed based on 
the heterologous nature of histone methylation to explain this. The model proposes that 
transcriptional inactivation is the result of high levels of methylation at a particular lysine 
residue – with lysine being capable of being mono-, di-, and tri- methylated. This creates a 
spectrum of histone methylation across a genetic domain, resulting in transcriptional 
repression unless a critical ‘low’ is reached. As a result, the transcriptional effects associated 
with histone methylation can be inherited intact mitotically, even if methylation levels are not 
completely stable from generation to generation214. This model indicates that post-
translational modifications of histones may constitute epigenetic programming to the same 
extent as DNA methylation. Interestingly, the demethylating agent 5’aza-2’cytidine described 
in Chapter 4 can impact on both DNA methylation and histone methylation195.  
Another histone modification is acetylation. Histone acetylation – classically associated with 
gene repression – is directly opposed by enzymatic deacetylation58. The dynamic relationship 
between histone acetylation and deacetylation, coupled with histone methylation, creates an 
image of what has been called the ‘histone code,’ – the sum of modifications made to histones 
that affect expression of their associated genetic material55. 
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Larger polypeptides such as ubiquitin and SUMO (small ubiquitin-like modifier) have also 
been implemented in gene activation and repression, respectively, as a result of histone 
modification215. The complementary relationship between ubiquitin and SUMOylation seems 
to mirror that of acetylation and deacetylation, which together build a stronger argument for a 
coherent system of genetic control via histone modification. Even if they cannot be identified 
as being ‘epigenetic’ in the strictest sense of the term, these unique and dynamic molecular 
marks have attracted considerable attention in the field, bringing us closer to decoding the 
histone code.  
It has recently been found that LSD1 – a histone demethylase – is a folate binding protein216. 
With DHFR, an enzyme involved in one-carbon metabolism, localising from the cytoplasm to 
the nucleus in response to SUMOylation43, it is possible that a strong link exists between 
folate, its metabolic enzymes, and gene control. It is already well established that acetylation 
of non-histone proteins can regulate transcription217, alluding to the possibility that post-
translational modifications of DHFR may have an impact on gene expression.  
5.1.2: Post translational modifications of Dihydrofolate Reductase  
Non-histone lysine acetylation is one of the most common covalent modification in eukaryotic 
cells, possibly analogous to phosphorylation: the regulatory “master-switch” of protein 
biology218,219. 
Broadly speaking, acetylation of a lysine residue neutralises its positive charge, and has been 
associated with increasing enzyme stability218. Some studies have demonstrated nuclear 
localisation of particular proteins after lysine acetylation218,220,221, along with SUMOylation222. 
In 2007, Anderson et al.,  showed that dihydrofolate reductase is capable of being 
SUMOylated in vitro43.  
As described in Chapter 1, DHFR (dihydrofolate reductase) plays a crucial role in folate 
metabolism, generating the active form of folate utilised from its dietary and synthetic 
analogues in the presence of NADPH223. Due to its significance in cell proliferation, DHFR is 
the target of various anti-folate chemotherapeutics, such as methotrexate and pemetrexed28,224.   
No evidence has been found for acetylation of DHFR in vitro, with Anderson et al., (2007)43 
being the only publication to show in vitro SUMOylation of the same enzyme. This, together 
with recent data suggesting an interaction between folate and LSD1, opens up the possibility 
that acetylation and SUMOylation compete for the same lysine residue, potentially playing a 
unique role in the compartmentalisation of enzymes involved in one-carbon metabolism.  
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5.1.3: Aims and Objectives 
Aim:  
This chapter aims to investigate the SUMOylation and acetylation capabilities of DHFR to 
begin to unravel the varied roles it’s likely to play during nuclear localisation. 
Objectives:  
•To identify potential SUMOylation and acetylation sites for DHFR in silico. 
• To produce a purified GST-tagged DHFR protein. 
• To confirm that the purified fusion protein exhibits reductase activity. 
• To compare SUMOylation and acetylation of DHFR in vitro.  
5.2: Methods 
5.2.1: In Silico Post-translational modification analysis 
Two programs were used to carry out our own in silico analyses: SeeSUMO 
(bioinfo.ggc.org/seesumo/) and SUMOplot (http://www.abgent.com/tools/). SeeSUMO uses 
random forest algorithms to compare up to 40 amino acid residues adjacent to the target lysine 
against other motifs found to be SUMOylated in the literature – approximately 35% of known 
SUMOylation sites do not contain the ΨKXE motif225. SUMOplot, on the other hand, aligns 
the input amino acid sequence against a SUMO consensus sequence known to bind to SUMO 
conjugating enzyme UBC9, incorporating possible amino acid substitutions with those 
exhibiting similar hydrophobicity in the case of mis-matching226. For acetylation sites, the 
software Scan-X was used, which takes a similar approach as SeeSUMO, but with a position 
weight matrix used instead of a random forest algorithm227. 
5.2.2: Recombinant protein production 
OneShot BL21-DE3 cells (New England Biolabs) were transformed as described in Section 
2.3.7 using a GST-tagged DHFR cloned in the pDEST15TM Gateway Cloning vector.  Cells 
were grown overnight and prepared as described in Section 2.3.8 before lysis and fractionation 
(Section 2.3.9). From this, soluble and insoluble fractions of protein were collected. The 
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soluble fraction was concentrated and diluted in bacterial lysis buffer as described in Section 
2.3.10. 
5.2.3: Recombinant protein analysis 
Soluble fractions were analysed using SDS PAGE and Western blotting (Section 2.3.4). Blots 
were probed with rabbit anti-DHFR (Abcam) at 1:10,000 in 5% fat free milk, followed by a 
HRP-conjugated anti-rabbit secondary antibody (Abcam) at a ratio of 1:50,000 in TBST 
(Section 2.1.2). DHFR fused to GST has an expected molecular weight of 48 kDa, while the 
purified recombinant DHFR protein from Sigma-Aldrich (used here as a positive control) has 
a molecular weight of 25 kDa. Unless otherwise stated, all blots were exposed for 15 – 30 
seconds with SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) for 
imaging.  
5.2.4: Solubilisation of DHFR-GST insoluble fractions 
Following fractionation and Western blotting, it could be seen that most of the DHFR fusion 
protein was remaining in the insoluble fraction so two strategies to resolubilise the protein 
were undertaken.  
The first has been previously described by Sirawaraporn et al., (1993)151. Briefly, the protein 
is denatured using 6M guanidine HCl, and then refolded with 20% glycerol (Section 2.3.11), 
solubilising the protein in the process. The second method, taken from the Molecular Probes 
manual for Glutathione agarose (G2879)228, requires the protein’s insoluble fraction to be 
resuspended in a buffer containing 1.5% N-lauroyl-sarcosine, 25mM triethanolamine, and 
1mM EDTA (pH 8.0) (Section 2.3.12). As in vitro SUMOylation analysis was to be carried 
out on resolubilised protein, it was imperative that it retained its enzyme activity, as this an 
indication that it has refolded into its functional conformation. 
5.2.5: Purification of GST-bound DHFR 
Purification of recombinant, GST-bound protein was carried out using affinity 
chromatography with glutathione agarose beads. This process exploits the strong binding 
affinity between GST and glutathione. Two methods were used to purify GST-bound protein: 
gravity-flow purification (for larger volumes), and batch purification (for small volumes) 
outlined in Section 2.3.13 and 2.3.14, respectively. Both processes produced three protein 
fractions: an unbound fraction, with protein that passed through the column without binding; 
a wash fraction, with loosely bound protein removed by the wash buffer; and an elution 
fraction, which should contain the target protein bound to GST. In most cases, the elution 
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fractions were concentrated using 35 kDa centrifugal filter-units (Millipore) before SDS 
PAGE analysis (Section 2.3.4). In these instances, the eluted protein has been divided further 
into three separate fractions; elution-neat, representative of the elution fraction prior to 
concentration; elution-concentrated, the concentrated form of the former; and elution-runoff, 
the by-product of the concentration process, which contains all protein molecules < 35 kDa, 
which excludes DHFR-GST at 48 kDa. 
All purified protein samples were stored at -20oC, and quantified using the Bradford assay 
described in Section 2.3.15. 
5.2.6: In vitro SUMOylation 
All in vitro SUMOylation reactions were carried out using the Active Motif SUMO-link kit, 
following the manufacturer’s instructions with any variations outlined in Section 2.3.17. 
Briefly, three reactions were set up for each protein of interest (POI): POI + SUMO, to test if 
the protein of interest is capable of being modified; POI + mutSUMO, which contains the 
protein of interest in the presence of a mutant SUMO molecule with a lower capacity to bind 
to its target; and a no-protein negative control, with no protein of interest present in the 
reaction. The negative control contains all the required components of the reaction, including 
the active SUMO protein.  
Recombinant p53 was supplied in the kit as an internal positive control, along with anti-p53 
and anti-SUMO antibodies. Antibody concentrations for these were prepared as per the kit 
protocol (1:5000 and 1:4000, respectively), with Western blots otherwise carried out as 
described in Section 2.3.4. 
5.2.7: Dihydrofolate Reductase Activity Assay 
Activity of purified and partially purified DHFR was analysed using the Dihydrofolate 
Reductase kit from Sigma-Aldrich (CS0340). The kit uses the decrease in absorbance at A340nm 
that occurs as NADPH is utilised by DHFR to measure the rate of the reaction. Taking into 
account the change in OD over time with the concentration of enzyme used and the extinction 
coefficient of the reaction, the specific activity of DHFR can be calculated. This calculation 
is summarised in the following formula: 
Units/mg P = (∆OD/min.sample) - (∆OD/min.blank) X d 
12.3 x V x mg P/ml 
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Where ∆OD/min represents the change in optical density over time; sample and blank refer to 
the ∆OD of the protein of interest and the same reaction without DHF, respectively; d refers 
to the enzyme’s dilution factor; V and mg P/ml refer to the volume and concentration of 
protein used, respectively. Finally, 12.3 is the extinction co-efficient of this reaction.  
Details of the protocol itself are described in Section 2.3.16. As mentioned previously, the 
blank used in the formula contains all the components of the reaction except for DHF in order 
to control for the background reduction of NADPH independent of DHFR. Inhibition assays 
were carried out on samples containing partially purified protein to control for impurities that 
may also reduce NADPH to NAD+. These assays involved the addition of methotrexate into 
the test reaction to see if the decrease in absorbance was completely arrested, thus confirming 
all changes previously observed were caused by DHFR activity alone. 
5.3: Results 
5.3.1 In silico analysis of DHFR post-translational modifications 
In silico analysis was carried out on the DHFR protein sequence to determine if it contained 
potential SUMOylation sites. Anderson et al., (2007) concluded that DHFR contains the 
known SUMOylation motif ΨKXE conserved across numerous species43, where Ψ is any 
hydrophobic amino acid, K is the lysine to be SUMOylated, X is any other amino acid, and E 
is glutamic acid. The lysine they found to be SUMOylated was K179.  
Both programmes (SeeSUMO and SUMOplot, Section 5.2.1) found lysine K81 to have the 
highest probability of being SUMOylated, with a confidence level of 43.68 from SeeSUMO 
and a prediction score of 0.8 from SUMOplot (Figure 5.1). Scan-X found K179 to have the 
highest match for acetylation (Scan-X score of 6.156).  
A Clustal alignment of DHFR found the K81 SUMOylation motif to be conserved across 
mammalian species, along with K179 SUMOylation motif described by Anderson et al., 
(2007)43. The K179 acetylation motif – being longer than the SUMOylation motif – does not 
share the same level of sequence homology across multiple species (Figure 5.2).  
5.3.2: DHFR is primarily found in the insoluble fraction when the human protein is 
expressed by BL21-DE3 cells 
After lysis and fractionation of BL21-DE3 cells transformed with the pDEST15TM Gateway 
Cloning vector (Section 5.2.2), a significant portion of DHFR-GST was found to be in the 
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insoluble fraction when analysed via Western blot. This may be the result of the protein being 
misfolded and stored as inclusion bodies when produced too quickly for the cells to process 
properly.  Attempts to optimise the induction of DHFR-GST by varying temperature, time, 
and concentration of IPTG did not improve solubility. As the expression vector pDEST15 
with the DHFR gene contains a “leaky” promoter – producing a relatively small amount of 
the protein when uninduced – removing the induction step entirely resulted in the production 
of a small amount of soluble DHFR-GST (Figure 5.3). Large cultures of bacteria (2L) were 
used to compensate for the low levels of soluble protein produced when the culture is not 
induced. 
5.3.3: Glutathione agarose purification of soluble DHFR and Western blot analysis  
Eluted fractions from purified DHFR-GST were concentrated and 150ng of protein was run 
out on an SDS-PAGE gel with a positive control: the DHFR supplied by Sigma-Aldrich’s 
Dihydrofolate Reductase kit. Following Western blotting as outlined in Section 2.3.4 and 
under optimised exposure for the DHFR antibody (15-30 seconds) no DHFR-GST was visible 
on the blot, though a clear band at 25 kDa representing the positive control was visible. By 
increasing the exposure time to 5 minutes, 48 kDa bands indicative of DHFR-GST were 
visualised for the concentrated protein fraction (Figure 5.4). The concentration of DHFR-GST 
was found to be 0.0031µg/µl when quantified by Bradford assay (Figure 5.5). In vitro 
SUMOylation analysis requires 0.5µg in a 500µl reaction. 
5.3.4: Resolubilisation of DHFR insoluble fraction with Guanidine-HCl and Glycerol 
When 2L of bacterial culture did not produce enough soluble DHFR-GST to carry out the 
SUMOylation experiments, two methods for recovering DHFR-GST from the insoluble 
fraction were identified from the literature.  
The first151, described in Section 5.2.4, involves denaturing and refolding the protein in two 
separate steps. In both the soluble and insoluble fractions generated during the refolding 
process, the majority of DHFR-GST remained insoluble while a small portion was 
successfully solubilised (Figure 5.6).  
Purification of this soluble fraction, however, resulted in the same issue as before. Each 
fraction obtained from the purification process was analysed on a Western blot probed with 
DHFR antibody. Significant portions of DHFR-GST were present in the unbound and wash 
fractions, with very little in the eluted fraction, even when concentrated (Figure 5.7). Bradford 
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analysis on this product found the protein concentration to be too low for SUMOylation 
analysis (0.00182µg/µl).  
5.3.5: Resolubilisation of DHFR with N-lauroyl-sarcosine and triethanolamine 
Since the first resolubilisation method didn’t produce enough protein for the SUMOylation 
experiment, a different method was undertaken228. The insoluble fraction containing DHFR 
was resuspended in a ‘resolubilisation buffer’ containing N-lauroyl-sarcosine and 
triethanolamine (Section 5.2.4) and subjected to glutathione batch-purification. Fractions 
obtained from the purification process were analysed on a Western blot probed with anti-
DHFR antibody. Strong bands in the unbound and wash fractions indicate that very little 
DHFR-GST has bound to the column, further demonstrated by the weak band in the eluted-
concentrated fraction (Figure 5.8).  
As the protein visible in Figure 5.8 was from 14% of the total 2L culture, one final attempt to 
purify soluble DHFR was carried out by combining all of the remaining pellets from this 
culture. When purified the resolubilised protein failed to bind to the glutathione column. 
However, a significant portion of DHFR-GST was found in the wash fraction, in comparison 
to those eluted and concentrated (Figure 5.9). As 18µl of 25ml was loaded into lane 3 (in 
comparison to 18µl of 300µl in lane 5), this wash fraction was taken and concentrated in a 35 
kDa centrifugal filter-unit to be analysed on a separate gel. 
Figure 5.10 shows this concentrated wash-fraction with a significant portion of DHFR when 
compared to a positive control. ImageJ – a semi-quantitative image processing programme – 
was used to estimate the concentration of protein in this band. The process involved comparing 
the intensity of the DHFR-GST band to that of the positive control. With the concentration of 
the recombinant DHFR from Sigma-Aldrich known to be 0.044µg/µl, the concentration of 
DHFR-GST was estimated at 0.032µg/µl. In a total volume of 1ml, a total yield of 32µg 
partially purified DHFR has been successfully produced from 2L of bacterial culture. 
When subjected to the DHFR reductase assay, the purified enzyme was found to be inactive. 
In a reaction containing DHF and NADPH, no depletion of NADPH was observed over the 
course of 2 minutes with DHFR-GST (Figure 5.11). In comparison to the positive control 
supplied by the kit with a specific activity of 2.822µmol/min/mg, recombinant DHFR-GST 
was found to have activity of 0.203µmol/min/mg. When examined in the presence of 
methotrexate – an anti-folate that inhibits DHFR – the activity of the reaction was found to be 
0.121µmol/min/mg, representative of background NADPH depletion. Subtracting these two 
values gives the negligible value of 0.083µmol/min/mg for recombinant DHFR-GST activity.  
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5.3.6: In vitro SUMOylation of DHFR 
As reductase activity could not be retained with the solubilisation of DHFR-GST, we moved 
forward with the in vitro SUMOylation experiments on commercially available DHFR. The 
recombinant DHFR used in these experiments was supplied by Sigma-Aldrich – the same 
DHFR enzyme used as a positive control on the Western blots and enzyme kinetics assays 
throughout this chapter. 
The SUMOlink kit supplied by Active Motif uses a set of SUMOylation and conjugating 
enzymes to add a SUMO moiety to the protein of interest, which can be visualised on a 
Western blot as a 15 kDa band shift. A mutant SUMO protein (mutSUMO) incapable of 
forming a thioester with UBC9 – which required for UBC9-catalysed SUMOylation43 – acts 
as a negative control. A second negative control recommended by the kit includes all of the 
required components for SUMOylation with the protein of interest omitted. This is to control 
for self-SUMOylation of the kit’s own components.  
On a Western blot probed with DHFR antibody, a strong shift of 15 kDa was present in a 
DHFR-SUMO reaction when compared to a reaction containing DHFR and mutSUMO. In a 
blot probed with a SUMO antibody, the same 40 kDa band appeared in the DHFR-SUMO 
reaction, with 15 kDa bands representing free SUMO. On the no-protein negative control of 
this blot, however, the same 40 kDa band was visible, along with many other bands consistent 
with self-SUMOylation of the kit’s components. The free-SUMO band at 15 kDa appears 
fainter here, further confirmation that SUMOylation has taken place (Figure 5.12). 
The band at ~40 kDa in the no-protein negative control complicates these results. The nature 
of the band at this size in the DHFR-SUMO reaction of the anti-SUMO gel is now unclear, as 
this could be the result of the same self-SUMOylation event that produced the band in the no 
protein negative control lane. The role of the anti-SUMO Western was to confirm that the shift 
observed in the anti-DHFR gel was indeed caused by SUMOylation. As a result of this 
inconsistency, it cannot be concluded that the shift of the DHFR band was caused by 
SUMOylation alone.  
A gel from another SUMOylation experiment was stained with coomassie blue. The image 
illustrates the range and quantities of other proteins present in the reaction. Bands for DHFR 
(25 kDa) and p53 (53 kDa) are visible, along with many other bands representing the 
conjugating and SUMOylating enzymes of the reaction, including one at ~18 kDa in each 
lane, possibly for UBC9 (Figure 5.13). 
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The second SUMOylation experiment aimed to examine the effects of this post-translational 
modification on a protein known to be capable of being SUMOylated in vitro. Active Motif 
provides aliquots of recombinant p53 protein with the SUMOylation kits for this very purpose. 
When probed with anti-p53, a shift consistent with what was depicted in the SUMO-link 
manual was observed – from 53 kDa to ~70 kDa. Likewise, the position of this SUMOylated 
protein is confirmed on the anti-SUMO blot. Note that there is a band present in this location 
on both the DHFR-SUMO1 and no-protein negative lanes, but the p53-SUMO lane is the only 
one to contain a doublet, suggesting one band is SUMOylated p53, and the other a consistent, 
non-specific, self-SUMOylation event (Figure 5.14) 
All of the DHFR experiments were carried out on Sigma-Aldrich’s commercially available 
recombinant DHFR. The enzyme was supplied at a concentration of ~0.044µg/µl. In order to 
carry out a 20µl reaction with 0.5µg total DHFR, the protein was vacuum-concentrated and 
resuspended in H2O. It was hypothesised that this drying and resuspending process may 
damage the enzyme thereby eliminating its SUMOylation capacity. However, an enzyme 
activity assay (Figure 5.15) shows that even when processed in this manner, DHFR still retains 
its dihydrofolate reductase activity (4.3µmol/min/mg before drying down, 2.13µmol/min/mg 
afterwards). 
All of the above suggests that the components of the kit are being SUMOylated, with one in 
particular exhibiting a shift in molecular weight similar to DHFR.  Two of the components of 
the kit, activating enzyme UBA2 and conjugating enzyme UBC9, have molecular weights of 
72 kDa and 18 kDa, respectively (Uniprot). An 18 kDa band for what could be UBC9 is visible 
in Figure 5.13, and close enough in mass to DHFR that the SUMOylation of the former could 
be mistaken for that of the SUMOylation of the latter. An in silico analysis of UBC9 showed 
that not only is this conjugating enzyme in possession of SUMOylation motifs, but scores 
higher than DHFR as a candidate for SUMOylation according to both algorithms (Figure 
5.16).  
5.3.7: In vitro Acetylation of DHFR 
Given the difficulties in purifying active DHFR-GST, an in vitro acetylation assay could not 
be optimised. Using the Sigma-Aldrich recombinant DHFR, a “one-shot” experiment was 
carried out following the protocol described by Levy et al., (2004)229, using commercial p300 
acetlytransferase and [14C]acetyl-CoA. Proteins were resolved on an SDS-PAGE gel, but no 
bands were observed with auto-radiographic imaging (data not shown).  
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5.4: Discussion 
Post-translational modifications such as SUMOylation and acetylation have been implicated 
in a variety of biological processes such as localisation and degredation218,219,222. In 2007, it 
was discovered that DHFR – an enzyme with a pivotal role in one-carbon metabolism – is 
capable of being SUMOylated in vitro43. Our own in silico analysis on DHFR found that the 
same lysine residue found to be SUMOylated by Anderson et al., (2007) can also be 
acetylated, opening up the possibility that both these post-translational modifications are in 
direct competition with one another for DHFR.  
The in silico analysis completed here found K81 to have the highest potential to be 
SUMOylated, with K179 (cited by Anderson et al., (2007)43) not appearing in either analysis. 
This may be due to the fact that leucine – the amino acid at the Ψ position of the K81 site – is 
far more hydrophobic at pH 7 than tyrosine, the Ψ amino acid at the K179 site. Anderson et 
al., (2011), however, has put more weight on K179, as the ΨKXE motif is conserved across 
multiple species43, this was also found to be the case for K81.  
The aim of this work was to first produce recombinant DHFR, then carry out in vitro 
SUMOylation and acetylation analysis. Achieving this first objective, however, proved to be 
more difficult than anticipated. 
The major issues in producing recombinant GST-tagged DHFR were caused by the inability 
of the protein to fold correctly when expressed in BL21-DE3 cells. Initially, the vast majority 
of the protein was produced in the form of insoluble inclusion bodies, a typical response for 
bacteria being forced to express non-bacterial proteins at a high level230. By increasing the size 
of the bacterial cultures, enough DHFR was produced in the soluble factions for use in the 
intended downstream analysis.  
However, efficient purification of DHFR from the soluble fraction could not be obtained, due 
a lack of binding between GST and the glutathione column. After many attempts to re-
solubilise the aforementioned insoluble fractions, the same problem persisted: no binding 
between GST and glutathione was taking place implying the tag was misfolded and thereby 
unavailable to the resin. The SUMOylation analysis required 500ng protein in a 20µl. The 
most protein successfully purified in was ~3ng/µl in a volume of ~100µl. 
It was initially speculated that this was also due to misfolding of DHFR while it was processed 
as an inclusion body. Analysis of partially-purified DHFR that failed to bind to the glutathione 
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column found the enzyme to have no reductase activity, further proof that GST-DHFR fusion 
proteins have been misfolded.  
Although McEntee et al., (2011)40 generated enough GST-DHFR for enzyme kinetic analysis, 
the concentrations required for the SUMOylation experiments could not be obtained. Other 
publications have had more success with generating recombinant DHFR through His-nickel 
binding43,231,232.  
The failure of recombinant proteins to fold correctly is a major obstacle in the field, even 
though the exact mechanism for inclusion body formation is poorly understood233. As a result, 
methods for correctly refolding proteins are typically tailored to the target protein itself. Still, 
most strategies in the field follow the general protocol of using the first resolubilisation 
process described here233.  
There are plenty of other methods available, but not necessarily relevant to DHFR. For 
example, proteins that contain cysteine residues may form disulfide bonds as part of their 
three-dimensional structure. In the cytoplasm of E.coli, however, disulfide bonds could form 
erroneously. This can be corrected by adding a reducing agent like DTT to the lysis buffer, 
and preventing the formation of disulfide bonds until later on in the purification process234. 
DHFR, however, does not form disulfide bonds, so this is a non-issue for this protein235.  
Another way to remove protein from bacterial inclusion bodies is to expose insoluble fractions 
to high hydrostatic pressure236. Commercially available pressure-cells can be used to exert a 
large amount of pressure on the aggregates to free protein from the inclusion bodies without 
damaging the enzyme itself. Methods based on this technology, however, require specialised 
equipment.  
As no recombinant protein was obtained, the effect of in vitro SUMOylation on commercially 
purchased DHFR was examined. The results of this experiment were inconclusive. While the 
appropriate band shift was observed (Figure 5.14), the negative control indicated that the 
putative SUMOylated DHFR band also contained a mixture of self-SUMOylated proteins.  
The manufacturers of the kit recommended including a no-protein negative control in all 
experiments, due to the reaction’s susceptibility to produce false positives. Indeed, 
SUMOylation of UBC9 – a conjugating protein involved in the reaction – manifests as a shift 
identical to what would be expected with DHFR. By taking into account evidence from anti-
SUMO and anti-p53 Western blots, it is clear that shifts observed from the former cannot be 
interpreted to be caused by SUMOylation of DHFR if a similar shift occurs in the no-protein 
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lane. Furthermore, shifts in anti-DHFR Western blots cannot be conclusively interpreted to 
represent SUMOylation events without a complementary shift in anti-SUMO blots. Although 
a shift from ~25kD to ~40kD was observed when probed with anti-DHFR, this shift being 
caused by some other artefact – like a self-dimer of DHFR – cannot be ruled out. Furthermore, 
self-SUMOylation of K14 of UBC9 as predicted by the SeeSUMO software may be the source 
of the band in the no protein negative control. UBC9 has also been established to be capable 
of SUMOylation in vitro237.  To fully prove that the DHFR ~40kD band shift observed is due 
to SUMOylation, mass spectrometry could be carried out on the purified equivalent sized band 
from the anti-SUMO blot.  
The in silico acetylation analysis of DHFR found that K179 – the same lysine shown to be 
SUMOylated by Anderson et al., (2007)43– is also a potential acetylation site. There are no 
commercially available kits for in vitro acetylation analysis, with methods described in the 
literature using recombinant p300 acetyltransferase produced in-lab with acetyl coenzyme A 
bound to 14C, with detection carried out using auto-radiographic imaging or scintillation 
counting used for detection238. Although this method was attempted, given the limited amount 
of available protein and time restriction, the technical details of the method could not be 
optimised to address whether DHFR is in fact acetylated in vitro.  
Although we couldn’t prove that DHFR is subject to both SUMOylation and acetylation in 
vitro, this area is still warrants further investigation. Our in silico analyses shows that the K179 
residue of DHFR is susceptible to acetylation: the same lysine stated to be SUMOylated by 
Anderson et al., (2007)43. Similarly, both acetylation and ubiquitination have been shown to 
compete for the same lysine of p53, with the former found to increase its DNA binding 
affinity239. Ubiquitination of p53, however, marks the protein for degradation240, which can be 
prevented by acetylation, hinting towards a complex system of competing post-translational 
modifications.  If applied to DHFR, this suggests that SUMOylation of DHFR would localise 
it to the nucleus, with acetylation then triggering a yet unknown role in gene control. 
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Figure 5.1: In Silico Post Translation Modification Analysis of DHFR 
The peptide sequence of DHFR was examined for potential SUMOylation sites using 
SeeSUMO (A) and SUMOplot (B). Both the K81 and K109 lysine residues were predicted to 
be SUMOylated according to SeeSUMO, with K81 scoring highest for SUMOplot. In silico 
acetylation analysis was carried by Scan-X (C), which found K179 to be a potential acetylation 
site. K179 was also demonstrated to be capable of SUMOyaltion according to Anderson et al., 
(2007)43. Green amino acids are represented in the motif, with those in red under-represented.. 
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Figure 5.2: Peptide sequence alignment and conserved SUMOylation sites in mammals 
The SUMOylation motif for K179 (blue) as described by Anderson et al43., is conserved across 
Homo sapiens, Canis familiaris, Mus Musculus and Rattus norvegicus DHFR peptide 
sequences. The motif for K81 (yellow) as identified by SeeSUMO and SUMOplot is also 
conserved across the same species.  The acetylation site identified by Scan-X does not contain 
the same level of homology across the mammalian species, though the region that differs was 
not found to be representative of an acetylation motif from Scan-X analysis.  
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Figure 5.3: Soluble and insoluble fractions of BL21-DE3 cell lysates 
Coomassie stained PAGE SDS gel (A) and Western blot probed with DHFR antibody (B) with 
insoluble fractions (lanes 2 and 3) and soluble fractions (lanes 4 and 5) of BL21-DE3 cell 
lysates. The expected band-size for DHFR-GST is 48 kDa, which is present in both images. 
A higher concentration of our protein is evident in the insoluble fraction. When exposed for 
15 – 30 seconds, very high levels of protein in the insoluble fraction caused scorching of the 
membrane, which appears as a black band in lanes 2 and 3.   
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Figure 5.4: Eluted soluble DHFR  
Western blot probed with DHFR antibody. (A)At a normal exposure (15 – 30 seconds), no 
bands for DHFR-GST are visible for the eluted-concentrated protein (lane 2) and eluted-
unconcentrated protein (lane 3). A strong band for recombinant DHFR (positive control 
Sigma-Aldrich) is visible in lane 6. (B) At prolonged exposure (5 minutes), a weak band for 
DHFR-GST is visible for the eluted-concentrated protein (lane 2) but not for the eluted-
unconcentrated protein (lane 3). 
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Figure 5.5: Standard Curve for Bradford Assay  
A sample standard curve on a set of BSA standards (0.25mg/ml – 1.25mg/ml) measured on a 
Tecan Plate Reader at A595nm. Only standard curves with R2 values > 0.99 were used to 
determine protein concentration.  
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Figure 5.6: Resolubilisation of DHFR using Guanidine-HCl and Glycerol  
Coomassie stained SDS PAGE gel (A) and Western blot probed with DHFR antibody (B). 
Resolubilisation of DHFR-GST generated a new insoluble fraction (lane 1) and soluble 
fraction (lane 2). Majority of recombinant protein lies in the insoluble fraction, with a strong 
band at ~48 kDa. Sharp bands at the same molecular weight in lane 2 indicate DHFR has been 
successfully resolubilised. Recombinant DHFR from Sigma-Aldrich (25 kDa) was used as a 
positive control (lane 3).  
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Figure 5.7: Purification of resolubilised DHFR-GST using Glutathione Agarose Beads 
Coomassie stained SDS PAGE gel (A) and Western blot probed with DHFR antibody (B). 
Images depict products from gravity-flow affinity chromatography of soluble DHFR-GST 
with glutathione agarose beads. A strong band at ~48 kDa in the unpurified fraction (lane 2) 
indicates very high levels of protein. The unbound fraction (lane 3) is almost identical to the 
unpurified fraction. The wash fraction (lane 4) contains a weaker band at 48 kDa, as is the 
case in the eluted-unconcentrated (lane 5) the eluted-concentrated (lane 6) and the 
concentration-runoff fractions (lane 7). Recombinant DHFR from Sigma-Aldrich was used as 
a positive control (lane 8). 
A 
B 
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Figure 5.8: Glutathione purification of DHFR-GST resolubilised with N-lauroyl-
sarcosine and triethanolamine 
Coomassie stained SDS PAGE gel (A) and Western blot probed with DHFR antibody (B). 
Images depict products from batch affinity chromatography of soluble DHFR-GST with 
glutathione agarose beads.  A scorched band in unbound fraction (lane 2) indicates very high 
levels of GST-DHFR and other protein from non-specific binding of the secondary antibody. 
The wash fraction (lane 3) contains a weak 48 kDa band. No protein is visible in the eluted-
unconcentrated (lane 4) the concentration-runoff (lane 5) and the eluted-concentrated fractions 
(lane 6). Recombinant DHFR from Sigma-Aldrich was used as a positive control (lane 7). 
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Figure 5.9: Glutathione column-purification of combined DHFR-GST pellets 
resolubilised with N-lauroyl-sarcosine and triethanolamine 
Coomassie stained SDS PAGE gel (A) and Western blot probed with DHFR antibody (B). 
Images depict products from gravity-flow affinity chromatography of soluble DHFR-GST 
with glutathione agarose beads.  A scorched band in unbound fraction (lane 2) indicates very 
high levels of GST-DHFR and other protein from non-specific binding of the secondary 
antibody. The wash fraction (lane 3) contains a strong 48 kDa band with some low molecular 
weight non-specifics. Eluted-unconcentrated (lane 4) and eluted-concentrated (lane 5) contain 
weak 48 kDa bands in comparison to the recombinant Sigma-Aldrich DHFR used as a positive 
control (lane 3). 
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Figure 5.10: Concentration DHFR-GST wash fraction from protein resolubilised with 
N-lauroyl-sarcosine and triethanolamine 
Western blot probed with DHFR antibody. This image depicts the concentrated DHFR-GST 
wash fraction obtained from gravity-column purification of protein resolubilised with N-
lauroyl-sarcosine and triethanolamine (lane 2). A strong band at 48 kDa indicates DHFR-GST 
has been partially purified. Recombinant Sigma-Aldrich DHFR (25 kDa) used as a positive 
control (lane 6). 
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Figure 5.11: DHFR Enzyme Activity Assay on DHFR-GST Partially Purified from 
Resolubilised Protein Wash Fraction 
Enzyme Activity of DHFR-GST partially purified from resolubilised protein wash fraction 
was analysed using Sigma-Aldrich’s Dihydrofolate Reductase Assay Kit. Activity was 
measured for recombinant DHFR supplied with the kit (A) and recombinant DHFR-GST (B). 
An inhibition assay was also carried out for recombinant DHFR-GST (B) using methotrexate. 
A linear depletion NADPH over time was observed for recombinant DHFR (R2 = 0.9944), but 
not for DHFR-GST (R2 = 0.6478). The inhibition assay for DHFR-GST exhibited an absence 
of NADPH depletion similar to DHFR-GST alone. 
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Figure 5.12: Products of In vitro SUMOylation assay of DHFR probed with anti-DHFR 
and anti-SUMO 
The SUMOylation of Sigma-Aldrich’s DHFR enzyme (used previously as positive control) 
was examined using an in vitro assay.  Three reactions were included in each experiment. One 
containing DHFR with SUMO (lane 3), one with a mutant SUMO protein used instead of 
wild-type SUMO (lane 4), and one with the protein of interest omitted to control for self-
SUMOylation of the conjugating enzymes (lane 5). Two Westerns were carried out, probed 
with DHFR antibody (A) and with SUMO1 antibody (B). In the anti-DHFR blot, a shift of 
~15 kDa is present in the test sample (lane 3), while being less prominent in the mutant SUMO 
control (lane 4). Multiple Bands in no-protein negative control suggest self-SUMOylation of 
the reaction’s components. Bands for free SUMO are also present on this blot at 15 kDa.  
A B 
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Figure 5.13: Coomassie stain of gel used in SUMOylation experiments highlights the 
range of proteins present in the reaction 
Coomassie-stained SDS PAGE gel of in vitro SUMOylation assay carried out on Sigma-
Aldrich’s recombinant DHFR and recombinant p53 supplied with the Active Motif kit. The 
products of five reactions were run on this gel: DHFR +SUMO (lane 2), DHFR + mutSUMO 
(lane 3), p53 + SUMO1 (lane 4), p53 + mutSUMO (lane 5), and a no-protein negative control 
(lane 6). Bands for recombinant DHFR and p53 are visible at 25 kDa and 53 kDa in their 
respective reactions, while other bands represent the other components of the kit.  
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Figure 5.14: In vitro SUMOylation reactions on recombinant DHFR and P53 probed 
with anti-p53 and anti-SUMO 
Two separate Western blots were carried out on products of the same set of reactions: DHFR 
+ SUMO (lane 2), DHFR + mutSUMO (lane 3), P53 + SUMO (lane 4), P53 + mutSUMO 
(lane 5), and no-protein negative-control (lane 6). Westerns were probed with anti-p53 
antibody (A) and anti-DHFR antibody (B). On the anti-P53 Western, a clear shift from 53 kDa 
to ~70 kDa is evident in lane 4 while being less pronounced in lane 5. In lane 4, a strong band 
at ~70 kDa indicates P53 has been SUMOylated. Free SUMO appears at the bottom of the gel 
(~15 kDa).  
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Figure 5.15: DHFR Enzyme Activity Assay on dried down recombinant DHFR from 
Sigma-Aldrich  
Enzyme Activity of recombinant DHFR from Sigma-Aldrich dried down in the same manner 
as used in the in vitro SUMOylation reactions. Activity was measured for recombinant DHFR 
supplied with the kit (A) along with activity of the same enzyme dried down and resuspended 
in H2O (B). A linear depletion of NADPH over time was observed in both reactions (R2 = 
0.9974, R2 = 0.9924).  
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Figure 5.16: In Silico SUMOylation analysis on UBC9 
Peptide sequences of UBC9 were examined for potential SUMOylation sites using SeeSUMO 
(A) and SUMOplot (B). According to the former, K14, K49, K65 and K76 have a high 
capacity to be SUMOylated, with confidence levels higher than those found in DHFR. For the 
same peptide sequence, SUMOplot found K65 to have the highest change of being 
SUMOylated, again, with a score higher than those found for the folate enzyme. 
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Chapter 6:   
Discussion and Future 
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6.1: The Impact of Folic Acid Supplementation on DNA methylation 
Folic acid supplementation has been demonstrated to prevent birth defects in numerous trials 
and studies over the past two decades13,15,241,242. Still, the biological basis through which folic 
acid exerts its beneficial effects is still relatively unknown, and concern is growing over 
studies that have linked elevated folate levels with tumourigenesis21,24. Although a recent 
meta-analysis has found no significant link between folic acid supplementation and cancer25, 
it is still of paramount importance that these biological mechanisms are elucidated.  
S-adenosylmethionine is a methyl donor for many methylation reactions throughout the cell, 
including DNA methylation, produced from folate-mediated one carbon metabolism6. A 
number of studies have shown that changes in one-carbon metabolism, such as increased 
levels of folate, can have a direct effect on the methylation of different genes throughout the 
genome109,111. DNA methylation is an epigenetic modification that is intricately associated 
with gene expression. As a result, it is plausible that increased folate levels may cause changes 
in DNA methylation and gene expression, thus establishing a biological mechanism by which 
folic acid supplementation can impact on the health status of an individual. This was the basis 
of this study. 
Recently, an intervention study was carried out by the University of Ulster to investigate the 
effect of folic acid supplementation during the second and third trimester of pregnancy on 
folate status and homocysteine levels4. Blood samples were taken from 119 individuals before 
and after intervention, where one group received a daily supplement of folic acid, while 
participants from the other group received a placebo. A post-intervention sample was taken 
after 36 weeks of pregnancy, along with another blood sample from the umbilical cord upon 
delivery. Biochemical data was recorded from these blood samples, and DNA was extracted. 
These DNA samples made up the foundation of this study.  
DNA methylation alone is a difficult modification to measure, so various strategies have been 
employed to measure and quantify it on both a genome-wide and gene-specific basis5. An in-
depth review was carried out on these methods, and one that suited the aims, objectives, and 
resources of this study was selected: Modified Methylation Specific Digital Karyotyping 
(MMSDK)133. 
In a series of pilot studies using DNA from the bacteriophage lambda, MMSDK was found to 
work effectively on a small genome. However, scaling this up to human genomic DNA proved 
to be technically challenging, so an alternative genome-wide method was considered. 
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Methylated DNA immunoprecipitation (MeDIP) was found to efficiently enrich for 
methylated DNA though QC tests using qPCR, and the DNA microarray approach was 
selected as a route of analysis instead of MMSDK. 
The DNA microarray analysis produced twelve large datasets, each of which was analysed in 
excel using macros scripted in Visual Basic 6. After this analysis, a preliminary list of 19 novel 
FS-DMRs was produced, along with 11 regions observed to change their methylation status 
in response to pregnancy, independent of folate status. Through examination of the 
microarray’s raw data – the specific probe enrichment score that make up each analysed region 
– the preliminary list of FS-DMRs was narrowed down to five, three of which were selected 
for further analysis with a gene-specific method of analysis – Sensitive Melting after Real 
Time Methylation-Specific PCR (SMART-MSP)146 – over the rest of the FASSTT cohort.  
One of the regions analysed was adjacent to the coding region of IP6K1, a gene encoding a 
kinase responsible for synthesis of inositol pyrophosphates involved in multiple cellular 
processes such as chromatin remodelling and cell aging176,177. The second was adjacent to the 
coding region of RASA4, a small GTP binding signalling molecule involved in gene expression 
and cell cycle control183, hypomethylation of which has been correlated with poor prognosis 
in juvenile myelomonocytic leukemia184. The third region, annotated as Chromosome 9, Open-
Reading Frame 44, does not lie adjacent to a known protein coding region.  
When analysed across the rest of the FASSTT cohort using SMART-MSP, changes in DNA 
methylation did not reach statistical significance. In a cell culture model treated with 
demethylating agent 5’azacytidine, an increase in gene expression for IP6K1 and RASA4 were 
observed in response to demethylation of their associated promoter region. GPS2, a gene with 
an FS-DMR increasing in methylation from the preliminary list of 19 regions found from the 
MeDIP analysis, also exhibited increased expression in response to demethylation at the 
region examined by the microarray. 
In this investigation into the effects of folic acid supplementation on DNA methylation, no 
significant impact was found. Most studies from the literature using MeDIP and promoter 
microarray hybridisation have investigated the effect of conditions more dramatic than folic 
acid supplementation – healthy cells versus tumour cells, differences across species, etc.169–
173,175. Regarding the FASSTT study, all women recruited were healthy, with folic acid 
supplementation being a relatively minor experimental condition imposed upon the 
participants. If we had the resources available to use a more sensitive method initially, i.e., 
next generation bisulfite sequencing producing single base-pair resolution data, robust FS-
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DMR may have been found.  However, using the MeDIP microarray approach did not yield 
consistent FS-DMRs in the samples studied.  
Various studies have examined the effect of dramatic folate deficiency on mice. When 
examining changes in global DNA methylation – total DNA methylation across the genome 
without regional context – Caudill et al., (2001) found no significant changes in liver 
hypomethylation in response to folate deficiency243. Using a more sensitive technique, Mejos 
et al., (2013) found a significant correlation between hepatic folate and global DNA 
methylation levels in rats244. Of course, these methods of global analysis tell us very little 
about DNA methylation on a practical scale. Using gene-specific bisulfite sequencing, Geo et 
al., (2012) found that folate deficiency in mice caused a decrease in DNA methylation of Esr1, 
the gene encoding estrogen receptor 1245.  
In human studies, examining folate deficiency is more difficult due to ethical concerns. In 
some instances, researchers have examined the effect of the polymorphism MTHFR 677 C>T 
on DNA methylation; a variation known to inhibit folate metabolism246. Across a numerous 
candidate genes, including ESR1, Hanks et al., (2013) found no methylation changes attributed 
to the MTHFR  677 C>T genotype204, mirroring results previously found by the same research 
group247,248. A recent study by Bollati et al., (2014) examined the impact of nutrient intake on 
DNA methylation in obese subjects, finding a negative correlation between TNFα methylation 
and folic acid intake determined from a standardised food frequency questionnaire. DNA 
methylation levels were determined using Pyrosequencing technology249.  
With respect to folic acid supplementation during pregnancy, Fryer et al., (2009) found  no 
correlation between folic acid intake and methylation of LINE-1 repetitive elements 
(representative of global methylation), but saw an inverse correlation between plasma 
homocysteine levels and LINE-1 methylation250. The same group later examined the 
relationship between homocysteine levels and genome-wide methylation using the Illumina 
27k methylation bead array111, and found 5 CpG sites directly correlated with homocysteine 
levels, and 12 CpG with inverse correlation. No confirmation analysis was carried out on these 
regions obtained from a sample size of n=12.  
More recently, Amarasekera et al., (2014) found 7 FS-DMRs in neonatal cord blood correlated 
with foetal folate status. Of the regions found, the promoter upstream of the gene ZFP57, its 
product a regulator of DNA methylation during development251. In both the high folate and 
low folate groups, the study found a significant correlation between maternal serum folate 
levels measured at the third trimester of pregnancy, and those of the umbilical cord measured 
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upon delivery. This study suggests that folate levels during pregnancy – even as late as the 
third trimester – can have a significant impact on DNA methylation. These results mirror those 
of previous studies, suggesting that periconceptional folic acid supplementation – as reported 
by the mother after birth – is correlated with IGF2 methylation in children108, and inversely 
correlated with HI9 methylation under similar conditions252.  
Although our MeDIP and SMART-MSP analysis found no correlation between folic acid 
supplementation and DNA methylation, it is likely that the changes in methylation levels were 
too subtle to analyse using the methods described here. Sensitive methods examining DNA 
methylation at a single-base pair resolution – like next generation sequencing and 
Pyrosequencing following sodium bisulfite treatment – may overcome this challenge.  
6.2: Investigation of post-translational modifications affecting 
dihydrofolate reductase 
Complementing the aforementioned DNA methylation analysis, an investigation was carried 
out on the potential post-translational modifications affecting dihydrofolate reductase 
(DHFR), the enzyme responsible for breaking folic acid down to its functional form.  
In silico analysis of DHFR’s primary structure found potential SUMOylation and acetylation 
sites. During the process of producing recombinant GST-bound DHFR for in vitro analysis, 
however, a number of significant challenges were encountered. On examining the soluble and 
insoluble fractions of BL21-DE3 cells, the majority of DHFR was found to exist in the latter. 
The culture was scaled up to make up for the small portion of DHFR in the soluble fraction, 
but this could not be purified via affinity chromatography with glutathione agarose beads.  
Attempts were made to resolubilise the insoluble fraction using two different methods from 
the literature. Although one did succeed in partially purifying a large volume of DHFR-GST, 
when tested for reductase activity, the recombinant protein was found to have no enzyme 
activity.  
SUMOylation experiments were carried out in vitro on commercially available DHFR from 
Sigma-Aldrich. This was found to be inconclusive due to self-SUMOylation of the kit’s 
components, with a band-shift for DHFR possibly mistaken for that of UBC9: a SUMO 
conjugating enzyme.  
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These in vitro SUMOylation experiments were carried out as described by Anderson et al., 
(2007)43, but did not confirm or refute these published findings due to results obtained by our 
a no-protein negative controls for the in vitro SUMOylation experiments, and an in silico 
analysis of the UBC9 primary sequence. Further steps may be taken to confirm the identity of 
these bands, discussed in more detail below. 
6.3: Future Work  
The DNA methylation methods described here did not find a significant association between 
DNA methylation changes and folic acid supplementation. If such an association does exist, 
however, and our approach is limited by the power of these methods of analysis alone, then 
perhaps a more specific or sensitive platform may be used to further investigate the impact of 
folic acid supplementation on DNA. Apart from the limitations of the MeDIP microarray 
approach, a more preferable gene-specific DNA methylation analysis method would be 
Pyrosequencing.  There is a potential for other DMRs described here to be analysed in this 
manner, such as the pregnancy-specific DMRs listed in Chapter 4, and the candidate genes 
listed in the literature review by Parle-McDermott and Ozaki3. With such significant strides 
being made technology over just the past few years, carrying out a genome-wide, single base-
pair resolution DNA methylation analysis across the entire FASSTT cohort may be a viable 
option in the future.  
Two aspects of the FASSTT cohort have not been explored in this project. Firstly, data for the 
MTHFR 677 C>T polymorphism was collected for each participant. Due to MTHFR’s role in 
supplying the one-carbon units for the methylation cycle, a decrease in enzyme activity caused 
by the TT variant may amplify the effects of declining folate levels on DNA methylation.  
However, statistical power is likely to be an issue for such an analysis.  Secondly, DNA 
extracted from the umbilical cord of children born to the FASSTT participants is also available 
for methylation analysis. Had we found a FS-DMR with a consistent change across the 
FASSTT cohort, examining its capacity to perpetuate transgenerationally would be a 
fascinating route to take. Of course, this approach would not be without its challenges, with 
paternal genotypic influences possibly affecting offspring DNA methylation patterns.  
In the investigation into DHFR post-translational modifications, steps can be taken to 
overcome the most significant challenge in producing recombinant DHFR: its inability to fold 
correctly when bound to GST. Other studies have had more success in producing HIS-tagged 
DHFR for affinity purification via nickel-chromatography43,231. If high concentrations of 
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recombinant DHFR can be produced, the in vitro SUMOylation experiment could be repeated 
under the very same conditions described by Anderson et al., (2007)43, confirming or refuting 
the results found using commercially available DHFR. Likewise, protein recombinant 
technology could be used to produce DHFRL1 – the protein coded by the formally annotated 
pseudogene, as described by McEntee et al., (2011)40, addressing the as-yet unknown factors 
influencing mitochondrial localisation of DHFRL1.  
With more time and resources, the in vitro acetylation experiments described in Section 6.3.7 
could also be optimised and carried out on recombinant DHFR, allowing us to explore the 
potential for SUMOylation and acetylation competition for the same lysine residue in more 
detail. These results would aid in creating a full picture of the effects of post-translational 
modifications to DHFR on sub-cellular localisation.  
In this investigation into the effects of folic acid supplementation on DNA methylation, a total 
of 3 genomic sites were screened for potential FS-DMRs and found to be inconsistent across 
the FASSTT cohort. However, it cannot be concluded that no FS-DMRs exist under the 
supplementation conditions examined. An in-depth, single base-pair resolution method of 
DNA methylation screening, such as bisulfite NGS, may find FS-DMRs still elusive to us. 
The approaches described here were made complicated by a number of factors, such as genetic 
variation amongst participants influencing DNA methylation patterns even before 
intervention. The nutritional intervention carried out as part of the FASSTT study was 
relatively minor compared to what these methods of DNA methylation analysis have been 
used to study in the literature, and it may be that MeDIP and SMART-MSP are not sensitive 
enough to measure potential DNA methylation changes associated with it.  
Nonetheless, the work presented here constitutes a significant contribution to the field. As the 
aforementioned studies illustrate, examining the effects of folate levels on DNA methylation 
in humans is particularly challenging. This thesis has examined the limits of conventional 
DNA methylation techniques, but major strides in technology over the past few years indicate 
that we are only beginning to scale this Everest of the epigenetic landscape. 
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A.1: Sub Macros used for removing and pasting mismatched entries 
Sub NuBlueCut(Rng As Range)     
    Rng.Resize(, 4).Copy     
    Rng.Offset(, 5).Insert xlDown 
    Rng.Resize(, 4).Delete xlUp     
End Sub 
 
Sub NuRedCut(Rng As Range) 
    Rng.Offset(, -4).Resize(, 4).Copy 
    Rng.Offset(, 10).Insert xlDown 
    Rng.Offset(, -4).Resize(, 4).Delete xlUp 
End Sub 
 
A.2 Looping Macro for Step 1 of data analysis 
Sub StepOne() 
Dim Rng As Range 
Dim i As Long 
i = 2 
Application.ScreenUpdating = False 
While i <= 40043 
Set Rng = Range("E" & i) 
 
If Rng > Rng.Offset(, -1) Then 
NuRedCut Rng 
 
ElseIf Rng < Rng.Offset(, -1) Then 
NuBlueCut Rng 
 
ElseIf Rng = Rng.Offset(, -1) And Rng.Offset(, -3) > 
Rng.Offset(, 2) Then 
NuRedCut Rng 
 
ElseIf Rng = Rng.Offset(, -1) And Rng.Offset(, -3) < 
Rng.Offset(, 2) Then 
NuBlueCut Rng 
 
Else 
i = i + 1 
 
 
End If 
Wend 
End Sub 
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Both of the macros in Appendix A.1 were tied together in the Do While… loop named 
“StepOne” in Appendix A.2. The opening lines of the code define the dimensions Rng and i 
as a range and a long integer, respectively. The next line, “i = 2”, defines the long integer i as 
2 to begin. “Application.Screenupdating = False” tells excel to not update this process on-
screen as it happens, making the process faster. The next line tells the code to only work while 
i is less than or equal to 40,043; the total number of rows in the dataset. Finally, the range is 
set to the cell at column E, row i, which has already been defined as 2. With this information, 
the looping macro begins at cell E2. 
Four conditions are specified next, and a consequence is listed for each. First, if the active 
range – like the accession number BC000008 – is greater than that immediately to the left of 
it, then the sub macro NuRedCut is called. If the active range is less than the cell immediately 
to the left of it, then the sub macro NuBlueCut is called. The following two conditions are 
similar to these, but they also include instructions that the chromosomal region must also 
match in each case. This is to ensure multiple entries with the same accession number are not 
confused.  
The final line, “Else”, says that if the active range, at this point E2, is not greater than or less 
than that in the adjacent row, then the value for i is increased by 1 and the macro starts again 
in cell E3.  
 
A.3 Sub Macros for Step 2 of data analysis 
Sub MiddleDelete(Rng As Range) 
    Rng.Resize(, 4).Delete Shift:=xlUp 
End Sub 
 
Sub LeftDelete(Rng As Range) 
    Rng.Offset(, -5).Resize(, 4).Delete Shift:=xlUp 
End Sub 
 
Sub RightDelete(Rng As Range) 
    Rng.Offset(, 5).Resize(, 4).Delete Shift:=xlUp 
End Sub 
 
Sub FKCutandPaste(Rng As Range) 
    Rng.Resize(, 9).Copy 
    Rng.Offset(, 19).Insert Shift:=xlDown 
    Rng.Resize(, 9).Delete Shift:=xlUp 
End Sub 
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Sub AKCutandPaste(Rng As Range) 
    Rng.Offset(, -5).Resize(, 4).Copy 
    Rng.Offset(, 45).Insert Shift:=xlDown 
    Rng.Offset(, -5).Resize(, 4).Delete Shift:=xlUp 
    Rng.Offset(, 5).Resize(, 4).Copy 
    Rng.Offset(, 50).Insert Shift:=xlDown 
    Rng.Resize(, 4).Delete Shift:=xlUp 
End Sub 
 
Sub AFCutandPaste(Rng As Range) 
    Rng.Offset(, -5).Resize(, 9).Copy 
    Rng.Offset(, 35).Insert Shift:=xlDown 
    Rng.Offset(, -5).Resize(, 9).Delete Shift:=xlUp 
End Sub 
 
Sub AFKCutandPaste(Rng As Range) 
    Rng.Offset(, -5).Resize(, 14).Copy 
    Rng.Offset(, 60).Insert Shift:=xlDown 
    Rng.Offset(, -5).Resize(, 14).Delete Shift:=xlUp 
End Sub 
 
A.4 Looping macro for Step 2 of data analysis 
Sub RemoveRow() 
Dim i As Long 
Dim Rng As Range 
i = 2 
Application.ScreenUpdating = False 
 
Do While i <= 4043 
Set Rng = Range("F" & i) 
     
    If Rng < Rng.Offset(, -5) And Rng < Rng.Offset(, 5) 
Then 
        MiddleDelete Rng 
      
    ElseIf Rng.Offset(, 5) < Rng And Rng.Offset(, 5) < 
Rng.Offset(, -5) Then 
        RightDelete Rng 
       
    ElseIf Rng.Offset(, -5) < Rng And Rng.Offset(, -5) < 
Rng.Offset(, 5) Then 
        LeftDelete Rng 
       
    ElseIf Rng = Rng.Offset(, 5) And Rng <> Rng.Offset(, 
-5) Then 
        FKCutandPaste Rng 
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     ElseIf Rng.Offset(, -5) = Rng.Offset(, 5) And Rng <> 
Rng.Offset(, -5) Then 
        AKCutandPaste Rng 
         
     ElseIf Rng.Offset(, -5) = Rng And Rng <> Rng.Offset(, 
5) Then 
        AFCutandPaste Rng 
            
     ElseIf Rng = Rng.Offset(, -5) And Rng = Rng.Offset(, 
5) Then 
        AFKCutandPaste Rng 
            
Else: Stop 
End If 
Loop 
End Sub 
 
A.5: Sub Macros for comparing Intervention DMRs against Placebo DMRs 
Sub PlaceboCut(Rng) 
    Rng.Resize(, 4).Delete Shift:=xlUp 
End Sub 
 
Sub FACut(Rng) 
    Rng.Offset(, -5).Resize(, 4).Copy 
    Rng.Offset(, 10).Insert Shift:=xlDown 
    Rng.Offset(, -5).Resize(, 4).Delete Shift:=xlUp 
End Sub 
 
Sub BothCut(Rng) 
    Rng.Offset(, -5).Resize(, 9).Copy 
    Rng.Offset(, 18).Insert Shift:=xlDown 
    Rng.Offset(, -5).Resize(, 9).Delete Shift:=xlUp 
End Sub 
A.6: Looping Macro to Remove DMRs Common in Placebo and Intervention Groups 
Sub PlaceboCompare() 
Dim i As Long 
Dim Rng As Range 
 
i = 2 
 
Do While i <= 4043 
    Set Rng = Range("F" & i) 
     
    If Rng < Rng.Offset(, -5) Then 
        PlaceboCut Rng 
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    ElseIf Rng = Rng.Offset(, -5) And Rng.Offset(, -3) < 
Rng.Offset(, 2) Then 
        PlaceboCut Rng 
      
    ElseIf Rng.Offset(, -5) < Rng Then 
        FACut Rng 
    ElseIf Rng = Rng.Offset(, -5) And Rng.Offset(, -3) > 
Rng.Offset(, 2) Then 
        FACut Rng 
       
    ElseIf Rng.Offset(, -5) = Rng And Rng.Offset(, -3) = 
Rng.Offset(, 2) Then 
        BothCut Rng 
                  
Else: Stop 
End If    
Loop 
End 
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Appendix B:       
Raw data from MeDIP 
qPCR QC analysis. 
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Figure B.1: H19 qPCR Data 
Raw data from qPCR QC analysis on MeDIP FASSTT DNA and Input DNA for the long non-
coding RNA gene H19, known to be methylated. 
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Figure B.2: H3b qPCR Data 
Raw data from qPCR QC analysis on MeDIP FASSTT DNA and Input DNA for the histone 
H3b gene known to be unmethylated 
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Appendix C:       
Pregnancy Related 
Differentially Methylated 
Regions  
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Appendix C.1: Genes that exhibited a decrease in methylation at their promoter regions 
in response to pregnancy 
Description Fold Change  STDEV 
splicing factor 3b, subunit 4, 49kDa  -2.82  1.5976  
death-domain associated protein  -2.32  0.9864  
RhoA/RAC/CDC42 exchange factor  -2.26  1.3798  
talin 2  -2.09  1.2596  
melanoma antigen family D, 4  -2.01  1.2154  
melanoma antigen family D, 4B  -2.01  1.2154  
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Appendix D:  
SMART MSP Assay Data 
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Figure D.1: IP6K1 SMART-MSP Assay 
Sequence and location information on the SMART MSP assay designed for Inositol 
hexakisphosphate kiniase 1 (IP6K1).  Probe data taken from the highlighted portion of Figure 
3.13, with sequence data from primary assembly GRCh37.p13. Primer sequences were 
derived from sodium bisulfite treatment of this region, with red cytosines anticipated to 
deaminate to thymidines. Probe position indicated by parentheses. For fully methylated DNA, 
CpG dinucleotides (highlighted in green) will retain their parent sequence. In the gene map 
below, the green rectangle refers to where this sequence lies relative to the introns and exons 
of IP6K1, and direction of transcription is indicated by the green arrow.  The regulatory region 
of IP6K1, 3:49823786-49823961 is covered by this region. The TSS for IP6K1 lies at 
3:49785433. 
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Figure D.2: Chr9ORF44 SMART MSP Assay 
Sequence and location information on the SMART MSP assay designed for Chromosome 9 
Open Reading Frame 44 (Chr9ORF44).  Probe data taken from the highlighted portion of 
Figure 3.14, with sequence data from primary assembly GRCh37. Primer sequences were 
derived from sodium bisulfite treatment of this region, with red cytosines anticipated to 
deaminate to thymidines. Probe position indicated by parentheses. For fully methylated DNA, 
CpG dinucleotides (highlighted in green) will retain their parent sequence. No gene map is 
displayed, as this probe region does not lie adjacent to a known expressed gene.  
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Figure D.3: RASA4 SMART MSP Assay 
Sequence and location information on the SMART MSP assay designed for Ras protein 
activator 4 (RASA4).  Probe data taken from the highlighted portion of Figure 3.15, with 
sequence data from primary assembly GRCh37. Primer sequences were derived from sodium 
bisulfite treatment of this region, with red cytosines anticipated to deaminate to thymidines. 
For fully methylated DNA, CpG dinucleotides (highlighted in green) will retain their parent 
sequence. This MeDIP probe region lies upstream of the RASA4 regulatory region, 
7:102158157-102158228, with its TSS at positon 3:102158158. 
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Figure D.4: GPS2 SMART MSP Assay  
Sequence and location information on the SMART MSP assay designed for G protein pathway 
suppressor 2 (GPS2). Primer sequences were derived from sodium bisulfite-treatment of this 
region, with red cytosines anticipated to deaminate to thymidines. For fully methylated DNA, 
CpG dinucleotides (highlighted in green) will retain their parent sequence. This MeDIP probe 
region lies upstream of the GPS2 regulatory region, 17:7218371-7218663, with its TSS at 
positon 3:7218370. 
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 Cp1 Cp2 Average  STDEV 
1 in 5 30.51 30.68 30.6 0.0601 
1 in 25 32.66 32.3 32.48 0.1272 
1 in 125 34.85 33.94 34.4 0.3217 
1 in 625 35.54 36.58 36.06 0.3677 
 
Figure D.5: COL2A1 SMART MSP Assay Standard Curve  
Standard curve graph generated from the Roche Lightcycler 480 system. Data derived from a 
standard dilution of sodium bisulfite treated DNA from 1/5 to 1/625. COL2A1 has a PCR 
efficiency of 2.012.  
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  Cp Cp  Average  STDEV Tm  Tm Average  STDEV 
Neat 25.66 25.90 25.78 0.1697 76.81 76.81 76.81 0.0000 
1 in 2 27.55 27.70 27.63 0.1061 76.79 76.72 76.76 0.0495 
1 in 4 28.17 28.03 28.10 0.0990 76.75 76.72 76.74 0.0212 
1 in 8 28.97 29.04 29.01 0.0495 76.78 76.81 76.80 0.0212 
1 in 16 29.70 29.93 29.82 0.1626 76.64 76.45 76.55 0.1344 
neg 35.50 35.85 35.68 0.2475 74.99 74.96 74.98 0.0212 
 
Figure D.6: IP6K1 SMART MSP Assay Standard Curve  
Standard curve graph generated from the Roche Lightcycler 480 system. Data derived from a 
doubling dilution of sodium bisulfite treated DNA from 1/2 to 1/8. IP6K1 has a PCR efficiency 
of 1.829.  
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  Cp Cp  Average  STDEV Tm  Tm Average  STDEV 
Neat 26.21 26.45 26.33 0.1697 78.88 78.95 78.92 0.0495 
1 in 5 28.74 28.75 28.75 0.0071 78.88 78.94 78.91 0.0424 
1 in 25 31.08 31.48 31.28 0.2828 78.85 78.96 78.91 0.0778 
1 in 125 33.56 33.32 33.44 0.1697 78.95 78.94 78.95 0.0071 
1 in 625 36.08 36.73 36.41 0.4596 78.93 78.91 78.92 0.0141 
neg N/A N/A N/A N/A N/A N/A N/A N/A 
 
Figure D.7: Chr9ORF44 SMART MSP Assay Standard Curve  
Standard curve graph generated from the Roche Lightcycler 480 system. Data derived from a 
doubling dilution of sodium bisulfite treated DNA from 1/2 to 1/8. Chr9ORF44 has a PCR 
efficiency of 1.961.  
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  Cp Cp  Average  STDEV Tm  Tm Average  STDEV 
Neat 24.54 24.8 24.67 0.1838 76.96  76.8  76.88  0.1131  
1 in 5 27.05 26.78 26.92 0.1909       76.44          76.26         76.35  0.1273 
1 in 25 31.08 31.48 31.28 0.2828       76.75        76.15  76.45 0.4243 
1 in 125 33.56 33.32 33.44 0.1697 Early Peak Early Peak   Early Peak Early Peak 
1 in 625 36.08 36.73 36.41 0.4596 Early Peak Early Peak Early Peak Early Peak 
neg 34.83 33.50 34.165 0.9405 Early Peak Early Peak Early Peak Early Peak 
 
Figure D.8: RASA4 SMART MSP Assay Standard Curve  
Standard curve graph generated from the Roche Lightcycler 480 system. Data derived from a 
serial dilution of sodium bisulfite treated DNA from 1/5 to 1/125. RASA4 has a PCR 
efficiency of 2.062.  
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  Cp Cp  Average  STDEV Tm  Tm Average  STDEV 
Neat 32.04 31.79 31.92 0.1768 80.62 80.62 80.62 0.0000 
1 in 2 32.88 33.17 33.03 0.2051 80.59 80.57 80.58 0.0141 
1 in 4 34.04 34.27 34.16 0.1626 80.64 80.62 80.63 0.0141 
1 in 8 35.35 35.38 35.37 0.0212 80.68 80.67 80.68 0.0071 
1 in 16 36.46 37.20 36.83 0.5233 80.23 80.69 80.46 0.3253 
neg N/A N/A N/A N/A N/A N/A N/A N/A 
  
Figure D.9: GPS2 SMART MSP Assay Standard Curve  
Standard curve graph generated from the Roche Lightcycler 480 system. Data derived from a 
doubling dilution of sodium bisulfite treated DNA from 1/2 to 1/16. GPS2 has a PCR 
efficiency of 1.855. 
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Appendix E:          
FASSTT Cohort Data 
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Appendix E.1: COL2A1 Screening Experiments 
  
 Mean (A) 
COL2A1 
STDEV (A) 
COL2A1 
100% (A) 
COL2A1 
Mean (B) 
COL2A1 
STDEV 
(B) 
COL2A1 
100% (B) 
COL2A1 
Relative 
Ratio (A) 
Relative 
Ratio (B) 
Verdict 
1074 A 29.82 0.0636 29.24 26.10 0.7920 25.11 1.02 1.34 N/A 
1074 B 40.00 0.0000 29.24 26.71 0.1414 25.11    
1085 A 28.84 0.0424 29.24 26.15 0.1131 25.11 1.01 1.02 Pass 
1085 B 29.54 0.1344 29.24 26.51 0.0071 25.11    
1010 A 29.24 0.0141 29.24 26.31 0.1202 25.11 1.03 1.32 N/A 
1010 B 38.54 2.0718 29.24 27.06 0.0354 25.11    
1156 A 32.67 0.1909 29.24 27.13 0.0000 25.11 0.93 1.18 N/A 
1156 B 38.39 2.2769 29.24 25.22 0.0354 25.11    
1099 A 29.77 0.0071 29.24 26.79 0.0849 25.11 0.94 0.90 Pass 
1099 B 26.87 0.0354 29.24 25.30 0.0849 25.11    
1061 A 30.91 0.1626 29.24 27.01 0.1556 25.11 0.92 0.86 Pass 
1061 B 26.72 0.0990 29.24 24.92 0.0424 25.11    
1069 A 35.48 0.0141 29.24 35.14 0.5374 29.02 0.97 0.99 Pass 
1069 B 35.07 0.0566 29.24 33.93 0.0707 29.02    
1160 A 36.15 5.4447 29.24 30.85 0.0566 28.35 0.99 1.11 N/A 
1160 B 40.00 0.0000 29.24 30.57 1.8243 28.35    
1092 A 32.03 0.3748 29.24 30.95 0.0849 28.35 0.93 0.95 Pass 
1092 B 30.49 0.2333 29.24 28.88 0.0566 28.35    
1123 A 30.29 0.0919 29.24 28.65 0.0283 28.35 1.28 1.23 Pass 
1123 B 37.31 1.6193 29.24 36.67 0.5798 28.35    
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1132 A 33.67 0.1697 29.24 32.07 0.2263 28.35 0.85 0.86 Pass 
1132 B 28.91 0.0707 29.24 27.26 0.1061 28.35    
1157 A 30.90 0.1344 29.24 29.35 0.1838 28.35 0.99 0.99 Pass 
1157 B 30.61 0.0495 29.24 28.96 0.0636 28.35    
1082 A 33.34 0.4172 29.24 32.53 0.0636 28.35 0.92 0.94 Pass 
1082 B 31.25 0.1485 29.24 29.78 0.1202 28.35    
1168 A 33.64 0.1697 29.24 32.28 0.7354 28.35 0.81 0.83 Pass 
1168 B 28.03 0.0000 29.24 26.30 0.2687 28.35    
1174 A 36.00 0.2546 29.24 31.72 6.2367 28.35 0.86 0.80 Pass 
1174 B 28.71 0.0071 29.24 27.15 0.0849 28.35    
1180 A 35.52 0.7637 29.24 34.89 0.5798 28.35 0.79 0.83 Pass 
1180 B 29.36 0.9970 29.24 27.40 0.1768 28.35    
1222 A 35.87 5.8478 29.24 31.74 0.0636 28.35 1.26 1.09 Pass 
1222 B 39.23 1.0889 29.24 40.00 0.0000 28.35    
1224 A 32.99 0.0778 29.24 30.95 0.0566 28.35 0.91 0.90 Pass 
1224 B 29.82 0.0000 29.24 28.08 0.0566 28.35    
1003 A 33.50 0.1980 29.24 31.49 0.3889 28.35 0.89 0.88 Pass 
1003 B 29.59 0.0071 29.24 28.00 0.0141 28.35    
1004 A 38.52 2.1001 29.24 21.01 0.1344 25.11 1.24 0.71 N/A 
1004 B 27.47 0.0566 29.24 26.05 0.0071 27.98    
1005 A 27.70 0.0424 29.26 26.69 0.0919 28.35 1.00 1.04 Pass 
1005 B 28.76 0.2616 29.26 26.65 0.0990 28.35    
1007 A 27.35 0.9192 29.26 25.78 0.0707 28.35 1.07 1.08 Pass 
1007 B 29.63 0.4808 29.26 27.57 0.1344 28.35    
1008 A 29.53 0.7920 29.26 27.24 0.0990 28.35 1.01 0.99 Pass 
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1008 B 29.21 0.3606 29.26 27.58 0.0778 28.35    
1009 A 30.95 0.4243 29.26 29.07 0.2192 28.35 0.95 0.95 Pass 
1009 B 29.26 0.2828 29.26 27.69 0.0354 28.35    
1012 A 30.38 0.4667 29.26 28.61 0.1202 28.35 0.94 0.94 Pass 
1012 B 28.61 0.0566 29.26 26.84 0.0354 28.35    
1018 A 28.45 0.1061 29.26 26.13 0.0566 28.35 1.02 1.06 Pass 
1018 B 30.06 0.0849 29.26 26.60 0.0141 28.35    
1019 A 40.00 0.0000 29.26 40.00 0.0000 28.35 0.64 0.71 Pass 
1019 B 28.28 0.0849 29.26 25.77 0.1273 28.35    
1020 A 28.75 0.2192 29.26 25.68 0.1485 28.35 1.10 1.04 Pass 
1020 B 29.94 0.6081 29.26 28.23 0.1273 28.35    
1022 A 29.81 0.2404 29.26 29.87 0.0354 29.02 1.03 1.08 Pass 
1022 B 32.06 0.0636 29.26 30.63 0.1768 29.02    
1023 A 31.73 0.1061 29.26 28.99 0.0141 29.02 0.96 0.99 Pass 
1023 B 31.40 0.1485 29.26 27.88 0.0919 29.02    
 1024 A 32.84 0.2970 29.26 30.08 0.1344 29.02 0.92 0.96 Pass 
 1024 B 31.47 0.6223 29.26 27.62 0.0000 29.02    
 1028 A 29.90 0.1980 29.26 27.93 0.0283 29.02 0.96 0.92 Pass 
 1028 B 27.37 0.1909 29.26 26.95 0.0495 29.02    
 1030 A 25.22 0.1131 29.26 24.20 0.0071 29.02 1.22 1.21 Pass 
 1030 B 30.53 0.2687 29.26 29.48 0.0566 29.02    
 1031 A 34.94 0.1061 29.26 31.16 0.0212 29.02 1.23 1.14 Pass 
 1031 B 40.00 0.0000 29.26 38.46 2.1779 29.02    
 1032 A 40.00 0.0000 29.26 38.54 2.0648 29.02 1.04 1.00 Pass 
 1032 B 40.00 0.0000 29.26 40.00 0.0000 29.02    
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 1033 A 27.01 0.4738 29.26 26.25 0.0141 29.02 0.96 1.05 Pass 
 1033 B 28.49 0.7920 29.26 25.32 3.2032 29.02    
 1035 A 31.28 0.1061 29.26 29.80 0.2333 27.98 0.91 0.95 Pass 
 1035 B 29.68 0.6293 29.26 27.04 0.1273 27.98    
 1037 A 35.10 0.0990 29.26 21.02 0.4313 25.11 1.32 0.90 Fail 
 1037 B 31.44 0.0778 29.26 27.70 0.0283 27.98    
 1041 A 32.72 0.2404 29.26 29.59 0.0141 27.98 0.98 1.00 Pass 
 1041 B 32.79 0.1838 29.26 29.11 0.5303 27.98    
 1042 A 34.88 0.1273 29.26 30.86 0.1768 27.98 0.94 0.93 Pass 
 1042 B 32.35 0.9405 29.26 29.04 0.0990 27.98    
 1043 A 30.16 0.5303 28.56 29.47 0.0071 27.98 0.92 0.95 Pass 
 1043 B 28.52 0.6293 28.56 27.25 0.0424 27.98    
 1050 A 28.97 0.4879 28.56 29.05 0.6293 27.98 0.87 0.90 Pass 
 1050 B 26.10 0.7071 28.56 25.17 0.0636 27.98    
 1052 A 28.28 0.6647 28.56 28.37 1.2374 27.98 0.97 1.04 Pass 
 1052 B 29.48 1.2940 28.56 27.65 0.0495 27.98    
 1053 A 28.26 0.3465 28.56 21.52 0.1344 25.11 1.29 0.95 Fail 
 1053 B 26.71 0.0707 28.56 27.70 0.7142 27.98    
 1062 A 31.83 0.2616 28.56 26.81 0.1414 27.98 1.03 0.90 Fail 
 1062 B 28.76 0.0495 28.56 27.60 0.0071 27.98    
 1063 A 31.83 0.2616 28.56 31.32 0.3606 27.98 0.88 0.90 Pass 
 1063 B 28.78 0.2121 28.56 27.58 0.0424 27.98    
 1064 A 30.61 0.0778 28.56 29.50 0.0495 27.98 0.92 0.92 Pass 
 1064 B 28.24 0.0424 28.56 27.27 0.0849 27.98    
 1066 A 31.20 0.0990 28.56 30.25 0.0495 27.98 0.96 0.96 Pass 
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 1066 B 29.94 0.3889 28.56 28.93 0.0141 27.98    
 1067 A 29.68 0.1980 28.56 29.43 0.2051 28.50 1.03 0.97 Fail 
 1067 B 28.76 0.0495 28.56 30.17 0.4384 28.50    
 1070 A 31.83 0.2616 28.56 24.76 0.0424 28.50 1.10 0.92 Fail 
 1070 B 29.33 0.7707 28.56 27.23 0.0849 28.50    
 1076 A 31.06 0.3465 28.56 30.20 0.0354 28.50 0.94 0.92 Pass 
 1076 B 28.59 0.0778 28.56 28.51 0.0141 28.50    
 1077 A 33.76 4.2497 28.56 30.18 0.0354 28.50 0.77 0.80 Pass 
 1077 B 27.03 0.0849 28.56 23.33 0.5728 25.11    
1078 A 28.54 0.4525 28.56 28.29 0.2475 28.50 0.96 0.98 Pass 
 1078 B 27.88 0.1061 28.56 27.05 0.0071 28.50    
 1090 A 32.81 0.2687 28.56 29.75 0.1202 28.50 0.98 0.93 Pass 
 1090 B 30.40 0.0071 28.56 29.28 0.1273 28.50    
 1091 A 28.84 0.0000 28.56 27.73 0.0849 28.50 0.93 0.93 Pass 
 1091 B 26.89 0.5162 28.56 25.83 0.0778 28.50    
 1093 A 29.35 0.3394 28.56 29.57 0.0919 28.50 0.84 0.88 Pass 
 1093 B 25.95 0.4031 28.56 24.76 0.0636 28.50    
 1095 A 31.64 0.3323 28.56 30.52 0.3394 28.50 0.93 0.99 Pass 
 1095 B 31.33 0.4101 28.56 28.43 0.1273 28.50    
 1100 A 30.71 0.2263 28.56 28.74 0.0000 28.50 1.06 1.01 Pass 
 1100 B 31.11 0.2758 28.56 30.37 0.1414 28.50    
 1102 A 28.47 0.2263 28.56 27.82 0.0212 28.50 1.01 1.02 Pass 
 1102 B 28.96 0.0212 28.56 27.98 0.1485 28.50    
 1107 A 28.40 0.1909 28.56 27.98 0.0000 28.50 1.01 1.08 Pass 
 1107 B 30.79 0.8415 28.56 28.29 0.0566 28.50    
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 1108 A 35.78 0.6788 28.56 28.49 0.4384 28.50 0.98 1.00 Pass 
 1108 B 35.69 1.6829 28.56 27.79 0.0424 28.50    
 1109 A 34.38 1.1526 28.56 29.96 0.4950 28.50 0.71 0.87 Pass 
 1109 B 30.08 0.6010 28.56 21.37 0.0000 25.11    
 1110 A 33.11 1.9658 28.56 29.51 0.0212 28.50 0.91 0.97 Pass 
 1110 B 32.07 0.5869 28.56 26.95 0.4243 28.50    
 1112 A 33.57 0.2899 28.56 30.27 0.0212 28.50 0.82 0.86 Pass 
 1112 B 28.82 0.8202 28.56 24.94 0.0354 28.50    
 1113 A 31.73 0.3182 28.56 27.15 0.0283 28.50 1.01 1.07 Pass 
 1113 B 34.08 0.0849 28.56 27.48 0.0495 28.50    
 1114 A 36.07 0.7778 28.56 29.75 0.0636 28.50 0.91 0.94 Pass 
 1114 B 34.05 0.0636 28.56 27.22 0.1061 28.50    
 1114 B 33.41 0.2192 28.56 22.84 0.1414 25.11    
 1115 A 35.49 0.9405 28.56 22.09 0.1697 25.11 1.17 0.81 Fail 
 1115 B 28.74 2.0718 28.56 25.89 0.0071 28.50    
 1116 A 31.88 0.2121 28.56 29.95 0.1980 28.94 0.94 0.98 Pass 
 1116 B 31.11 0.2404 28.56 28.07 0.1061 28.94    
 1118 A 34.53 0.4879 28.56 29.28 0.1131 28.94 0.77 1.06 Fail 
 1118 B 36.55 0.9970 28.56 22.64 0.0424 28.94    
 1119 A 32.60 0.0566 28.56 27.51 0.0071 28.94 0.96 6.00 Fail 
 1119 B 32.10 0.3818 28.56 26.30 0.0424 28.94    
 1120 A 35.51 0.6505 28.56 28.76 0.0636 28.94 0.95 1.44 Fail 
 1120 B 30.57 0.0566 28.56 27.41 0.0919 28.94    
 1122 A 30.23 0.0707 29.20 29.60 0.0354 28.94 0.91 0.92 Pass 
 1122 B 27.80 0.0354 29.20 26.91 0.0212 28.94    
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 1126 A 30.83 0.0141 29.20 29.92 0.1626 28.94 0.94 0.92 Pass 
 1126 B 28.46 0.1556 29.20 28.04 0.0071 28.94    
 1127 A 27.62 0.1273 29.20 26.69 0.0495 28.94 1.00 0.99 Pass 
 1127 B 27.41 0.0566 29.20 26.76 0.0141 28.94    
 1131 A 28.38 0.1061 29.20 27.64 0.0212 28.94 1.11 1.00 Fail 
 1131 B 28.41 0.3818 29.20 30.67 0.8556 28.94    
 1136 A 31.93 0.0636 29.20 30.37 0.1131 28.94 0.91 0.91 Pass 
 1136 B 29.03 0.0990 29.20 27.69 0.0354 28.94    
 1138 A 33.42 3.3375 29.20 29.75 0.4031 28.94 0.85 0.79 Pass 
 1138 B 26.26 0.0778 29.20 25.22 0.0636 28.94    
 1139 A 36.40 5.0912 29.20 30.52 0.3465 28.94 0.91 0.79 Pass 
 1139 B 28.80 0.6364 29.20 27.81 0.4738 28.94    
 1141 A 31.01 0.3748 29.20 30.91 0.1061 28.94 0.81 0.82 Pass 
 1141 B 25.40 0.2192 29.20 24.99 0.0141 28.94    
 1144 A 24.91 0.0424 29.20 24.10 0.0141 28.94 1.15 1.14 Pass 
 1144 B 28.48 0.2192 29.20 27.76 0.0071 28.94    
 1145 A 30.50 0.0424 29.20 29.28 0.0636 28.94 0.92 0.91 Pass 
 1145 B 27.85 0.0849 29.20 26.91 0.0141 28.94    
 1151 A 29.63 0.0424 29.20 28.81 0.1414 28.94 1.04 1.02 Pass 
 1151 B 30.21 0.0212 29.20 29.88 0.0495 28.94    
 1152 A 31.57 0.0424 29.20 30.04 0.1909 28.94 0.92 0.89 Pass 
 1152 B 28.06 0.0495 29.20 27.66 0.0212 28.94    
 1153 A 30.88 0.0424 29.20 30.40 0.1344 28.94 0.88 0.89 Pass 
 1153 B 27.35 0.1838 29.20 26.84 0.0566 28.94    
 1154 A 31.94 0.0283 29.20 31.25 0.1768 28.94 0.81 0.81 Pass 
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 1154 B 25.95 0.0354 29.20 25.44 0.5020 28.94    
 1155 A 28.62 0.0778 29.20 28.09 0.1980 28.94 0.98 0.98 Pass 
 1155 B 28.04 0.2051 29.20 27.59 0.0071 28.94    
 1161 A 31.07 0.0212 29.20 31.37 0.1414 28.53 0.84 0.82 Pass 
 1161 B 25.53 0.0354 29.20 26.44 0.0000 28.53    
 1163 A 24.89 0.0495 29.20 31.08 0.3394 28.53 0.88 1.14 Fail 
 1163 B 28.47 0.0071 29.20 27.26 0.4525 28.53    
 1166 A 30.52 0.0212 29.20 25.62 0.0778 28.53 1.08 0.91 Fail 
 1166 B 27.77 0.0636 29.20 27.68 0.0849 28.53    
 1171 A 29.77 0.1202 29.20 26.97 0.0566 28.53 1.02 1.01 Pass 
 1171 B 29.99 0.1485 29.20 27.64 0.1556 28.53    
 1173 A 26.72 0.0566 29.17 26.03 0.0495 28.53 1.05 1.05 Pass 
 1173 B 27.96 0.0849 29.17 27.25 0.1556 28.53    
 1177 A 28.34 0.0283 29.17 27.75 0.1838 28.53 0.99 0.97 Pass 
 1177 B 27.63 0.2333 29.17 27.35 0.4313 28.53    
 1183 A 30.83 0.1273 29.17 22.33 0.2758 25.11 1.29 0.96 Fail 
 1183 B 29.70 0.0566 29.17 28.91 0.0354 28.53    
 1185 A 28.67 0.2333 29.17 27.72 0.0354 28.53 1.09 1.01 Pass 
 1185 B 29.06 0.2263 29.17 30.19 2.7224 28.53    
 1185 B 27.35 0.0141 29.17 22.92 0.8061 25.11    
 1187 A 30.02 0.2051 29.17 22.68 0.5445 25.11 1.15 0.90 Fail 
 1187 B 27.05 0.0141 29.17 26.17 0.0849 28.53    
 1188 A 31.58 0.3323 29.17 23.83 0.2192 25.11 1.16 0.90 Fail 
 1188 B 28.28 0.0849 29.17 27.66 0.0212 28.53    
 1189 A 33.77 0.0919 29.17 33.23 0.0636 28.53 0.88 0.89 Pass 
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 1189 B 30.07 0.1202 29.17 29.30 0.0919 28.53    
 1190 A 30.91 0.2192 29.17 30.15 0.0919 28.53 0.99 0.99 Pass 
 1190 B 30.54 0.0424 29.17 29.72 0.0424 28.53    
 1192 A 32.92 0.0566 29.17 32.43 0.2546 28.53 0.89 0.89 Pass 
 1192 B 29.34 0.0071 29.17 28.91 0.0849 28.53    
 1193 A 33.15 0.1909 29.17 33.00 0.2546 28.53 0.89 0.90 Pass 
 1193 B 29.74 0.1697 29.17 29.22 0.0707 28.53    
 1194 A 31.86 0.0424 29.17 31.67 0.0283 28.53 0.96 0.96 Pass 
 1194 B 30.65 0.0849 29.17 30.31 0.0566 28.53    
 1195 A 31.52 0.3465 29.17 31.30 0.0495 28.53 0.92 0.94 Pass 
 1195 B 29.48 0.0354 29.17 28.94 0.0212 28.53    
 1197 A 31.44 0.0919 29.17 31.64 0.0000 28.53 0.95 0.97 Pass 
 1197 B 30.47 0.2828 29.17 29.98 0.0071 28.53    
 1198 A 30.91 0.1202 29.17 30.58 0.1202 28.53    
 1199 A 32.70 0.1061 29.17 32.91 0.1838 28.53 0.99 1.00 Pass 
 1199 B 32.62 0.4313 29.17 32.61 0.0071 28.53    
 1200 A 35.89 0.8132 29.17 40.00 0.0000 28.53 0.75 0.92 Pass 
 1200 B 33.04 3.4436 29.17 30.20 0.0212 28.53    
 1201 A 30.63 0.0495 29.58 32.81 0.1909 28.53 0.96 0.96 Pass 
 1201 B 29.35 0.0000 29.58 31.43 0.0636 28.53    
 1203 A 35.60 1.2445 29.58 40.00 0.0000 28.53 0.79 0.84 Pass 
 1203 B 29.83 0.0354 29.58 31.77 0.0212 28.53    
 1205 A 40.00 0.0000 29.58 40.00 0.0000 29.02 0.69 0.71 Pass 
 1205 B 28.44 0.0071 29.58 27.60 0.0071 29.02    
 1206 A 27.50 0.0071 29.58 29.48 0.2970 28.53 1.01 1.01 Pass 
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 1206 B 27.81 0.0566 29.58 29.65 0.0849 28.53    
 1209 A 30.94 0.1061 29.58 32.68 0.1980 28.53 0.95 0.94 Pass 
 1209 B 29.07 0.0636 29.58 30.91 0.0636 28.53    
 1211 A 35.63 0.8344 29.58 40.00 0.0000  0.78 0.83 Pass 
 1211 B 29.69 0.1414 29.58 31.12 0.0424 28.53    
 1212 A 31.27 0.0283 29.58 32.78 0.0778 28.53 0.93 0.92 Pass 
 1212 B 28.72 0.1909 29.58 30.34 0.1838 28.53    
 1214 A 29.09 0.0424 29.58 31.18 0.0636 28.53 0.96 0.96 Pass 
 1214 B 28.01 0.0424 29.58 29.92 0.0141 28.53    
 1215 A 30.58 0.0849 29.58 32.36 0.1344 28.53 0.82 0.81 Pass 
 1215 B 24.83 0.0919 29.58 26.66 0.0000 28.53    
 1216 A 28.55 0.1131 29.58 31.56 0.1485 28.53 0.84 0.93 Pass 
 1216 B 26.45 0.1909 29.58 26.38 2.6799 28.53    
 1217 A 27.69 0.0354 29.58 30.06 0.1414 28.53 1.05 1.04 Pass 
 1217 B 28.91 0.0778 29.58 31.42 0.0849 28.53    
 1218 A 30.80 0.0566 29.58 33.73 0.2404 28.53 1.19 1.19 Pass 
 1218 B 36.66 1.0112 29.58 40.00 0.0000     
 1219 A 31.93 0.1414 29.58 33.87 0.0707 28.53 0.92 0.92 Pass 
 1219 B 29.37 0.1556 29.58 31.06 0.3677 28.53    
 1220 A 31.33 0.2051 29.58 30.68 0.0000 28.53 1.04 0.95 Fail 
 1220 B 29.65 0.1273 29.58 31.80 0.2121 28.53    
 1225 A 30.99 0.1909 29.58 33.73 0.2333 28.53 0.93 0.94 Pass 
 1225 B 29.18 0.0141 29.58 31.34 0.0212 28.53    
 1226 A 28.74 0.0283 29.58 30.55 0.0566 28.53 0.99 0.98 Pass 
 1226 B 28.23 0.0000 29.58 30.16 0.1344 28.53    
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Appendix E.2: IP6K1 SMART-MSP Raw Data  
Sample Name Methylation % Intervention Methylation % Change Outcome 
 1003 A 1.83 2   
 1003 B 1.54 2 -0.29 No Change 
 1005 A 11.11 2   
 1005 B 6.70 2 -4.41 No Change 
 1007 A 15.18 1   
 1007 B 14.66 1 -0.52 No Change 
 1008 A 12.20 1   
 1008 B 12.12 1 -0.08 No Change 
 1009 A 14.01 2   
 1009 B 14.76 2 0.75 No Change 
 1012 A 11.30 2   
 1012 B 5.31 2 -5.99 No Change 
 1018 A 7.08 2   
 1018 B 5.27 2 -1.81 No Change 
 1022 A 18.11 2   
 1022 B 14.61 2 -3.50 No Change 
 1023 A 8.36 1   
 1023 B 7.36 1 -1.01 No Change 
 1024 A 9.67 1   
 1024 B 2.56 1 -7.11 No Change 
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 1028 A 6.12 2   
 1028 B 8.57 2 2.45 No Change 
 1030 A 6.06 1   
 1030 B 13.26 1 7.20 No Change 
 1033 A 7.43 1   
 1033 B 1.34 1 -6.09 No Change 
 1037 A 0.18 2   
 1037 B 9.54 2 9.36 No Change 
 1041 A 12.16 2   
 1041 B 10.58 2 -1.57 No Change 
 1042 A 25.88 1   
 1042 B 18.62 1 -7.26 No Change 
 1043 A 1.05 1   
 1043 B 0.27 1 -0.78 No Change 
 1050 A 1.13 2   
 1050 B 0.23 2 -0.90 No Change 
 1052 A 2.70 1   
 1052 B 3.67 1 0.96 No Change 
 1053 A 0.34 2   
 1053 B 4.00 2 3.66 No Change 
 1061 A 4.42 1   
 1061 B 16.04 1 11.62 Up 
 1062 A 2.36 1   
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 1062 B 3.90 1 1.54 No Change 
 1063 A 34.99 2   
 1063 B 2.57 2 -32.42 Down 
 1064 A 1.68 2   
 1064 B 2.23 2 0.54 No Change 
 1066 A 3.89 2   
 1066 B 3.44 2 -0.44 No Change 
 1067 A 3.44 2   
 1067 B 1.29 2 -2.16 No Change 
 1069 A 6.89 2   
 1069 B 4.04 2 -2.85 No Change 
 1070 A 1.63 2   
 1070 B 0.94 2 -0.69 No Change 
 1074 A 9.51 1   
 1074 B 16.38 1 6.87 No Change 
 1076 A 3.78 2   
 1076 B 3.85 2 0.07 No Change 
 1077 A 5.87 1   
 1077 B 1.33 1 -4.54 No Change 
FIP1078 A 4.74 1   
 1078 B 3.25 1 -1.49 No Change 
 1082 A 4.80 2   
 1082 B 2.58 2 -2.22 No Change 
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 1085 A 15.02 2   
 1085 B 10.26 2 -4.76 No Change 
 1091 A 2.07 1   
 1091 B 1.55 1 -0.52 No Change 
 1092 A 3.73 2   
 1092 B 2.56 2 -1.17 No Change 
 1093 A 6.23 1   
 1093 B 1.72 1 -4.51 No Change 
 1095 A 0.63 2   
 1095 B 0.16 2 -0.47 No Change 
 1099 A 10.29 2   
 1099 B 15.88 2 5.58 No Change 
 1100 A 0.01 1   
 1100 B 0.04 1 0.03 No Change 
 1102 A 0.15 2   
 1102 B 0.31 2 0.17 No Change 
 1107 A 0.32 1   
 1107 B 3.69 1 3.38 No Change 
 1108 A 0.84 2   
 1108 B 0.99 2 0.15 No Change 
 1109 A 4.12 1   
 1109 B 0.62 1 -3.50 No Change 
 1110 A 3.49 1   
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 1110 B 2.78 1 -0.71 No Change 
 1112 A 4.31 2   
 1112 B 1.90 2 -2.41 No Change 
 1113 A 2.03 1   
 1113 B 1.60 1 -0.43 No Change 
 1114 A 2.86 2   
 1114 B 1.79 2 -1.06 No Change 
 1115 A 0.11 2   
 1115 B 3.30 2 3.19 No Change 
 1116 A 4.58 1   
 1116 B 2.60 1 -1.97 No Change 
 1118 A 2.18 2   
 1118 B 0.28 2 -1.89 No Change 
 1119 A 1.41 1   
 1119 B 1.26 1 -0.15 No Change 
 1120 A 0.88 1   
 1120 B 2.75 1 1.87 No Change 
 1122 A 4.15 1   
 1122 B 1.70 1 -2.45 No Change 
 1123 A 2.13 1   
 1123 B 20.88 1 18.74 Up 
 1132 A 2.68 1   
 1132 B 0.08 1 -2.61 No Change 
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 1136 A 1.67 1   
 1136 B 1.37 1 -0.30 No Change 
 1138 A 1.15 1   
 1138 B 0.62 1 -0.54 No Change 
 1139 A 2.08 1   
 1139 B 3.69 1 1.61 No Change 
 1141 A 10.77 1   
 1141 B 1.79 1 -8.98 No Change 
 1144 A 1.47 2   
 1144 B 1.50 2 0.03 No Change 
 1145 A 1.73 1   
 1145 B 1.31 1 -0.42 No Change 
 1151 A 1.86 1   
 1151 B 4.33 1 2.47 No Change 
 1152 A 4.17 1   
 1152 B 1.40 1 -2.77 No Change 
 1153 A 4.04 2   
 1153 B 1.97 2 -2.07 No Change 
 1154 A 6.14 1   
 1154 B 1.73 1 -4.41 No Change 
 1155 A 3.47 1   
 1155 B 2.30 1 -1.16 No Change 
 1156 A 2.55 2   
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 1156 B 29.02 2 26.47 Up 
 1157 A 2.60 1   
 1157 B 2.70 1 0.10 No Change 
 1160 A 2.23 2   
 1160 B 23.65 2 21.42 Up 
 1161 A 14.66 1   
 1161 B 1.63 1 -13.03 Down 
 1163 A 6.14 2   
 1163 B 1.02 2 -5.12 No Change 
 1166 A 0.63 2   
 1166 B 2.34 2 1.70 No Change 
 1168 A 1.70 1   
 1168 B 0.89 1 -0.81 No Change 
 1171 A 1.90 1   
 1171 B 2.26 1 0.36 No Change 
 1173 A 4.58 1   
 1173 B 2.97 1 -1.61 No Change 
 1174 A 1.03 1   
 1174 B 1.53 1 0.50 No Change 
 1177 A 1.65 1   
 1177 B 1.18 1 -0.46 No Change 
 1180 A 11.34 1   
 1180 B 1.47 1 -9.87 No Change 
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 1183 A 0.18 1   
 1183 B 2.34 1 2.16 No Change 
 1185 A 2.10 2   
 1185 B 11.87 2 9.77 No Change 
 1187 A 0.39 1   
 1187 B 0.15 1 -0.24 No Change 
 1188 A 1.13 2   
 1188 B 0.54 2 -0.58 No Change 
 1190 A 5.42 1   
 1190 B 16.49 1 11.07 Up 
 1192 A 100.00 2   
 1192 B 24.40 2 -75.60 Down 
 1194 A 100.00 2   
 1194 B 78.46 2 -21.54 Down 
 1195 A 100.00 2   
 1195 B 28.62 2 -71.38 Down 
 1197 A 75.26 2   
 1197 B 67.83 2 -7.43 No Change 
 1201 A 5.11 2   
 1201 B 2.08 2 -3.03 No Change 
 1206 A 0.54 1   
 1206 B 0.70 1 0.17 No Change 
 1209 A 4.02 1   
240 
 
 
 1209 B 1.28 1 -2.74 No Change 
 1212 A 13.12 1   
 1212 B 3.29 1 -9.83 No Change 
 1214 A 1.19 2   
 1214 B 0.68 2 -0.51 No Change 
 1215 A 2.23 1   
 1215 B 0.11 1 -2.12 No Change 
 1216 A 0.57 2   
 1216 B 0.22 2 -0.35 No Change 
 1217 A 0.36 2   
 1217 B 0.25 2 -0.12 No Change 
 1219 A 1.19 1   
 1219 B 0.22 1 -0.97 No Change 
 1220 A 0.88 2   
 1220 B 0.30 2 -0.59 No Change 
 1225 A 1.02 2   
 1225 B 0.35 2 -0.67 No Change 
 1226 A 0.10 2   
 1226 B 0.03 2 -0.07 No Change 
Intervention: Folic Acid Supplementation 1, Placebo, 2 
 
Appendix E.3: Chr9ORF44 SMART-MSP Raw Data  
Sample Name Methylation % Group Methylation % Change Outcome 
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 1003 A 17.80 2   
 1003 B 23.90 2 6.10 No Change 
 1005 A 53.77 2   
 1005 B 43.68 2 -10.10 Down 
 1007 A 44.75 1   
 1007 B 50.52 1 5.77 No Change 
 1008 A 41.90 1   
 1008 B 35.97 1 -5.93 No Change 
 1009 A 25.26 2   
 1009 B 55.67 2 30.41 Up 
 1012 A 37.89 2   
 1012 B 40.75 2 2.86 No Change 
 1018 A 33.56 2   
 1018 B 36.35 2 2.79 No Change 
 1022 A 61.99 2   
 1022 B 17.99 2 -44.00 Down 
 1023 A 33.22 1   
 1023 B 34.03 1 0.82 No Change 
 1024 A 34.51 1   
 1024 B 40.47 1 5.96 No Change 
 1028 A 45.85 2   
 1028 B 53.03 2 7.18 No Change 
 1030 A 41.04 1   
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 1030 B 35.97 1 -5.06 No Change 
 1033 A 45.06 1   
 1033 B 11.19 1 -33.87 Down 
 1037 A 0.07 2   
 1037 B 33.68 2 33.61 Up 
 1041 A 30.99 2   
 1041 B 23.41 2 -7.59 No Change 
 1042 A 19.14 1   
 1042 B 41.61 1 22.47 Up 
 1043 A 50.70 1   
 1043 B 40.75 1 -9.94 No Change 
 1050 A 66.90 2   
 1050 B 62.42 2 -4.48 No Change 
 1052 A 92.34 1   
 1052 B 36.10 1 -56.24 Down 
 1053 A 3.87 2   
 1053 B 69.74 2 65.86 Up 
 1061 A 64.39 1   
 1061 B 100.00 1 35.61 Up 
 1062 A 68.07 1   
 1062 B 38.96 1 -29.11 Down 
 1063 A 52.67 2   
 1063 B 49.48 2 -3.19 No Change 
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 1064 A 33.22 2   
 1064 B 35.11 2 1.89 No Change 
 1066 A 29.02 2   
 1066 B 40.61 2 11.60 Up 
 1067 A 35.85 2   
 1067 B 20.52 2 -15.33 Down 
 1069 A 47.14 2   
 1069 B 19.14 2 -27.99 Down 
 1070 A 54.53 2   
 1070 B 31.10 2 -23.43 Down 
 1074 A 92.66 1   
 1074 B 32.99 1 -59.67 Down 
 1076 A 26.06 2   
 1076 B 43.08 2 17.02 Up 
 1077 A 32.09 1   
 1077 B 22.61 1 -9.48 No Change 
FIP1078 A 47.14 1   
 1078 B 41.75 1 -5.38 No Change 
 1082 A 30.15 2   
 1082 B 31.64 2 1.50 No Change 
 1085 A 39.37 2   
 1085 B 25.00 2 -14.37 Down 
 1091 A 30.46 1   
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 1091 B 28.52 1 -1.94 No Change 
 1092 A 42.93 2   
 1092 B 38.16 2 -4.77 No Change 
 1093 A 51.94 1   
 1093 B 34.75 1 -17.19 Down 
 1095 A 24.57 2   
 1095 B 18.49 2 -6.08 No Change 
 1099 A 100.00 2   
 1099 B 100.00 2 0.00 No Change 
 1100 A 22.30 1   
 1100 B 28.03 1 5.73 No Change 
 1102 A 31.32 2   
 1102 B 27.17 2 -4.15 No Change 
 1107 A 37.89 1   
 1107 B 26.52 1 -11.38 Down 
 1108 A 14.56 2   
 1108 B 16.72 2 2.16 No Change 
 1109 A 42.04 1   
 1109 B 9.15 1 -32.89 Down 
 1110 A 40.61 1   
 1110 B 48.30 1 7.68 No Change 
 1112 A 24.91 2   
 1112 B 38.56 2 13.64 Up 
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 1113 A 27.26 1   
 1113 B 22.93 1 -4.34 No Change 
 1114 A 26.24 2   
 1114 B 29.22 2 2.98 No Change 
 1115 A 0.85 2   
 1115 B 33.10 2 32.26 Up 
 1116 A 44.14 1   
 1116 B 19.68 1 -24.45 Down 
 1118 A 36.73 2   
 1118 B 21.84 2 -14.89 Down 
 1119 A 25.53 1   
 1119 B 31.10 1 5.57 No Change 
 1120 A 18.49 1   
 1120 B 35.11 1 16.62 Up 
 1122 A 30.35 1   
 1122 B 22.38 1 -7.98 No Change 
 1123 A 37.37 1   
 1123 B 80.39 1 43.01 Up 
 1132 A 26.52 1   
 1132 B 38.56 1 12.04 Up 
 1136 A 15.88 1   
 1136 B 21.10 1 5.22 No Change 
 1138 A 21.39 1   
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 1138 B 21.69 1 0.30 No Change 
 1139 A 21.61 1   
 1139 B 56.06 1 34.44 Up 
 1141 A 47.47 1   
 1141 B 47.96 1 0.50 No Change 
 1144 A 33.56 2   
 1144 B 35.23 2 1.67 No Change 
 1145 A 13.82 1   
 1145 B 23.57 1 9.75 No Change 
 1151 A 25.88 1   
 1151 B 41.47 1 15.58 Up 
 1152 A 11.50 1   
 1152 B 34.27 1 22.77 Up 
 1153 A 31.75 2   
 1153 B 41.18 2 9.43 No Change 
 1154 A 32.42 1   
 1154 B 33.68 1 1.26 No Change 
 1155 A 42.04 1   
 1155 B 36.73 1 -5.32 No Change 
 1156 A 41.32 2   
 1156 B 34.27 2 -7.05 No Change 
 1157 A 33.22 1   
 1157 B 38.56 1 5.34 No Change 
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 1161 A 34.27 1   
 1161 B 17.80 1 -16.47 Down 
 1163 A 15.12 2   
 1163 B 25.26 2 10.14 Up 
 1166 A 45.22 2   
 1166 B 32.53 2 -12.69 Down 
 1168 A 55.86 1   
 1168 B 34.39 1 -21.48 Down 
 1171 A 50.87 1   
 1171 B 65.98 1 15.10 Up 
 1173 A 70.47 1   
 1173 B 42.63 1 -27.83 Down 
 1174 A 3.47 1   
 1174 B 44.44 1 40.97 Up 
 1177 A 34.27 1   
 1177 B 52.67 1 18.40 Up 
 1180 A 68.54 1   
 1180 B 39.37 1 -29.17 Down 
 1183 A 1.91 1   
 1183 B 35.11 1 33.20 Up 
 1185 A 37.63 2   
 1185 B 12.29 2 -25.35 Down 
 1187 A 32.53 1   
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 1187 B 2.80 1 -29.74 Down 
 1188 A 2.19 2   
 1188 B 41.04 2 38.85 Up 
 1189 A 0.00 1   
 1189 B 34.51 1 34.51 Up 
 1190 A 36.60 1   
 1190 B 34.03 1 -2.57 No Change 
 1192 A 28.32 2   
 1192 B 54.53 2 26.20 Up 
 1193 A 52.49 1   
 1193 B 35.23 1 -17.25 Down 
 1194 A 35.48 2   
 1194 B 56.84 2 21.36 Up 
 1195 A 52.85 2   
 1195 B 54.15 2 1.30 No Change 
 1197 A 52.30 2   
 1197 B 51.76 2 -0.54 No Change 
 1199 A 39.78 1   
 1199 B 22.07 1 -17.71 Down 
 1201 A 8.63 2   
 1201 B 8.36 2 -0.26 No Change 
 1203 A 0.10 1   
 1203 B 7.78 1 7.68 No Change 
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 1204 A 0.13 2   
 1204 B 7.30 2 7.18 No Change 
 1205 A 2.02 1   
 1205 B 8.54 1 6.52 No Change 
 1206 A 8.16 1   
 1206 B 7.56 1 -0.60 No Change 
 1209 A 7.56 1   
 1209 B 8.19 1 0.63 No Change 
 1211 A 0.10 2   
 1211 B 7.43 2 7.33 No Change 
 1212 A 5.75 1   
 1212 B 7.54 1 1.79 No Change 
 1214 A 5.13 2   
 1214 B 6.77 2 1.64 No Change 
 1215 A 8.02 1   
 1215 B 6.08 1 -1.94 No Change 
 1216 A 5.83 2   
 1216 B 6.14 2 0.31 No Change 
 1217 A 6.96 2   
 1217 B 5.95 2 -1.00 No Change 
 1218 A 0.00 1   
 1218 B 0.13 1 0.13 No Change 
 1219 A 7.03 1   
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 1219 B 6.52 1 -0.52 No Change 
 1220 A 5.61 2   
 1220 B 5.44 2 -0.17 No Change 
 1222 A 40.05 1   
 1222 B 35.11 1 -4.94 No Change 
 1224 A 34.51 2   
 1224 B 39.09 2 4.59 No Change 
 1225 A 5.40 2   
 1225 B 6.98 2 1.58 No Change 
 1226 A 5.69 2   
 1226 B 7.25 2 1.56 No Change 
Intervention: Folic Acid Supplementation 1, Placebo, 2 
 
 
 
 
 
 
 
 
Appendix E.4: RASA4 SMART-MSP Raw Data 
Sample Name  Methylation % Group Methylation % Change Outcome 
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 1003 A 0.00 2   
 1003 B <5 2 5.00 No Change 
 1005 A 27.93 2   
 1005 B <5 2 -22.00 Down 
 1007 A 19.14 1   
 1007 B <5 1 -15.00 Down 
 1008 A <5 1   
 1008 B <5 1 0.00 No Change 
 1009 A <5 2   
 1009 B <5 2 0.00 No Change 
 1012 A 0.00 2   
 1012 B <5 2 5.00 No Change 
 1018 A 19.28 2   
 1018 B <5 2 -14.00 Down 
 1022 A 0.00 2   
 1022 B 0.00 2 0.00 No Change 
 1023 A <5 1   
 1023 B <5 1 0.00 No Change 
 1024 A 0.00 1   
 1024 B 0.00 1 0.00 No Change 
 1028 A 22.45 2   
 1028 B 22.22 2 -0.23 No Change 
 1030 A 7.46 1   
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 1030 B 0.00 1 -7.46 No Change 
 1033 A 10.22 1   
 1033 B <5 1 -5.00 No Change 
 1037 A 0.00 2   
 1037 B <5 2 5.00 No Change 
 1041 A 0.00 2   
 1041 B 0.00 2 0.00 No Change 
 1042 A 0.00 1   
 1042 B <5            1 5.00 No Change 
 1043 A 0.00 1   
 1043 B <5 1 5.00 No Change 
 1050 A 0.00 2   
 1050 B 14.26 2 14.26 Up 
 1052 A <5 1   
 1052 B 0.00 1 -5.00 No Change 
 1053 A 4.07 2   
 1053 B 46.01 2 41.94 Up 
 1061 A 0.00 1   
 1061 B 60.50 1 60.50 Up 
 1062 A 32.09 1   
 1062 B <5 1 27.00 Up 
 1064 A 0.00 2   
 1064 B <5 2 5.00 No Change 
253 
 
 
 1066 A 0.00 2   
 1066 B 0.00 2 0.00 No Change 
 1067 A 0.00 2   
 1067 B 0.00 2 0.00 No Change 
 1069 A 0.00 2   
 1069 B 0.00 2 0.00 No Change 
 1070 A 0.00 2   
 1070 B 16.44 2 16.44 Up 
 1074 A <5 1   
 1074 B <5 1 0.00 No Change 
 1076 A <5 2   
 1076 B <5 2 0.00 No Change 
 1077 A <5 1   
 1077 B 18.17 1 13.00 Up 
FIP1078 A <5 1   
 1078 B 21.99 1 17.00 Up 
 1082 A 0.00 2   
 1082 B 0.00 2 0.00 No Change 
 1085 A 0.00 2   
 1085 B <5 2 5.00 No Change 
 1091 A <5 1   
 1091 B 9.61 1 4.00 No Change 
 1092 A 0.00 2   
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 1092 B 0.00 2 0.00 No Change 
 1093 A 0.00 1   
 1093 B 5.01 1 5.01 No Change 
 1095 A 0.00 2   
 1095 B <5 2 5.00 No Change 
 1099 A 0.00 2   
 1099 B <5 2 5.00 No Change 
 1100 A 0.00 1   
 1100 B 0.00 1 0.00 No Change 
 1102 A 35.36 2   
 1102 B 40.33 2 4.98 No Change 
 1107 A 0.00 1   
 1107 B 0.00 1 0.00 No Change 
 1108 A 0.00 2   
 1108 B 0.00 2 0.00 No Change 
 1109 A 0.00 1   
 1109 B 0.00 1 0.00 No Change 
 1110 A 0.00 1   
 1110 B 0.00 1 0.00 No Change 
 1112 A 0.00 2   
 1112 B 0.00 2 0.00 No Change 
 1113 A 0.00 1   
 1113 B 0.00 1 0.00 No Change 
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 1114 A 0.00 2   
 1114 B 0.00 2 0.00 No Change 
 1115 A 0.00 2   
 1115 B 0.00 2 0.00 No Change 
 1116 A 0.00 1   
 1116 B 0.00 1 0.00 No Change 
 1119 A 0.00 1   
 1119 B 0.00 1 0.00 No Change 
 1120 A 0.00 1   
 1120 B 0.00 1 0.00 No Change 
 1122 A 0.00 1   
 1122 B 0.00 1 0.00 No Change 
 1123 A 0.00 1   
 1123 B 0.00 1 0.00 No Change 
 1132 A 0.00 1   
 1132 B 0.00 1 0.00 No Change 
 1136 A 0.00 1   
 1136 B 0.00 1 0.00 No Change 
 1138 A 0.00 1   
 1138 B 0.00 1 0.00 No Change 
 1139 A 0.00 1   
 1139 B 0.00 1 0.00 No Change 
 1141 A 0.00 1   
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 1141 B 0.00 1 0.00 No Change 
 1144 A 0.00 2   
 1144 B 0.00 2 0.00 No Change 
 1145 A 0.00 1   
 1145 B 0.00 1 0.00 No Change 
 1151 A 0.00 1   
 1151 B 0.00 1 0.00 No Change 
 1152 A 0.00 1   
 1152 B 0.00 1 0.00 No Change 
 1153 A 0.00 2   
 1153 B 0.00 2 0.00 No Change 
 1154 A 0.00 1   
 1154 B 5.84 1 5.84 No Change 
 1155 A 0.00 1   
 1155 B 0.00 1 0.00 No Change 
 1156 A 0.00 2   
 1156 B 9.34 2 9.34 No Change 
 1157 A <5 1   
 1157 B <5 1 0.00 No Change 
 1160 A 0.00 2   
 1160 B 100.00 2 100.00 Up 
 1161 A 0.00 1   
 1161 B 0.00 1 0.00 No Change 
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 1163 A 0.00 2   
 1163 B 0.00 2 0.00 No Change 
 1166 A <5 2   
 1166 B 0.00 2 -5.00 No Change 
 1168 A 0.00 1   
 1168 B 7.54 1 -4.00 No Change 
 1171 A <5 1   
 1171 B <5 1 0.00 No Change 
 1173 A <5 1   
 1173 B <5 1 0.00 No Change 
 1174 A 0.00 1   
 1174 B 20.73 1 20.73 Up 
 1177 A 0.00 1   
 1177 B 0.00 1 0.00 No Change 
 1180 A 0.00 1   
 1180 B 100.00 1 100.00 Up 
 1183 A 0.00 1   
 1183 B 0.00 1 0.00 No Change 
 1185 A 0.00 2   
 1185 B 0.00 2 0.00 No Change 
 1187 A <5 1   
 1187 B 0.00 1 -5.00 No Change 
 1188 A 0.00 2   
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 1188 B 0.00 2 0.00 No Change 
 1189 A 0.00 1   
 1189 B 0.00 1 0.00 No Change 
 1190 A 0.00 1   
 1190 B 0.00 1 0.00 No Change 
 1192 A 0.00 2   
 1192 B 0.00 2 0.00 No Change 
 1193 A 0.00 1   
 1193 B 0.00 1 0.00 No Change 
 1194 A 0.00 2   
 1194 B 0.00 2 0.00 No Change 
 1195 A 0.00 2   
 1195 B 0.00 2 0.00 No Change 
 1197 A 0.00 2   
 1197 B 0.00 2 0.00 No Change 
 1199 A 0.00 1   
 1199 B 0.00 1 0.00 No Change 
 1200 A 0.00 2   
 1200 B 0.00 2 0.00 No Change 
 1201 A 0.00 2   
 1201 B 0.00 2 0.00 No Change 
 1203 A 0.00 1   
 1203 B 0.00 1 0.00 No Change 
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 1204 A 0.00 2   
 1204 B 0.00 2 0.00 No Change 
 1205 A 0.00 1   
 1205 B 0.00 1 0.00 No Change 
 1206 A 0.00 1   
 1206 B 0.00 1 0.00 No Change 
 1209 A 0.00 1   
 1209 B 0.00 1 0.00 No Change 
 1211 A 0.00 2   
 1211 B 0.00 2 0.00 No Change 
 1212 A 0.00 1   
 1212 B 0.00 1 0.00 No Change 
 1214 A 0.00 2   
 1214 B 0.00 2 0.00 No Change 
 1215 A 0.00 1   
 1215 B <5 1 5.00 No Change 
 1216 A 0.00 2   
 1216 B <5 2 5.00 No Change 
 1217 A 0.00 2   
 1217 B 0.00 2 0.00 No Change 
 1222 A 0.00 1   
 1222 B 0.00 1 0.00 No Change 
 1224 A 0.00 2   
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 1224 B 0.00 2 0.00 No Change 
 1225 A 0.00 2   
 1225 B 0.00 2 0.00 No Change 
 1226 A 0.00 2   
 1226 B 0.00 2 0.00 No Change 
Intervention: Folic Acid Supplementation 1, Placebo, 2. >5 scores based on melting peak data  
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Appendix F:          
Cell culture raw data 
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Appendix F.1: HEK293 5’azacytidine Cytotoxicity Assay Raw Data 
5aC Concentration Abs1  Abs2 Mean Standard Deviation 
0.5 3.5986 3.8035 3.7010 0.1449 
3 2.5505 2.2706 2.4105 0.1979 
6 1.5357 1.4892 1.5124 0.0329 
12 1.3412 1.3326 1.3369 0.0061 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
263 
 
 
Appendix G:            
RT qPCR Raw Data  
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Appendix G.1 GUS RT qPCR data 
Gene Name Cp1 CP2 Average STDEV 
GUS 0uM 25.95 25.99 25.97 0.0283 
GUS 5uM 27.85 28.34 28.10 0.3465 
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Appendix G.2 IP6K1 rt qPCR assay standard Curve 
Standard curve graph generated from the Roche Lightcycler 480 system. Data derived from a 
doubling dilution of cDNA from 1/2 to 1/16. IP6K1 has a PCR efficiency of 1.72. 
 
 
 
Appendix G.3 RASA4 RTqPCR assay standard Curve 
Standard curve graph generated from the Roche Lightcycler 480 system. Data derived from a 
doubling dilution of cDNA from 1/2 to 1/8. RASA4 has a PCR efficiency of 1.79. 
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Appendix G.4 GPS2 RTqPCR assay standard Curve 
Standard curve graph generated from the Roche Lightcycler 480 system. Data derived from a 
doubling dilution of cDNA from 1/2 to 1/8. GPS2 has a PCR efficiency of 1.71. 
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Appendix G.5: IP6K1 RT qPCR data  
 Target Mean Cp Target Error Ref. Mean Cp Ref. Error Target/Ref Error 
A 0µM 5aC  32.92 0.16 30.8 0.21 40.02 5.583 
A 5µM 5ac   32.77 0.16 33.53 0.28 287.8 50.54 
B 0µM 5aC 31.65 0.01 28.95 0.05 21.94 0.6 
B 5µM 5aC 31.08 0.05 32.54 0.12 357.4 26.08 
 
Appendix G.6: RASA4 RT qPCR data 
 Target Mean Cp Target Error Ref. Mean Cp Ref. Error Target/Ref Error 
A 0µM 5aC  33.14 0.21 30.8 0.21 7.833 2.532 
A 5µM 5ac   34.97 0.22 33.53 0.28 17.89 4.591 
B 0µM 5aC 31.76 0.12 28.95 0.05 4.851 0.264 
B 5µM 5aC 33.33 0.04 32.54 0.12 23.31 2.354 
 
Appendix G.7 GPS2 RT qPCR data  
 Target Mean Cp Target Error Ref. Mean Cp Ref. Error Target/Ref Error 
A 0µM 5aC  24.99 0.04 26.1 0.13 30.17 2.345 
A 5µM 5ac   24.12 0.04 28 0.15 187.8 16.37 
B 0µM 5aC 25.18 0.12 27.82 0.08 88.73 6.474 
B 5µM 5aC 24.91 0.01 31.2 0.1 1086 58.64 
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DNA methylation is a biochemical process where a DNA base, usually cytosine, is enzy-
matically methylated at the 5-carbon position. An epigenetic modiﬁcation associated with
gene regulation, DNA methylation is of paramount importance to biological health and
disease. Recently, the quest to unravel the Human Epigenome commenced, calling for a
modernization of previous DNA methylation proﬁling techniques. Here, we describe the
major developments in the methodologies used over the past three decades to exam-
ine the elusive epigenome (or methylome). The earliest techniques were based on the
separation of methylated and unmethylated cytosines via chromatography. The follow-
ing years would see molecular techniques being employed to indirectly examine DNA
methylation levels at both a genome-wide and locus-speciﬁc context, notably immuno-
precipitation via anti-5′methylcytosine and selective digestion with methylation-sensitive
restriction endonucleases.With the advent of sodium bisulﬁte treatment of DNA, a deam-
ination reaction that converts cytosine to uracil only when unmethylated, the epigenetic
modiﬁcation can now be identiﬁed in the same manner as a DNA base-pair change. More
recently, these three techniques have been applied to more technically advanced systems
such as DNA microarrays and next-generation sequencing platforms, bringing us closer to
unveiling a complete human epigenetic proﬁle.
Keywords: DNA, methylation, bisulfite, sequencing, methods
INTRODUCTION
When theHumanGenomeProjectwas completed in 2003,50 years
after the discovery of theDoubleHelix, it was clear that the full pic-
ture had yet to be elucidated (Claverie, 2001; Kruglyak and Nick-
erson, 2001; Lander et al., 2001). The sequence of bases that make
up the human genome alone was not enough to account for what
makes the human populace so diverse. Five years later, giant leaps
in technological advances paved the way for the announcement
of the 1000 Genomes Project, aiming to sequence the genomes of
1000 anonymous individuals to visualize the genomic differences
that make each person unique (Kaiser, 2008; Durbin et al., 2010).
However,mounting evidence from the past fewdecades is pointing
to a new set of variables that contribute to our individuality. The
HumanGenomeProject has already unveiled the genetic hardware
needed to create a person, but the search for the biochemical soft-
ware is still underway. The next major milestone in deﬁning life is
The Epigenome: the sum of heritable chemical and chromosomal
modiﬁcations to genetic material that inﬂuences the development
of complex organisms. We focus on DNA methylation, the incor-
poration of a methyl group in mostly a CpG motif, which was ﬁrst
found to inﬂuence gene expression in 1975 (Holliday and Pugh,
1975; Riggs, 1975).
At the time, it had been accepted that bacteria were capable
of methylating both adenine and cytosine residues while higher
organisms possessed mainly methylated cytosines (Wyatt, 1950;
Doskocil and Sorm, 1962;Meselson et al., 1972; Smith et al., 1973).
The enzyme DNA adenine methylase (Dam) in E. coli speciﬁ-
cally methylates GATC sequences, and DNA cytosine methylase
(Dcm) methylates the duplex sequence CCWGG (W denotes A
or T; Casadesús and Low, 2006). As a defence mechanism, bac-
teria use a plethora of very speciﬁc DNA digesting enzymes to
ward off invading phages. These enzymes cleave DNA based on
a target nucleotide sequence, usually a palindrome motif of sev-
eral bases, so the enzymes have no way of differentiating between
viral and bacterial DNA. A restriction/modiﬁcation mechanism
allows bacterial cells to protect their own DNA from restriction
enzymes by introducing a DNA methylation signature into newly
synthesized strands (reviewed in Bickle and Krüger, 1993). It was
understood that these bacteria carried out methylation in a highly
speciﬁc manner, but the signiﬁcance of cytosine methylation in
eukaryotes was not fully realized until later. Even though there
was no direct evidence of a speciﬁc methylating enzyme, Holli-
day and Pugh (1975) based their early DNA methylation model in
eukaryotes on the mechanisms of bacterial methylating enzymes,
and the fact that methyl groups are distributed about the genome
in a non-random manner. Amongst their concluding remarks,
they suggest “it may be signiﬁcant that the doublet CpG is the
most highly methylated,” oblivious to how important this state-
ment would be in context of the huge strides in the ﬁeld to come
in the following decades. Independently, a similar paper by Arthur
Riggs presented the same hypothesis, this time focusing on the
role of DNA methylation in X-inactivation and in mediating DNA
binding proteins (Riggs, 1975). Both papers brought considerable
attention to the phenomena of DNA methylation, whilst alluding
to a new somatically heritable information system that lay within
the genetic code.
DNA methylation is now considered to be an important mol-
ecular mechanism in a number of biological processes including
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genomic imprinting, X-inactivation, tissue speciﬁc gene expres-
sion, and possibly trans-generational effects (Riggs, 1975; Razin
and Ceder, 1991; Li et al., 1993). However, the methods to ana-
lyze genome-wide DNA methylation patterns is still evolving. We
review the development of DNA methylation methodologies from
the late 1970s to the present day (Figure 1).
EARLY NON-SPECIFIC METHODS
Early non-speciﬁc methods are summarized in Table 1 and
described in more detail below.
HPLC AND TLC METHODS
Ambitious attempts to map the Epigenome started long before the
era of theHumanGenome. In the fallout of theHolliday andRiggs
papers (Holliday and Pugh, 1975; Riggs, 1975), methods for mea-
suring and proﬁling these epigenetic variations were put forward.
The earliest breaches into the epigenetic landscape were based on
the separation of methylated and unmethylated deoxynucleosides.
The most signiﬁcant technique at the time was the separation of
purines and pyrimidines by Vischer and Chargaff (1948) through
paper chromatography. In the context of DNA methylation, Kuo
et al. (1980) established an analytical technique to measure 5-
methylcytosine (5mC) quantitatively using reversed-phase high
performance liquid chromatography (RP-HPLC). This method
is based on the quantitative hydrolysis of DNA using DNase I
and nuclease P1, followed by treatment with alkaline phosphatase.
The individual bases can then be monitored based on their UV
absorbances at 254 and280 nm.TheRP-HPLCmethodwas further
improved throughout the 1980s (Gomes and Chang, 1983; Patel
and Gopinathan, 1987) with incorporation of mass spectrometry
with standard HPLC by Annan et al. (1989). Of course, HPLC
based methods require specialized machinery, so naturally, alter-
native separation techniques came into use. Bestor et al. (1984)
used two restriction endonucleases, Msp1 and Taq1 to discrimi-
nate between methylated and unmethylated-CpG residues in their
restriction sites,CCGG andTCGA respectively. DigestedDNAwas
5′ end-labeled with a 32P isotope and subsequently hydrolyzed to
deoxyribonucleotide monophosphate followed by separation in
two dimensions via thin-layer chromatography (TLC). Quanti-
tative measurement of DNA methylation is based on the relative
intensity between C and 5mC fractions after separation.
The RP-HPLC and TLC methods described above were only
capable of measuring the relative ratio of methylated cytosine
residues against unmethylated cytosines. Although this has been
useful formany applications, such as comparing theDNAmethyla-
tion amongst different animal or plant species (Wagner and Cape-
sius, 1981; Gama-Sosa et al., 1983), fully charting the epigenome
was far out of reach using these methods. More speciﬁc and infor-
mative methods are now in practice to detect 5-methylcytosine,
but today, HPLC and TLC based methods are now best suited
to detecting hydroxymethylcytosine, an epigenetic modiﬁcation
once believed to be only found in bacteriophages, but recently dis-
covered to be abundant in humans and animals (Kriaucionis and
Heintz, 2009; Tahiliani et al., 2009).
RADIOLABELING
Instead of trying to separate and observe individually methy-
lated bases at a high resolution, more indirect approaches have
been devised. It is possible to enzymatically incorporate tritium
labeled methyl groups from S-adenosylmethionine to unmethy-
lated cytosines. Assays have been developed using bacterial SssI
methyltransferase to incorporate radiolabeled methyl groups into
CpG sites. The level of radioactivity measured is inversely propor-
tional to the level of DNA methylation of a sample (Wu et al., 1993;
Duthie et al., 2000).
ANTI-METHYLCYTOSINE
Other alternative methods include the wide range of immunolog-
ical DNA methylation assays that suddenly appeared after it was
FIGURE 1 |Timeline of DNA methylation analysis.The techniques for DNA
methylation analysis have developed from the ability to simply measure the
amount of 5-methylcytosine within a particular genome in the early 1980s to a
variety of basic comparative methods involving methylation-sensitive
restriction enzymes, immunoprecipitation or bisulﬁte sequencing usually in
combination with PCR up to the late 1990s. The introduction of microarray
technology and next-generation sequencing saw the adaption of these earlier
methods to these newer platforms during the 2000s. More details on
microarray/beadchip technologies and next-generation sequencing are
described inTables 1 and 2. RP-HPLC, reversed-phase high performance liquid
chromatography; 5mC, 5-methylcytosine; MS-SnuPe, methylation-sensitive
single nucleotide primer extension; COBRA, combined bisulﬁte restriction
analysis; AP-PCR, arbitrarily primed PCR; AIMS, ampliﬁcation of
inter-methylated sites; RRBS, reduced representation bisulﬁte sequencing.
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Table 1 | Summary of early non-specific methods.
Method Author
Restriction endonuclease digestion, isotope
incorporation, andTLC
Bestor et al. (1984)
Polyclonal leporine antibody, radiolabeled DNA Adouard et al. (1985)
RP-HPLC Kuo et al. (1980)
HPLC, mass spectrometry Annan et al. (1989)
SssI methyltransferase tritium labeling Wu et al. (1993)
Monoclonal, isothiocyanate labeled ﬂuorescent
anti-5mC
Oakeley et al. (1997)
TLC, thin-layer chromatography; RP-HPLC, reverse phase high performance liquid
chromatography; Anti-5mC, anti-5-methylcytosine.
ﬁrst found that methylcytosine was accessible to speciﬁc antibod-
ies in 1985 (Adouard et al., 1985). This vital development paved the
way for the possibility to chart the DNA methylation landscape on
a cell to cell basis. TheAdouardpaper introduces the quantiﬁcation
of radiolabeled DNA retained by leporine polyclonal antibodies,
visualized under electron microscopy. Later, confocal ﬂuorescence
microscopy was used to detect global changes in methylation
patterns. Using anti-5mC monoclonal antibodies and secondary
antibodies labeled with ﬂuorescent isothiocyanate, Oakeley et al.
(1997) devised an efﬁcient method to study global changes in
DNA methylation during tobacco pollen maturation. The use of
anti-5mC has been widely applied since its introduction but most
notably in the investigation of DNA methylation changes during
embryonic development. The mammalian genome undergoes a
mass loss of DNA methylation, followed by remethylation during
early embryonic development.Although this was established using
methylation-sensitive restriction enzymes (Monk et al., 1987) a
more precise proﬁle was obtained with anti-5mC antibody in
conjunction with confocal imaging (Santos et al., 2002). They
found that the paternal genomeundergoes selective demethylation
immediately after spermdecondensation,and is complete after 90–
120min. The de novo methylases DNMT3a and DNMT3b restore
DNA methylation later in development, which is maintained by
DNMT1 throughout life (Bestor, 2000).
Out of the methods discussed so far, the immunological
approach has seen the most signiﬁcant improvements and novel
applications over the past decade alone, due to advances in
microarray technology. Thesewill be discussed inmore detail later.
EARLY DIFFERENTIAL GENE METHYLATION ANALYSIS
Early differential gene methylation methods are summarized in
Table 2 and described in more detail below.
METHYLATION-SENSITIVE RESTRICTION ENZYMES
Restriction enzymes cleave DNA through recognition of speciﬁc
nucleotidemotifs.Amongst the variety of different types of restric-
tion enzymes that exist, only some are sensitive to DNA methyla-
tion. Given the considerable amount of redundancy amongst the
many different palindromemotifs targeted by restriction enzymes,
many pairs of restriction enzymes exist that both cut at the same
nucleotide sequence but with differing sensitivity to DNA methy-
lation signatures. Isoschizomer pairs like this can be used to
Table 2 | Summary of early differential gene methylation analysis.
Method Author
Isoschizomer digestion
and isotope incorporation
Cedar et al. (1979)
HpaII PCR Singer-Sam et al. (1990)
Methylation-speciﬁc RLGS Kawai et al. (1993), Hayashizaki et al. (1993)
AP-PCR Liang et al. (2002)
AIMS Frigola et al. (2002)
RLGS, restriction landmark genome scanning; AP-PCR, arbitrarily primed poly-
merase chain reaction; AIMS, ampliﬁcation of inter-methylated sites.
discriminate between methylated and unmethylated regions of the
genome in a laboratory setting (Bird and Southern, 1978) and ini-
tially exempliﬁed in 1979withHpaII andMspI (Cedar et al., 1979).
Both recognize and cut at the same sequence, CCGG, but methy-
lation of the second C in this motif prevents digestion by HpaII.
Detectionof digestedDNA fragmentswas initially by radiolabeling
and two dimensional TLC. Later Southern blotting was employed
(Southern, 1975) for visualization followed by the introduction of
methylation-sensitive PCR-based methods in 1990 (Singer-Sam
et al., 1990). However, efﬁciency of the restriction enzymes was a
likely issue for these techniques.
DIFFERENTIAL GENOME-WIDE SCANNING
Restriction landmark genomic scanning (RLGS) is a genomic
scanning method that takes advantage of the speciﬁcity of restric-
tion endonucleases and allows a low resolution comparison of
genome-wide differences between individuals (Hatada et al.,
1991). Radiolabeled DNA is digested with two restriction enzymes
and separated in two dimensions. This produces an autoradi-
ograph proﬁle of thousands of spots spread through the gel, each
spot representing a restriction site. This method was adapted for
DNA methylation analysis (RLGS-M) by employing methylation-
sensitive restriction enzymes (Hayashizaki et al., 1993; Kawai et al.,
1993) to differentiatemethylation differences between individuals.
Later, simpler and less expensive genome-wide screening strate-
gies came into use. Using a single primer and two low-stringency
annealing steps, Liang et al. (2002) found that methylation pro-
ﬁles couldbeobtainedbydigestingDNAwithmethylation-speciﬁc
endonucleases followed by a PCR reaction with random primers.
This process is known as arbitrarily primed PCR (AP-PCR), and
is based on a method developed by Welsh and McClelland (1990)
initially used to identify bacterial species. AP-PCR was adapted
in order to scour tumor genomes for new differential methyla-
tion sites (Gonzalgo et al., 1997; Liang et al., 2002). Ampliﬁcation
of inter-methylated sites (AIMS) is a similar but more effec-
tive PCR-based approach.Methylation-sensitive isoschizomers are
employed that cleave DNA leaving a blunt end or an overhang.
These properties are exploited by the addition of linkers that only
ligate to the methylated sites with subsequent PCR ampliﬁcation.
Fingerprints composed of multiple anonymous bands represent
methylated regions of the genome are generated and can be excised
out and characterized individually (Frigola et al., 2002).
It should be noted that the methods discussed so far are lim-
ited in the context of other genetic techniques at the time. This is
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because in vitro ampliﬁcation of methylated DNA strands via PCR
causes the target strand to lose itsmethylation status. Themethods
so far have aimed to detect 5-methylcytosine as it manifests natu-
rally. On a genome-wide or gene-speciﬁc scale, these approaches
are limited. In order to advance to the stage of possibly sequencing
the epigenome, a new approach was needed.
THE SODIUM BISULFITE ERA
In 1970, a chemical interaction between sodium bisulﬁte and
pyrimidines was described that would have a colossal impact on
how DNA methylation is studied (Hayatsu et al., 1970). It was
found that uracil, thymidine, and deoxycytidine were subjected
to sulfonation at position six of their pyrimidine rings. Ten years
later, this model was extended to 5-methylcytosine although the
reaction takes place at a slower rate than cytosine (Wang et al.,
1980). Frommer et al. (1992) described in a classic paper that
the differing reaction rates of 5mC to C could be exploited to
analyze DNA methylation patterns in genomic DNA. Treating
DNA with sodium bisulﬁte, they proposed, will deaminate cyto-
sine residues into uracil at a much faster rate than 5mC. This
phenomenon made it possible to change a chemical modiﬁca-
tion of DNA to an easily detected genetic element. At the time,
Maxim and Gilbert sequencing was used to pinpoint the changes,
but the methods put forward by Frommer and colleagues would
be revised and reﬁned as technological advances in the subse-
quent years would pave the way for large scale, next-generation
sequencing.
The Frommer et al. (1992) paper marked somewhat of a rev-
olution in the ﬁeld. Now the elusive biochemical software could
be converted to more tangible genetic hardware. Although it was
initially described how bisulﬁte modiﬁcation could be used to
augment sequencing-based methods, the concept itself would be
used to formulate entirely new methods to probe the genome for
DNA methylation in the following years. These methods are based
on the treatment of DNA with bisulﬁte such that unmethylated
cytosines are converted to uracil and methylated cytosines remain
as cytosines. The approaches to detect these conversions are vari-
ous and are summarized in Table 3 and described in more detail
below.
Table 3 | Summary of methods using sodium bisulfite treatment.
Method Author
Ligation-mediated PCR Pfeifer et al. (1989)
Bisulﬁte sequencing Frommer et al. (1992)
MS-PCR Herman et al. (1996)
MS-SNuPE Gonzalgo and Jones (1997)
MS-SSCA Bianco et al. (1999)
MS-HRM Wojdacz and Dobrovic (2007)
Bisulﬁte treatment to create
new restriction sites
Sadri and Hornsby (1996)
MS-PCR, methylation-speciﬁc polymerase chain reaction; MS-SNuPE,
methylation-speciﬁc single nucleotide primer extension; MS-SSCA, methylation-
speciﬁc single-strand conformation analysis; MS-HRM, methylation-speciﬁc high
resolution melting.
GENE-SPECIFIC APPROACHES
Methylation-speciﬁc PCR (MS-PCR) was one of the ﬁrst innova-
tive methods to incorporate bisulﬁte conversion outside the con-
text of sequencing (Herman et al., 1996). Primers were designed
to discriminate between methylated and unmethylated regions of
DNA after bisulﬁte treatment, so primer sites that were origi-
nally methylated would undergo ampliﬁcation only. The nature
of this rapid assay eliminated the frequent false positives associ-
ated with previous PCR-based endonuclease methods; however
PCR bias was an issue. Technical advances in genomics and mole-
cular biology in more recent years have allowed MS-PCR take on a
new form.
Many of the new techniques introduced during the Sodium
Bisulﬁte Era followed a similar strategy; using well established
genetic techniques to detect DNA methylation since the elusive
epigenetic modiﬁcation could be converted into the more tangible
nucleotide variant. Methylation-sensitive single nucleotide primer
extension (MS-SNuPE) is based on a conventional genotyping
technique, single nucleotide primer extension (Kuppuswamy et al.,
1991). MS-SNuPE (Gonzalgo and Jones, 1997) uses a PCR step
after bisulﬁte conversion to amplify a desired fragment. Once the
product is isolated, primers speciﬁc for the ampliﬁed fragments
are used in another PCR stage, this time incorporating 32P dNTPs
which can be used to quantify the nucleotides that have been con-
verted during bisulﬁte treatment, therefore quantifying the level
of DNA methylation in the initial genomic DNA.
Basedonanotherwell-knownPCRmethod for resolving single-
base restriction fragment length polymorphisms (Poduslo et al.,
1991), methylation-sensitive single-strand conformation analysis
(MS-SSCA) is a method to screen and analyze DNA methylation
in a gene-speciﬁc manner (Bianco et al., 1999). Genomic DNA is
bisulﬁte treated and the gene of interest is ampliﬁed with PCR,
and then cut with frequently cutting restriction enzymes. The
digestion patterns of samples are compared to a methylation stan-
dard and variations in pattern imply changes in DNA methylation.
Methylationdifferences are characterizedusing a gel stabbing tech-
nique and sequencing (Wilton et al., 1997). This method has been
expanded by Suzuki et al. (2000) to include high performance
capillary electrophoresis (HPCE).
High resolution melting (HRM) was originally used to geno-
type Single Nucleotide Polymorphisms (Wittwer et al., 2003)
but was adopted to detect DNA methylation changes in bisulﬁte
treated DNA (Wojdacz and Dobrovic, 2007). Single base differ-
ences can be detected by their distinct melting proﬁles utilizing
speciﬁc ﬂuorescent dyes. The difference between 5-methylcytosine
and cytosine,manifests as a single base change after DNA is treated
with sodium bisulﬁte. With careful primer design to eliminate
PCR bias, it is possible to estimate the methylation levels of a test
sample by comparison of its melting curve with that of a series
of controls of known methylated and unmethylated percentages
(Wojdacz et al., 2008).
The“bisulﬁte revolution”was not limited to the importation of
early genetic techniques to the ﬁeld of DNA methylation;methyla-
tion analysis mentioned earlier in this review would also receive a
renewal. The endonuclease-based protocols used up until the mid
1990s were limited to the detection of a negative result: the absence
of a band indicates a methylated site. This was ﬁrst improved by
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Sadri andHornsby (1996),whereDNAwas ﬁrst treatedwith bisul-
ﬁte according to a revised versionof the 1992bisulﬁte reaction (Feil
et al., 1994), then exposed to two rounds of endonuclease digestion
including a newly created restriction site following bisulﬁte treat-
ment. This innovation was expanded by Xiong and Liard (1997)
to determine the methylation status of individual loci. Combined
bisulﬁte restriction analysis (COBRA), is based on the creation
of new methylation dependant restriction sites, or the retention
of pre-existing ones, by bisulﬁte conversion followed by PCR.
With phosphorimaging, the relative ratio of digested products can
be determined. Although it is a powerful technique, COBRA is
limited to the restriction sites of the enzymes used. Laird et al.
(2004) devised a technique known as “hairpin-bisulﬁte PCR” to
investigate DNA methylation symmetry at a speciﬁc locus. With
bisulﬁte treatment, the required denaturation steps make it dif-
ﬁcult to analyze the methylation pattern of two complementary
DNA strands from one molecule. By ligating a hairpin linker to
restriction-enzyme cleaved DNA, the team were able to establish a
covalent bond between complementary strands of the DNA mol-
ecule, which would allow a PCR product to span the linker and
cover both strands.
REGIONAL METHYLATION LEVELS
Another method already mentioned here that has received a
sodium bisulﬁte facelift is the SssI methyltransferase assay. In
its new incarnation, the enzymatic regional methylation assay
(ERMA), genomic DNA is treated with sodium bisulﬁte prior
to ampliﬁcation of a particular region of interest with non-
discriminating primers containing ﬂanking GATC sites. These
tetranucleotide sequences are required to standardize DNA quan-
tity in this assay, as they are dam sites that accept methyl groups
from dam methyltransferase. To quantify DNAmethylation,E. coli
cytosine methyltransferase SssI was used to speciﬁcally methy-
late the cytosine in all of the CpG dinucleotides that remained
after sodium bisulﬁte treatment, using 3H-labeled S-adenosyl-l-
methionine (SAM) as a methyl donor. For the aforementioned
standardization step, 14C-labeled SAM was incubated along with
dam methyltransferase so the total number of amplicons could be
visualized (Galm et al., 2002).
In 2001, the working draft of the Human Genome was pub-
lished in special issues of Nature and Science (Pennisi, 2001). Later
that year, Human chromosome 20 was fully sequenced, the third
chromosome to be completed in theHumanGenomeProject. This
year was also an important year for DNA methylation and epige-
netics too, because it was here that a new phrase entered the vocab-
ulary of the scientiﬁc community: The Methylome (Feinberg,
2001).
The post-genome era
By the beginning of the twenty-ﬁrst century, a great deal of the
epigenetic landscape had been explored. While the role and mech-
anism of gene regulation via DNA methylation was well under-
stood, the gene-speciﬁc methods described above helped bring
these ideas to the context of complex diseases states, especially
tumorigenesis (Jones and Laird, 1999). However, very little was
known about the genome-wide distribution of 5-methylcytosine
until robust array precipitation methods were devised.
COMPARATIVE METHYLATION PROFILING USING
MICROARRAY TECHNOLOGY
Throughout the 1990s, the development of DNA microarray tech-
nology was responsible for a revolution in functional genomics,
paving the way for high-throughput analysis of single nucleotide
polymorphisms and other genomic variants (Southern et al.,
1999). With the help of these novel tools, the three traditional
lines of attack on the DNA methylation landscape; immunopre-
cipitation,endonuclease digestion,and sodiumbisulﬁte treatment,
would each receive a post-genome era transformation (Figure 2).
These three DNA methylation differentiation and isolation meth-
ods have been the principal approaches used to compare the DNA
methylation patterns between samples over the last decade. In
the microarray assays discussed here, the underlying principle is
the same in each: methylated and unmethylated fragments of the
genome are separated and analyzed. Hybridization to a microar-
ray of known probes allows for quantiﬁcation and identiﬁcation
of areas of the genome that are methylated or unmethylated. All
of the microarray-based techniques discussed here are listed in
Table 4 and are based on one of the three approaches described
below and in Figure 2.
ENDONUCLEASE DIGESTION
Differential methylation hybridization (DMH) was the ﬁrst array-
based method for genome-wide screening of hypermethylated-
CpG islands in tumor cells (Huang et al., 1999). This early
array was only able to asses about 300 CpG islands at a time,
and suffered from major sequence bias. Genomic DNA was ﬁrst
sheared with a methylation insensitive restriction enzyme, MseI.
FIGURE 2 |The three main current approaches for DNA methylation
analysis of genomes.The analyses of DNA methylation patterns across a
genome at varying degrees of resolution involves three main approaches. In
Step 1 methylated and unmethylated cytosines need to be distinguished.
This can be achieved by using methods A, B, or C. (A) Immunoprecipitation
with an antibody against 5mC (Anti-5mC)/methyl-binding protein or
precipitation with speciﬁc methyl-binding proteins. (B) Digestion of DNA
with methyl-sensitive restriction enzymes (RE) that cleave methylated and
unmethylated cytosines differently. (C) Bisulﬁte treatment of DNA will
convert unmethylated cytosines to uracil, which are “read” asTs when PCR
ampliﬁed and sequenced. Methylated cytosines remain as cytosines when
sequenced. The 5mC sites can then be identiﬁed in Step 2 by either using a
microarray or beadchip platform or by next-generation sequencing.
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Table 4 | Applications of microarray technology to differential DNA
methylation analyses.
Method Array type Citation
Methyl-sensitive restriction
enzymes
CGI1 library Huang et al. (1999)
Anti-methylcytosine
immunoprecipitation3
SMRT2 Weber et al. (2005)
Anti-methylcytosine
immunoprecipitation
Promoter array Keshet et al. (2006)
Methyl-binding protein
precipitation4
CGI library Gebhard et al. (2006)
Methyl-binding protein
precipitation
CGI library Rauch et al. (2006)
Sodium bisulﬁte treatment Oligonucleotide Gitan et al. (2002)
Sodium bisulﬁte treatment Oligonucleotide Adorjan et al. (2002)
Sodium bisulﬁte treatment Oligonucleotide5 Reinders et al. (2008)
Sodium bisulﬁte treatment Illumina beadchip Sandoval et al. (2011)
1CGI, CpG island microarray.
2SMRT, submegabase resolution tiling array.
3MeDIP, methylated DNA immunoprecipitation.
4MeCIP, methyl-CpG immunoprecipitation.
5Whole genome oligonucleotide array.
Having a restriction recognition site at TTAA, MseI was unlikely
to interfere with any CpG islands. After the ligation of linkers
to the end of each DNA fragment, half of the pool was treated
with methylation-sensitive BstUI. As a result, the methylated
fragments, and those only treated with MseI remained intact,
and only these could be ampliﬁed via PCR, with primers spe-
ciﬁc to the linkers. These amplicons were differentially labeled
and co-hybridized to a CpG island array. As for any array-based
method, the analysis is limited to the number of genomic ele-
ments represented on the array. The array, used to determine the
methylation status of CpG islands in breast cancer cells, was con-
structed from a physical library of CpG islands generated from
a novel column separation strategy (Cross et al., 1994). Shortly
after it was introduced, DMH was used to detect speciﬁc methy-
lation proﬁles in breast and ovarian cancer cells (Yan et al., 2000;
Ahluwalia et al., 2001). Following on from this, the same group
improved on this method further (Yan et al., 2001; Chen et al.,
2003).
In 2005, the Promoter-associated methylated DNA ampliﬁca-
tion DNA chip was introduced. Contrary to the use of a second
wave of restriction enzymes, the restriction endonuclease McrBC
has been used to fractionate methylated regions of DNA. In a
protocol pioneered by Nouzova et al. (2004), DNA is treated with
MseI, and the fragments are ligated to linkers, in concurrence to the
previous methods. However, the fragments are then divided into
two pools: one to be treated with McrBC, while the other is not.
Unlike the other restriction enzymes discussed so far, McrBC only
cuts at methylated sequences. After PCR, both pools are differen-
tially labeled with Cy3 and Cy5 ﬂuorescent dyes and co-hybridized
to a CpG island array. In the Methylscope platform (Ordway et al.,
2006), DNA fragments are prepared in a similar way, but the DNA
is randomly sheared in the ﬁrst step.
Comprehensive high-throughput arrays for relative methyla-
tion (CHARM) is another platform for array-based methyla-
tion analysis (Irizarry et al., 2008). The workﬂow is based on
some of the methods already mentioned in this section, and
works to eliminate the disadvantages of each. CHARM was con-
ceived while Irizarry and colleagues were comparing three already
established methods for analyzing DNA methylation: methylated
DNA immunoprecipitation (MeDIP), HELP, and fractionation by
McrBC. The HELP assay (HpaII tiny fragment enrichment by
ligation-mediated PCR) is based again on the use of two sets of
restriction enzymes, but the fragments are ampliﬁed via ligation-
mediated PCR and hybridized to a custom microarray along with
separate ﬂuorochromes (Khulan et al., 2006). In the 2008 paper,
Irizarry points out signiﬁcant ﬂaws with each of the array-based
methods in use. MeDIP (also discussed below), was shown to have
a signiﬁcant bias to CpG islands, HELP had incomplete genomic
coverage andMcrBC fractionation displayed location imprecision.
After the rigorous comparison of these methods, the second half
of the paper discusses how a new platform of original array design
strategies and statistical procedures involving genome-weighted
averages from larger genomic areaswas capable of countering these
limitations (Irizarry et al., 2008).
IMMUNOPRECIPITATION
Differentiation between methylated DNA and non-methylated
DNA using anti-methyl antibodies has been discussed already.
However,with the requirement to enrichmethylatedDNAprior to
microarray hybridization, immunological separation techniques
became relevant again.
In 2005, MeDIP was used to immunocapture methylated
cytosines with an antibody speciﬁc for methylated cytosines for
array hybridization (Weber et al., 2005). Prior to immunoprecipi-
tation, genomic DNA was randomly fragmented via sonication or
enzyme restriction. Immunocaptured DNA and control genomic
DNA were both labeled with Cy5 and Cy3 ﬂuorescent dyes, pro-
ducing a ratio of green ﬂuorescence to red ﬂuorescence which
would be indicative of the relative levels of hypermethylation or
hypomethylation. In the 2005 paper, Weber and colleagues used a
submegabase resolution tiling (SMRT) array consisting of 32,433
overlapping BAC clones spanning the entire genome (Ishkanian
et al., 2004;Weber et al., 2005). Independently, Keshet et al. (2006)
devised a similar array-based approach: methyl-DNA immuno-
precipitation (MDIP). They found that tumor speciﬁc methylated
genes are found in clusters on chromosomes, and shared many
structural and functional features. This reinforced the hypothesis
that tumorigenesis arises as a result of de novo mechanisms. One
of the major drawbacks of MDIP and MeDIP is their inability to
pinpointDNAmethylation changes at a single base-pair resolution
(Beck and Rakyan, 2008). However, some argue that since neigh-
boring CpG islands spanning up to 1000 bp are co-methylated in
healthy cells, there is no need for methylation analyses with sin-
gle base-pair resolutions (Eckhardt et al., 2006). In 2006 MDIP
was responsible for producing the ﬁrst complete Methylome: Ara-
bidopsis thaliana (Zhang et al., 2006). Although much smaller
than the mammalian genome, the map of the plant’s methylome
represents an important milestone in epigenetics, while the data
produced was of interest in itself. It was found that one third
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of expressed genes contained DNA methylation in their tran-
scribed regions, and these regions were still highly expressed and
constitutionally active.
Methyl-CpG immunoprecipitation (MeCIP) is another
immunoprecipitation assay similar to MeDIP in terms of the
techniques used and its applications, but a recombinant pro-
tein complex with similar properties to an anti-methylcytosine
antibody is used (Gebhard et al., 2006). Epigenetic gene silenc-
ing via DNA methylation is caused by steric hindrance, resulting
from methylated DNA recruiting methyl-binding domain pro-
teins (MBDs; Thu et al., 2010). In the 2006 paper, Gebhard and
colleagues introduce a recombinant protein made up of MBD2
combined with the Fc tail of a human Ig1 with very high afﬁnity to
single-stranded methylated DNA, stronger than that of the MeDIP
and MDIP methods. Also, it is possible to separate DNA fragments
into fractions of increasing methylation density by eluting with a
salt gradient (Schilling and Rehli, 2007). This approach allows for
the quantiﬁcation of tissue speciﬁc methylation differences for a
wide range of DNA methylation densities.
Another protein complex, MBD3LI bound to MBD2, has also
been shown to have a high afﬁnity to methylated DNA (Rauch
and Pfeifer, 2005). Methylated-CpG island recovery assay (MIRA)
separates fragmented DNA by incubation with a matrix contain-
ing glutathione-S-transferase-MBD2b in the presence of methyl-
CpG-binding domain protein 3-like-1,which increases the afﬁnity
of MBD2b when paired. CpG island methylation can be detected
using PCR or array-based methods (Rauch et al., 2006, 2009).
BISULFITE TREATMENT
In 2002, the principles of DHM were expanded to the use of novel
methylation-speciﬁc oligonucleotide arrays (Adorjan et al., 2002;
Gitan et al., 2002). This time, DNA was prepared for hybridiza-
tion by bisulﬁte modiﬁcation and PCR ampliﬁcation to convert
unmethylated cytosines to thymidine, allowing the epigenetic
modiﬁcation to be detected via traditional hybridizationmethods.
This approach has the potential to detect methylated-CpG islands
at a single-base resolution, but the global conversion of cytosines
to thymidines results in a reduction in sequence complexity, mak-
ing it difﬁcult to design enough unique probes to scale up to a
genome-wide level (Beck and Rakyan, 2008). Although it is possi-
ble to design probes taken from ampliﬁed bisulﬁte treated DNA,
novel approaches have been devised. For small, methylation-rich
genomes, a method called bisulﬁte methylation proﬁling (BiMP)
can be employed (Reinders et al., 2008). The entire genome of
A. thaliana was ampliﬁed using a technique utilizing random
tetranucleotides primers reducing the ampliﬁcation bias usually
associated with bisulﬁte treated DNA. The BiMP data from the
paper was compared to theMDIP results cited earlier (Zhang et al.,
2006). Data from both studies were in concordance, although the
former exhibited proﬁles of considerably higher resolution than
the latter (Reinders et al., 2008). As a result, BiMP is more likely to
pick up speciﬁc, localized changes in DNA methylation patterns
that could prove elusive to detection via MDIP.
The Illumina Beadchip technology, while technically differ-
ent from the types of arrays discussed above, do fall under the
microarray category. Illumina Inﬁnium has been applied to the
DNA methylation analysis. Fryer et al. (2011) examined DNA
methylation patterns at 27,578 CpG sites using the Inﬁnium
HumanMethylation27K in cord blood samples and correlated to
homocysteine levels and birth weight. More recently, Illumina
have launched the Inﬁnium HumanMethylation450Karray which
allows the analysis of >450,000 DNA methylation sites (Sandoval
et al., 2011) with up to 12 samples at a time. This is by far the
most high-throughput comprehensive method available for whole
genome DNA methylation analysis outside of the next-generation
sequencing methods described below.
The use of microarrays for DNA methylation analysis proves
to be a versatile strategy for probing the methylome. Before
hybridization,methylatedDNAcanbepuriﬁedby anumber of dif-
ferent strategies, each with their own unique merits. The strengths
and weaknesses of most of these methods have been systemat-
ically evaluated in Laird (2010). DNA methylation microarrays
provide cheap and accessible genome-wide insights to the DNA
methylation status of a sample, or even a large number of samples.
However, as with the Human Genome Project, there needs to be a
trend toward a gold standard: a perfect assay. Although none exists
at time of writing, only sequencing-based assays have the potential
to provide such a detailed look at the enigmatic methylome, i.e.,
at single-base resolution.
SEQUENCING-BASED APPROACHES
SANGER SEQUENCING
Although the bisulﬁte reaction itself has been adapted and applied
to the conventional genetic techniques aforementioned, the tech-
nology has taken a novel routewhile genome sequencing platforms
have improved as the Human Genome Project progressed over the
subsequent years. At themoment, it is possible to directly sequence
the humangenomewith sophisticated technology; technology that
is starting to be applied to the ﬁeld of DNA methylation. First, it is
worth revisiting how sequencing-basedDNAmethylation analyses
have evolved over the past two decades.
The original bisulﬁte sequencing protocol from Frommer et al.
(1992) suffers from several difﬁculties. For example, relatively large
quantities of genomicDNAare needed for a full proﬁle, limiting its
proﬁciencies in a genome-wide perspective. In 1994, the same lab
(Clark et al., 1994), integrated a PCR ampliﬁcation step to increase
the assay’s sensitivity by 104 fold. The old protocol also required
DNA to be denatured in order to expose the individual bases
to bisulﬁte treatment. Some workarounds have been devised to
counter this, but according to a review by Oakeley (1999), the best
approach at the timewas to denatureDNA in solutionwithNaOH,
then mix with molten agarose. Cooling the agarose locks the DNA
in the denatured conformation, allowing subsequent reactions to
be performed on the agarose block (Olek et al., 1996).
In the pilot study of the Human Epigenome Project, Rakyan
et al. (2004) aimed to proﬁle the DNA methylation patterns of
the human major histocompatibility complex (MHC) located on
chromosome six. This region of the genome was selected as it is
associatedwithmore diseases than any other region of the genome,
and also it’s the most polymorphic area of the genome, so com-
plete sequencing and annotation from the Human Genome was
readily available for the study. This sequencing method was inno-
vative as it did not require a sub-cloning step, but utilized a novel
high-throughput method of direct sequencing of PCR products.
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An algorithm described by Lewin et al. (2004) allows for quantita-
tive analysis of DNA methylation from four-dye electropherogram
data obtained from direct sequencing. Although such data was
previously used in the human genome project and for analyzing
single-base SNPs (Qiu et al., 2003), earlier applications of bisul-
ﬁte treated PCR were impeded by unique technical difﬁculties.
The new software, called epigenetic sequencingmethylation analy-
sis software (ESME), corrects for incomplete bisulﬁte conversion,
performs quality control tests on data, andmapsmethylation posi-
tions to the reference sequence. This approach was also used in a
related paper reporting the DNA methylation proﬁles of human
chromosomes 6, 20, and 22 (Eckhardt et al., 2006).
Reduced representation bisulﬁte sequencing (RRBS) is a ran-
domsequencing-basedmethod for analyzing and comparingDNA
methylation patterns on a genome scale (Meissner et al., 2005).
Size selected BglII fragments of a whole genome were ﬁxed with
ligation linkers and denatured. Bisulﬁte treatment of these frag-
ments yielded single-stranded DNA, as complementarity between
both strands was lost when methylated cytosines were converted
to uracil residues. Converted fragments were ampliﬁed via PCR
and cloned into plasmid vectors for sequencing. Comparison of
the bisulﬁte treated DNA sequence to a reference sequence allows
the operator to pinpoint which cytosines have been methylated,
as those are the only ones to remain cytosines at this stage.
Thymidines that align to cytosines during this comparison stage
represent cytosines that were once unmethylated. RRBS has the
obvious advantage over PCR-based bisulﬁte sequencing methods
in generating a reproducible library of a small, deﬁned area of a
genome. This makes RRBS suitable for comparative methylation
studies across different tissue or cell types.
NEXT-GENERATION SEQUENCING
Up until 2005, most whole genome DNA sequencing strate-
gies were based on the cloning of fragments into bacterial vec-
tors, followed by ampliﬁcation and Sanger sequencing via chain
terminating ﬂuorescent signaling, visualized with capillary elec-
trophoresis (Prober et al., 1987). In recent years, however, a new
parallel sequencing method was developed that did not require a
sub-cloning step. It involves a previously established method for
genotyping known as pyrosequencing, which incidentally has also
been applied to the analysis of gene-speciﬁc/local DNA methy-
lation patterns (Tost and Gut, 2007). The emulsion based PCR
method, described by Margulies et al. (2005), utilizes a pyrose-
quencing protocol optimized for picoliter-scale volumes in the
high density picoliter “reactors” formed by the emulsion droplets.
In 2007, this massively parallel sequencing system (commercial-
ized as Roche 454 FLX) was employed for bisulﬁte sequencing
(Taylor et al., 2007). The pilot study showed robustness and superi-
ority of this approach by analyzing methylation in 25 gene-related
CpG rich regions from over 40 primary cell lines. During the
process, speciﬁc four-nucleotide tags were added to the 5′end
of each primer, so each amplicon could be individually indexed,
pooled, and manipulated (Taylor et al., 2007).
Further advances in next-generation sequencing including the
Illumina/Solexa Genome Analyzer and the Applied Biosystems
SOLiD™ System (reviewed in Mardis, 2008) has meant that going
forward, most genome-wide DNA methylation protocols will
Table 5 | Approaches for DNA methylation analyses by
next-generation sequencing.
Method Genome coverage Citation
Bisulﬁte
sequencing
Whole genome Cokus et al. (2008)
MeDIP-seq1
anti-5mC
Enriched Methylated DNA Maunakea et al. (2010)
MBDiGS2 Enriched Methylated DNA Serre et al. (2009)
MRE-seq3 Size selected fraction Maunakea et al. (2010)
MMSDK4 Representative genome tags Li et al. (2009)
1Sequencing of immunoprecipitated anti-5mC DNA.
2Methyl-binding protein precipitated sequencing.
3Methyl-sensitive restriction enzyme sequencing.
4Modiﬁed methylation-speciﬁc digital karyotyping.
feature some form of next-generation sequencing. The current
gold standard is to carry out whole genome bisulﬁte sequenc-
ing of target samples where a reference genome is available.
However, the costs for such an approach are still not triv-
ial and adaptations of methods to produce a representation of
genome-wide DNA methylation have been developed. Table 5
describes some of the current options for DNA methylation
analysis in combination with next-generation sequencing and are
described below. It is worth noting that similarly to microar-
ray analysis, for next-generation sequencing, the three principle
approaches still employ sodium bisulﬁte treatment, immuno-
precipitation, and the utilization of methyl-sensitive restriction
enzymes (Figure 2).
WHOLE GENOME SEQUENCING-BISULFITE TREATMENT
An entire DNA methylome can be assessed at a single nucleotide
resolution with sodium bisulﬁte treatment followed by whole
genome sequencing. This approach has been taken to generate a
DNA methylation map of A. thaliana (Cokus et al., 2008). Unlike
previous genome-wide approaches, this allowed for the sensitive
measurement of cytosine-methylation across the genome with
sequence speciﬁc contexts. When compared to array-based meth-
ods, the authors reported the discovery of new methylation sites
in previously inaccessible areas of the genome. A whole genome
approach was also recently applied to mammalian cells. The ﬁrst
humanDNAMethylome in embryonic and fetal cells at single-base
resolution was recently published (Lister et al., 2009), identify-
ing a signiﬁcant proportion of non-CG methylation. Additional
single-base resolution human methylomes continue to be pub-
lished (Maunakea et al., 2010) highlighting the importance of
intragenic DNA methylation in the regulation of gene expression.
Thus, the elusive Human DNA Methylome is more complex than
previously thought.
The whole genome approach is the most desirable with unlim-
ited resources, but realistically for a lot of laboratories this is not an
approach that can be taken for the analysis of numerous samples.
A more cost effective approach is to reduce the complexity of the
genome in order to reduce the amount of sequencing required per
sample. The methods described below are some examples of how
this can be done.
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METHYLATED DNA IMMUNOPRECIPITATION SEQUENCING
The methylated DNA immunoprecipitation sequencing (MeDIP-
seq) approach incorporates the anti-methylcytosine antibody
described earlier. Brieﬂy, methylated DNA is immunoprecipi-
tated using the antibody against 5-methylcytosine and sequenced
(Maunakea et al., 2010; Table 5). The portion of DNA that is
immunoprecipitated represents the methylated portion of DNA
and is identiﬁed by comparison to the reference genome.
METHYL-BINDING DOMAIN ISOLATED GENOME SEQUENCING
Methyl-binding domain isolated genome sequencing (MBDiGs)
uses recombinant MBD and MBD2 proteins to enrich methyl-rich
DNA fragments from a pool of sonicated genomic DNA (Serre
et al., 2009). According to the review by Hirst and Mara (2010),
MBDiGS is preferable over MeDIP-seq because a gradient in salt
concentrations can be used to elute DNA fragments at different
rates depending on their methylation status.
METHYL-SENSITIVE RESTRICTION ENZYME SEQUENCING
Methyl-sensitive restriction enzyme sequencing (MRE-seq), as its
name suggests, involves methylation-sensitive restriction enzymes
(Maunakea et al., 2010). Genomic DNA samples are digested with
the restriction enzymes and the subsequent DNA fragments are
size selected and sequenced. Differential DNA methylation may
be identiﬁed by comparison of the fragments sequenced between
samples and site speciﬁc information is identiﬁed by comparison
to a reference genome. This method analyses a different portion
of the genome compared to MeDIP-seq and therefore, they can be
viewed as complimentary approaches.
MODIFIED METHYLATION-SPECIFIC DIGITAL KARYOTYPING
Modiﬁed methylation-speciﬁc digital karyotyping (MMSDK) or
MSDK-seq (Li et al., 2009) is similar to MRE-seq in that a methyl-
sensitive restriction enzyme is employed but includes additional
steps that reduce the amount of sequencing required. Rather than
sequencing sections of the genome, speciﬁc regions of the genome
can be identiﬁed from their short sequence tags. This signiﬁcantly
reduces the amount of sequencing and in turn reduces the costs
of this approach.
COMPARISON OF CONTEMPORARY DNA METHYLATION
METHODS
In this review, we aim to detail the development and evolution of
these analytical methods over time with respect to advancements
made in genetics, nucleotide biochemistry, and DNA sequencing
technology. As a result, many of the methods discussed are obso-
lete today and have been replaced by more recent technologies.
However, some of the techniques described in the latter part of this
review have subtle strengths andweaknesses, and careful judgment
should be employed in adopting any of thesemethods in a research
laboratory. There are many recent reviews that compare most
recent methods of DNA methylation analysis as mentioned below.
Laird (2010) list the features and source of bias for vari-
ous sequencing and microarray-based techniques including CpG
ambiguity, fragment size bias, cross-hybridization bias. All of the
methods that involve sodium bisulﬁte treatment, they argue, are
subject to incomplete bisulﬁte conversion bias. Thu et al. (2010),
also compare the strengths and weaknesses of each method, with
a special focus on techniques based on immunoprecipitation. In
more detail, a paper byHarris et al. (2010) quantitatively compares
the sequencing-based methods MethylC-seq, RRBS, MeDIP-seq
and MBD-seq (2010). Due to the nature of their processes, the
two bisulﬁte-based methods yield data with single base-pair reso-
lution, augmentedwith the capacity to quantifymethylation levels.
At a reduced coverage, the enrichment methods both have a lower
cost-per-CpG in a genome-wide context, but not allowing precise
quantiﬁcation of methylation levels on a genome-wide scale. It
appears that none of the currently available methods are without
their ﬂaws but bisulﬁte treated whole genome sequencing offers
complete genome coverage at single-base resolution and is cur-
rently the method of choice for genome-wide DNA methylation
analysis where costs are not prohibitive.
FUTURE OF METHYLOME ANALYSIS
The Next-generation sequencing approaches for DNA methyla-
tion analysis will dominate for themoment.However, themethods
discussed here cannot detect non-cytosine related methylation
reactions, i.e., N6-methyladenine nor 5-hydroxymethylcytosine
and therefore, more sophisticated methods are required than cur-
rently on offer. Newer sequencing technologies such as single-
molecule real-time (SMRT) sequencing (Flusberg et al., 2010)
can directly detect all known DNA methylation reactions with-
out the need for bisulﬁte treatment and is likely to take over from
next-generation sequencing in the very near future.
The analysis of 5-hydroxymethylcytosine (5hmC) via HPLC
based methods has been discussed brieﬂy. Recently, two novel
approaches have been described to discern the genomic distrib-
ution of 5hmC (Pastor et al., 2011). The ﬁrst, called GLIB involves
the glucosylation, periodate oxidation, and biotinylation of 5mhC.
Biotin molecules can be added to newly formed aldehyde groups
on pretreated 5hmC. A glucose moiety is added to 5hmC via a
glucosyltransferase enzyme, which has its vicinal hydroxyl groups
converted to aldehydes via treatment with sodium periodate. We
have previously discussed at lengthhow sodiumbisulﬁte treatment
of 5mC does not result in a conversion in a similar time-frame
to unmethylated cytosine. However, treatment of 5hmC yields
another molecule: 5-methylenesulfonate. For the second method
discussed in the article, Pastor et al. (2011) have succeeded in selec-
tively isolating biotinylated 5hmC and sodium bisulﬁte converted
5hmC using streptavidin and anti-5-methylenesulfonate, respec-
tively. In another recent publication,Kinney et al. (2011) exploited
an isoschizomer pair of restriction enzymes, MspI and HpaII, that
can differentiate between 5hmC and its glucosylated form. Cou-
pled with qPCR, the team found that ES and brain cell genomic
DNA contains a considerable amount of 5hmC, and identiﬁed
novel loci containing 5hmC in both mouse ES and human brain
DNA (Kinney et al., 2011).
CONCLUSION
The major developments in the methodologies for proﬁling and
ﬁngerprinting the human methylome have followed a clear pro-
gression toward innovative sequencing techniques at a single
base-pair resolution. As this technology improves, the cost of
genome-wide sequencing will decrease, resulting in a new wave
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of DNA methylation data as more labs become fully immersed
in the ﬁeld. The bioinformatic tools will continue to improve in
order to accurately analyze the vast datasets that will no doubt be
generated in the coming years. The precedent for this has already
been set through the Human Genome Project. Earlier this year,
the International Human Epigenome Consortium was launched,
aiming to map 1000 Epigenome by 2020 (IHEC, 2010). This is by
no means an easy task, but if we see as many technical advances in
the ﬁeld in the next 10 years as we have in the previous decade, it
is a challenge we are more than capable of facing.
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